<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004157" GROUP_ID="NEUROMUSC" ID="458202070309445953" MERGED_FROM="" MODIFIED="2012-03-14 17:31:54 +0100" MODIFIED_BY="Ruth Brassington" REVIEW_NO="052" REVMAN_SUB_VERSION="5.1.6" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-03-14 17:31:54 +0100" MODIFIED_BY="Ruth Brassington">
<TITLE MODIFIED="2011-01-05 12:17:31 +0000" MODIFIED_BY="Kate Jewitt">Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease</TITLE>
<CONTACT MODIFIED="2012-03-14 17:31:54 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="15460" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Weber</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>markus.weber@kssg.ch</EMAIL_1><EMAIL_2>maus1@bluewin.ch</EMAIL_2><ADDRESS><DEPARTMENT>Muskelzentrum/ALS Clinic</DEPARTMENT><ORGANISATION>Kantonsspital St. Gallen</ORGANISATION><ADDRESS_1>Greithstrasse 20</ADDRESS_1><CITY>St. Gallen</CITY><ZIP>9007</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>++41 (0)71 494 3581</PHONE_1><FAX_1>++41 (0)71 494 6389</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-03-14 17:31:54 +0100" MODIFIED_BY="Ruth Brassington"><PERSON ID="F01922B682E26AA20125F76B2BF2D691" ROLE="AUTHOR"><FIRST_NAME>Reto</FIRST_NAME><LAST_NAME>Baldinger</LAST_NAME><SUFFIX>MD</SUFFIX><POSITION>Neurology Consultant</POSITION><EMAIL_1>reto.baldinger@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Muskelzentrum/ALS Clinic</DEPARTMENT><ORGANISATION>Kantonsspital St. Gallen</ORGANISATION><ADDRESS_1>Greithstrasse 20</ADDRESS_1><CITY>St. Gallen</CITY><ZIP>9007</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>+41 71 494 35 81</PHONE_1><FAX_1>+41 71 494 63 89</FAX_1></ADDRESS></PERSON><PERSON ID="E6D7243182E26AA2008044A27A91453B" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Hans Dieter</FIRST_NAME><LAST_NAME>Katzberg</LAST_NAME><POSITION>Assistant Professor of Medicine (Neurology</POSITION><EMAIL_1>hans.katzberg@utoronto.ca</EMAIL_1><ADDRESS><ORGANISATION>University of Toronto Toronto General Hospital / UHN</ORGANISATION><ADDRESS_1>200 Elizabeth Street</ADDRESS_1><CITY>5EC-306 Toronto</CITY><ZIP>ON  M5G 2C4</ZIP><COUNTRY CODE="CA">Canada</COUNTRY><PHONE_1>(416) 340-3662</PHONE_1><FAX_1>(416) 340-6708</FAX_1></ADDRESS></PERSON><PERSON ID="15460" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Markus</FIRST_NAME><LAST_NAME>Weber</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>markus.weber@kssg.ch</EMAIL_1><EMAIL_2>maus1@bluewin.ch</EMAIL_2><ADDRESS><DEPARTMENT>Muskelzentrum/ALS Clinic</DEPARTMENT><ORGANISATION>Kantonsspital St. Gallen</ORGANISATION><ADDRESS_1>Greithstrasse 20</ADDRESS_1><CITY>St. Gallen</CITY><ZIP>9007</ZIP><COUNTRY CODE="CH">Switzerland</COUNTRY><PHONE_1>++41 (0)71 494 3581</PHONE_1><FAX_1>++41 (0)71 494 6389</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-07-20 20:03:40 +0100" MODIFIED_BY="Ruth Brassington">
<UP_TO_DATE>
<DATE DAY="14" MONTH="2" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="2" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="2" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2003"/>
</DATES>
<WHATS_NEW MODIFIED="2011-06-02 14:35:38 +0100" MODIFIED_BY="Ruth Brassington"/>
<HISTORY MODIFIED="2011-06-02 14:35:38 +0100" MODIFIED_BY="Ruth Brassington">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-06-02 14:35:38 +0100" MODIFIED_BY="Ruth Brassington">
<DATE DAY="2" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2010-12-15 21:36:09 +0000" MODIFIED_BY="Reto Baldinger">
<INTERNAL_SOURCES MODIFIED="2010-12-15 21:33:42 +0000" MODIFIED_BY="Reto Baldinger">
<SOURCE MODIFIED="2010-12-15 21:33:42 +0000" MODIFIED_BY="Reto Baldinger">
<NAME>Kantonsspital St. Gallen</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2010-12-15 21:36:09 +0000" MODIFIED_BY="Reto Baldinger">
<SOURCE MODIFIED="2010-12-15 21:36:09 +0000" MODIFIED_BY="Reto Baldinger">
<NAME>Swiss ALS Foundation</NAME>
<COUNTRY CODE="CH">Switzerland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-03-14 16:30:44 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-03-14 13:05:26 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2011-01-05 12:30:49 +0000" MODIFIED_BY="Kate Jewitt">Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease</TITLE>
<SUMMARY_BODY MODIFIED="2012-03-14 13:05:26 +0000" MODIFIED_BY="[Empty name]">
<P>A cramp is a sudden, involuntary painful contraction of a muscle. Many people with amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), experience cramps during the course of the disease. These range from mild cramps that do not affect daily activities and sleep, through to very severe, painful cramps. Some medications that are used to treat cramps in people with no medical condition or with conditions other than ALS have been tested in ALS clinical trials. These medicines include vitamin E, creatine, quinidine, and gabapentin. Other medications such as quinine sulfate, magnesium, lioresal, dantrolene, clonazepam, diphenylhydantoin, and gabapentin have been used to treat cramps in people with ALS but their effectiveness is unknown. In 2006 and 2010 the US Food and Drugs Administration issued warnings concerning the use of quinine sulfate, which was the previously most widely prescribed medication for cramps in the US. This review sought to find out how effective medications and physical treatments for cramps are for people with ALS. The reviewers identified 20 randomised controlled trials in people with ALS comprising a total of 4789 participants. Only one trial, of the drug tetrahydrocannabinol (THC), directly investigated the effectiveness of an intervention for cramps. Thirteen randomised controlled ALS trials investigated cramps secondarily among other variables. The medications comprised vitamin E, baclofen, riluzole, L-threonine, xaliproden, indinavir, and memantine. Six randomised controlled ALS trials investigated cramps as adverse events. The medications comprised creatine, gabapentin, dextromethorphan, quinidine and lithium. None of the 20 studies could demonstrate any benefit, but the studies were small. Current evidence on the treatment of cramps in ALS is lacking and more research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-03-14 13:05:12 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-03-23 14:38:19 +0000" MODIFIED_BY="Reto Baldinger">
<P>Cramps are painful, involuntary muscle contractions. They commonly affect people with amyotrophic lateral sclerosis/motor neuron disease (ALS/MND) at all stages of the disease. To date, the treatment of muscle cramps in ALS has been largely empirical without any evidence from randomised controlled trials.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-03-13 15:22:32 +0000" MODIFIED_BY="[Empty name]">
<P>To systematically assess the effect of interventions on muscle cramps as a primary or secondary endpoint or adverse event in people with ALS/MND.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-03-13 15:22:39 +0000" MODIFIED_BY="Reto Baldinger">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (14 February 2011), the Cochrane Central Register of Controlled Trials (Issue 1, 2011 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011) and reference lists of articles searched using the terms motor neuron disease, motor neurone disease, motoneuron disease or amyotrophic lateral sclerosis. We contacted authors of trials for further information.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-03-13 15:22:46 +0000" MODIFIED_BY="[Empty name]">
<P>We included all randomised and quasi-randomised trials of oral medications in people with ALS which assessed cramps as a primary or secondary outcome measure or as an adverse event. We also included trials using subcutaneous or intravenous medications or physical therapy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-07-20 19:36:27 +0100" MODIFIED_BY="Ruth Brassington">
<P>All authors applied the selection criteria and assessed study quality independently, and all authors performed independent data extraction.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-03-14 13:05:12 +0000" MODIFIED_BY="[Empty name]">
<P>Twenty studies including 4789 participants were identified. Only one trial, of tetrahydrocannabinol (THC), assessed cramps as the primary endpoint. Thirteen studies assessed cramps as a secondary endpoint. The medications comprised vitamin E, baclofen, riluzole, L-threonine, xaliproden, indinavir, and memantine. Six studies assessed cramps as an adverse event. The medications comprised creatine, gabapentin, dextromethorphan, quinidine, and lithium. In all 20 studies no favourable effect for the treatment of cramps in ALS/MND could be demonstrated, but many studies were underpowered to draw a definite conclusion. A meta-analysis of two small studies showed a statistically nonsignificant result for the amino acid L-threonine for the treatment of cramps in ALS/MND. No study was identified using physical therapy as a therapeutic intervention for cramps.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-03-13 22:01:50 +0000" MODIFIED_BY="[Empty name]">
<P>There is no evidence to support the use of any intervention for muscle cramps in ALS/MND. More and larger randomised controlled trials evaluating treatments for muscle cramps in ALS/MND are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-03-14 16:01:23 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-03-14 11:10:10 +0000" MODIFIED_BY="[Empty name]">
<P>A cramp is a sudden, involuntary and painful muscle contraction, accompanied by palpable knotting of the muscle. The origin of cramps is incompletely understood and depends on the underlying condition (<LINK REF="REF-Kiernan-2001" TYPE="REFERENCE">Kiernan 2001</LINK>; <LINK REF="REF-Parisi-2000" TYPE="REFERENCE">Parisi 2000</LINK>; <LINK REF="REF-Roeleveld-2000" TYPE="REFERENCE">Roeleveld 2000</LINK>). Two different pathophysiological mechanisms have been proposed to cause cramps: abnormal excitation of the terminal branches of motor axons (<LINK REF="REF-Bertolasi-1993" TYPE="REFERENCE">Bertolasi 1993</LINK>; <LINK REF="REF-Denny_x002d_Brown-1953" TYPE="REFERENCE">Denny-Brown 1953</LINK>; <LINK REF="REF-Layzer-1994" TYPE="REFERENCE">Layzer 1994</LINK>) and hyperexcitability or bistability of motoneurons at a spinal level (<LINK REF="REF-Baldissera-1994" TYPE="REFERENCE">Baldissera 1994</LINK>; <LINK REF="REF-Norris-1957" TYPE="REFERENCE">Norris 1957</LINK>; <LINK REF="REF-Ross-1995" TYPE="REFERENCE">Ross 1995</LINK>). Both mechanisms may complement each other (<LINK REF="REF-Parisi-2000" TYPE="REFERENCE">Parisi 2000</LINK>). In amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND), cramps may result from impaired inhibitory mechanisms (for example impairment of interneurons mediated by GABA, the most abundant inhibitory neurotransmitter) (<LINK REF="REF-Obi-1993" TYPE="REFERENCE">Obi 1993</LINK>).</P>
<P>Many people with ALS/MND experience cramps during the course of the disease (<LINK REF="REF-Swash-2000" TYPE="REFERENCE">Swash 2000</LINK>). In a survey of symptom management in 84 people with ALS/MND, cramps were present in 62%, requiring treatment in 56% (<LINK REF="REF-Heiman_x002d_Patterson-2000" TYPE="REFERENCE">Heiman-Patterson 2000</LINK>). Frequently, cramps occur as the first symptom of the disease, months before the patients notice weakness and wasting (<LINK REF="REF-Gubbay-1985" TYPE="REFERENCE">Gubbay 1985</LINK>; <LINK REF="REF-Layzer-1982" TYPE="REFERENCE">Layzer 1982</LINK>). Severity varies from mild, without affecting daily activities and sleep, to disabling, where almost any voluntary muscle activity induces persistent, severely painful cramping. In ALS/MND, the cramps may affect any muscle or muscle group (for example jaw, abdomen, chest, back, neck, or extremities). Various medications such as quinine sulfate, magnesium, lioresal, dantrolene, clonazepam, diphenylhydantoin and gabapentin are used for the treatment of cramps in ALS/MND (<LINK REF="REF-Forshew-2003" TYPE="REFERENCE">Forshew 2003</LINK>). However, treatment of cramps in ALS/MND has been a primary endpoint only in a single randomised controlled trial with tetrahydrocannabinol (THC) (<LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>) and an open-label, nonrandomised study with levetiracetam (<LINK REF="REF-Bedlack-2009" TYPE="REFERENCE">Bedlack 2009</LINK>).<SUP> </SUP>Moreover, for quinine sulfate, the most widely prescribed medication for cramps in the US (<LINK REF="REF-Forshew-2003" TYPE="REFERENCE">Forshew 2003</LINK>) the FDA has repeatedly issued safety announcements that it is only approved for the treatment of malaria and not approved for the treatment or prevention of night time leg cramps (<LINK REF="REF-FDA-2006" TYPE="REFERENCE">FDA 2006</LINK>; <LINK REF="REF-FDA-2010" TYPE="REFERENCE">FDA 2010</LINK>). However, off-label use, for example in therapy-refractory muscle cramps, is also discussed and prescribing physicians are advised to be alert to possible serious adverse events such as thrombocytopenia. Also, the American Academy of Neurology (AAN) practice parameter issued safety concerns about prescribing quinine for muscle cramps (<LINK REF="REF-Miller-2009" TYPE="REFERENCE">Miller 2009</LINK>). By contrast, a recent Cochrane review on quinine for 'idiopathic' muscle cramps found moderate quality evidence that quinine is effective and moderate quality evidence of significantly increased minor adverse events (mainly gastrointestinal symptoms), but no significantly increased serious adverse events (<LINK REF="REF-El_x002d_Tawil-2010" TYPE="REFERENCE">El-Tawil 2010</LINK>).</P>
<P>In populations other than people with ALS, numerous medications, including vitamins (<LINK REF="REF-Chan-1998" TYPE="REFERENCE">Chan 1998</LINK>; <LINK REF="REF-Connolly-1992" TYPE="REFERENCE">Connolly 1992</LINK>; <LINK REF="REF-Khajehdehi-2001" TYPE="REFERENCE">Khajehdehi 2001</LINK>), gabapentin (<LINK REF="REF-Mueller-1997" TYPE="REFERENCE">Mueller 1997</LINK>; <LINK REF="REF-Serrao-2000" TYPE="REFERENCE">Serrao 2000</LINK>), quinine sulfate (<LINK REF="REF-Connolly-1992" TYPE="REFERENCE">Connolly 1992</LINK>; <LINK REF="REF-Gorlich-1991" TYPE="REFERENCE">Gorlich 1991</LINK>; <LINK REF="REF-Fowler-1997" TYPE="REFERENCE">Fowler 1997</LINK>; <LINK REF="REF-Fung-1989" TYPE="REFERENCE">Fung 1989</LINK>; <LINK REF="REF-Gorlich-1991" TYPE="REFERENCE">Gorlich 1991</LINK>; <LINK REF="REF-Jansen-1994" TYPE="REFERENCE">Jansen 1994</LINK>; <LINK REF="REF-Jansen-1997" TYPE="REFERENCE">Jansen 1997</LINK>; <LINK REF="REF-Lee-1991" TYPE="REFERENCE">Lee 1991</LINK>; <LINK REF="REF-Man_x002d_Son_x002d_Hing-1998" TYPE="REFERENCE">Man-Son-Hing 1998</LINK>), L-carnitine (<LINK REF="REF-Ahmad-1990" TYPE="REFERENCE">Ahmad 1990</LINK>), prazosin (<LINK REF="REF-Sidhom-1994" TYPE="REFERENCE">Sidhom 1994</LINK>), and magnesium (<LINK REF="REF-Frusso-1999" TYPE="REFERENCE">Frusso 1999</LINK>) have been investigated in controlled clinical trials evaluating the treatment of cramps. The conditions under investigation were haemodialysis (<LINK REF="REF-Ahmad-1990" TYPE="REFERENCE">Ahmad 1990</LINK>; <LINK REF="REF-Sidhom-1994" TYPE="REFERENCE">Sidhom 1994</LINK>), hypertension (<LINK REF="REF-Chan-1998" TYPE="REFERENCE">Chan 1998</LINK>), and disorders such as multiple sclerosis (<LINK REF="REF-Mueller-1997" TYPE="REFERENCE">Mueller 1997</LINK>), cirrhosis (<LINK REF="REF-Lee-1991" TYPE="REFERENCE">Lee 1991</LINK>), and undefined diseases (<LINK REF="REF-Gorlich-1991" TYPE="REFERENCE">Gorlich 1991</LINK>; <LINK REF="REF-Fowler-1997" TYPE="REFERENCE">Fowler 1997</LINK>; <LINK REF="REF-Serrao-2000" TYPE="REFERENCE">Serrao 2000</LINK>). Other study populations included healthy people (<LINK REF="REF-Connolly-1992" TYPE="REFERENCE">Connolly 1992</LINK>; <LINK REF="REF-Fung-1989" TYPE="REFERENCE">Fung 1989</LINK>; <LINK REF="REF-Jansen-1997" TYPE="REFERENCE">Jansen 1997</LINK>; <LINK REF="REF-Jansen-1994" TYPE="REFERENCE">Jansen 1994</LINK>; <LINK REF="REF-Lee-1991" TYPE="REFERENCE">Lee 1991</LINK>). A Cochrane review explored the interventions for leg cramps in pregnancy (<LINK REF="REF-Young-2002" TYPE="REFERENCE">Young 2002</LINK>). Most of the studies showed a significant positive effect in favour of the treatment arm. Contradictory results have been found for magnesium (positive in pregnancy (<LINK REF="REF-Young-2002" TYPE="REFERENCE">Young 2002</LINK>), negative in an undefined population (<LINK REF="REF-Frusso-1999" TYPE="REFERENCE">Frusso 1999</LINK>)) and vitamin E (positive in hemodialysis (<LINK REF="REF-Khajehdehi-2001" TYPE="REFERENCE">Khajehdehi 2001</LINK>), negative in veterans (<LINK REF="REF-Connolly-1992" TYPE="REFERENCE">Connolly 1992</LINK>)). Although the pathophysiology of cramps in these disorders and ALS/MND may differ (<LINK REF="REF-Obi-1993" TYPE="REFERENCE">Obi 1993</LINK>; <LINK REF="REF-Parisi-2000" TYPE="REFERENCE">Parisi 2000</LINK>; <LINK REF="REF-Piergies-1990" TYPE="REFERENCE">Piergies 1990</LINK>; <LINK REF="REF-Sidhom-1994" TYPE="REFERENCE">Sidhom 1994</LINK>), it is possible that some of the aforementioned compounds may be effective in ALS/MND. Among these compounds, vitamin E (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>), gabapentin (<LINK REF="STD-Miller-2001" TYPE="STUDY">Miller 2001</LINK>; <LINK REF="STD-Miller-1996" TYPE="STUDY">Miller 1996</LINK>) and dextromethorphan/quinidine (<LINK REF="STD-Brooks-2004" TYPE="STUDY">Brooks 2004</LINK>) have been investigated in randomised controlled clinical trials in people with ALS. None of them, including gabapentin (<LINK REF="STD-Miller-2001" TYPE="STUDY">Miller 2001</LINK>), seemed to alleviate cramps. All published trials used either the daily number of cramps and/or a visual analogue scale (VAS) reflecting the severity of cramps. However, the VAS for cramps has never been formally validated. Nevertheless, since self-assessment of cramps was part of many controlled clinical trials in ALS, data on the effect of the study medication on cramps should be available.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-03-13 15:29:38 +0000" MODIFIED_BY="Reto Baldinger">
<P>To systematically assess the effect of interventions on muscle cramps as a primary or secondary endpoint or adverse event in people with ALS/MND.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-03-14 13:06:04 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-03-13 15:29:42 +0000" MODIFIED_BY="[Empty name]">
<P>We included only randomised and quasi-randomised trials. We accepted all study designs.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-07-20 19:37:49 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included studies with participants diagnosed with probable, probable laboratory supported, or definite ALS according to the original (<LINK REF="REF-Brooks-1994" TYPE="REFERENCE">Brooks 1994</LINK>) or revised El Escorial criteria (<LINK REF="REF-Brooks-2000" TYPE="REFERENCE">Brooks 2000</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-07-20 19:37:51 +0100" MODIFIED_BY="Ruth Brassington">
<P>We included studies which used oral, subcutaneous and intravenous medications or physical treatment which potentially relieve cramps in ALS/MND.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-03-14 13:06:04 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-03-13 15:29:48 +0000" MODIFIED_BY="Ruth Brassington">
<P>The primary outcome measure was the reduction in the (patient's) global impression of muscle cramp burden over a period of time rated with a visual analogue scale (VAS). A VAS is a psychometric response scale used to measure subjective characteristics or attitudes about a particular symptom. As widely used in the assessment of pain, a VAS reflects a range of no symptom burden at all (i.e. 0 or 0%) to maximal imaginable symptom burden (i.e. a score of 10 or 100%). In this review, the muscle cramp burden reflects a summary of number, duration and intensity of muscle cramps over a period of time. This primary outcome measure was selected because it was most commonly used in the ALS studies.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-03-14 13:06:04 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Cramp intensity in the 24 hours preceding assessment by VAS.</LI>
<LI>Number of cramps in the 24 hours preceding assessment.</LI>
<LI>In studies where cramps were assessed as adverse events: ratio of participants experiencing cramps to total number of participants.</LI>
<LI>In studies primarily designed to treat cramps: quality of life measure, for example Short Form 36 Health Survey (SF-36).</LI>
<LI>In studies primarily designed to treat cramps: adverse effects.</LI>
</OL>
<P>In studies designed to study cramps as a primary outcome measure, quality of life measures and adverse effects are also assessed. 'Summary of findings' tables of the assessment of cramps using a VAS for each intervention have been included as additional tables.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Neuromuscular Disease Group Specialized Register (14 February 2011) using the following search terms 'amyotrophic lateral sclerosis' OR 'motor neuron disease' OR 'motor neuron disease'. We also searched the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2011 in <I>The Cochrane Library</I>), MEDLINE (January 1966 to January 2011) and EMBASE (January 1980 to January 2011). We contacted pharmaceutical companies and corresponding authors of relevant unpublished or published randomised placebo controlled clinical trials in ALS/MND (included in the Cochrane Neuromuscular Disease Group Specialized Register) personally to retrieve additional data on cramps.</P>
<P>Search strategies for MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials (CENTRAL) are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>, and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>, respectively.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-03-13 19:28:00 +0000" MODIFIED_BY="Ruth Brassington">
<P>All review authors screened abstracts for randomised controlled treatment trials in people with ALS/MND using the inclusion criteria stated above. If the inclusion criteria were met, we retrieved the full text article and screened it to determine whether muscle cramps were assessed. If the full text paper did not mention muscle cramps, we excluded the study. If muscle cramps were assessed as a primary or secondary outcome measure or as side effects, we included the study and contacted all corresponding authors by email, and some personally. All review authors independently performed the extraction of data relating to the primary and secondary outcome measures and rated the risk of bias in the included studies. We resolved disagreement by discussion.</P>
<P>Assessment of risk of bias took into account the randomisation method, allocation concealment, participant and observer blinding, reporting of incomplete data, selective reporting, and risk of other bias. We followed the grading scale proposed in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>5.1.0 (Table 8.5.c: Criteria for judging risk of bias in the &#8216;Risk of bias&#8217; assessment tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and graded each criterion as fulfilled ("Low risk"), not fulfilled ("High risk") or providing insufficient information to permit a "High risk" or "Low risk" judgement ("Unclear"). <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> provides a summary of the review authors' judgements about each risk of bias for the included studies.</P>
<P>We used the mean difference and 95% confidence intervals (CI) for continuous outcome measures (for example absolute change in VAS). We assessed categorical outcome measures (for example the ratio of participants experiencing cramps versus not experiencing cramps) using risk ratios (RR) and 95% CI. We planned to use a fixed-effect analysis unless we found evidence of heterogeneity.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-03-14 13:22:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-03-14 13:22:23 +0000" MODIFIED_BY="[Empty name]">
<P>The current search strategy (14 February 2011) identified 729 abstracts in MEDLINE, 796 abstracts in EMBASE, 257 abstracts in the Cochrane Neuromuscular Disease Group Specialized Register, and 455 abstracts in CENTRAL, adding up to a total of 2237 abstracts. After deduplication, the authors reviewed 1461 abstracts. Amongst them, we classified 1284 as not relevant to the review, leaving 177 abstracts of interest. We were unable to retrieve the full text of 13 articles (listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Among the 164 full text articles retrieved, the review authors identified 19 relevant articles with a total of 20 trials that met the selection criteria (<LINK REF="STD-Meininger-2004" TYPE="STUDY">Meininger 2004</LINK> comprises two studies). We excluded 158 studies (including one additional, unpublished study by <LINK REF="STD-Gelinas-2001" TYPE="STUDY">Gelinas 2001</LINK> (personal communication), as well as the aforementioned 13 studies in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>) because they did not meet the inclusion criteria. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for the full list of excluded studies. In only one instance (<LINK REF="STD-De-Carvalho-2010" TYPE="STUDY">De Carvalho 2010</LINK>) did the study authors provide original data. The 20 included trials comprised a total of 4789 participants. The studies are summarised in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and an ongoing trial is summarised in <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<P>Thirteen studies assessed muscle cramps on a VAS once every study visit. Thus, the whole time since the last study visit was reflected in a single rating. None of the studies reported additional assessments of muscle cramps (for example by a daily or weekly log) or whether cramp number or duration of cramps were assessed. None of them specified whether the assessment by VAS reflected a global impression of cramp burden or, for instance, cramp intensity. All of them assessed muscle cramps as a secondary outcome. The review authors identified only two studies that assessed muscle cramps as a primary outcome (<LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>; <LINK REF="STD-Strong-ongoing" TYPE="STUDY">Strong ongoing</LINK>). Both assessed cramp intensity and cramp number (<LINK REF="STD-Strong-ongoing" TYPE="STUDY">Strong ongoing</LINK> also duration) with a daily journal covering the last 24 hours. All other studies investigated medications that aimed to modify the course of the disease or to treat emotional lability (<LINK REF="STD-Brooks-2004" TYPE="STUDY">Brooks 2004</LINK>). Cramps were either assessed as secondary outcome measures, side effects or as part of the study protocol.</P>
<P>All studies except two (<LINK REF="STD-Brooks-2004" TYPE="STUDY">Brooks 2004</LINK>; <LINK REF="STD-Chi_x00f2_-2010" TYPE="STUDY">Chiò 2010</LINK>) were RCTs comparing oral medication to placebo. <LINK REF="STD-Brooks-2004" TYPE="STUDY">Brooks 2004</LINK> compared quinidine to dextromethorphan and a combination of the two substances, <LINK REF="STD-Chi_x00f2_-2010" TYPE="STUDY">Chiò 2010</LINK> compared therapeutic lithium serum levels to subtherapeutic levels. None of the studies used subcutaneous or intravenous applications and none of the studies used physical therapy as the therapeutic intervention.</P>
<P>One study was performed over 30 years ago (<LINK REF="STD-Norris-1979" TYPE="STUDY">Norris 1979</LINK>), one over 20 years ago (<LINK REF="STD-Blin-1989" TYPE="STUDY">Blin 1989</LINK>), nine more than 10 years ago and nine within the last 10 years. All studies examined outpatients. Five studies were carried out in the US, 15 in western Europe. One study (<LINK REF="STD-Bensimon-2002" TYPE="STUDY">Bensimon 2002</LINK>) explicitly studied people with ALS aged 75 years and older, all other studies included a wide range of ages (ranging from 20 to 75 years).</P>
<P>Study size varied considerably, ranging from very small (n = 12) to large scale (n = 959) trials. Five studies had 23 or fewer participants (<LINK REF="STD-Blin-1989" TYPE="STUDY">Blin 1989</LINK>; <LINK REF="STD-Blin-1992" TYPE="STUDY">Blin 1992</LINK>; <LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>; <LINK REF="STD-Norris-1979" TYPE="STUDY">Norris 1979</LINK>; <LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>); <LINK REF="STD-Scelsa-2005" TYPE="STUDY">Scelsa 2005</LINK> had 46 participants and <LINK REF="STD-De-Carvalho-2010" TYPE="STUDY">De Carvalho 2010</LINK> 63. All other studies had 107 or more participants. Three of the five small-scale (n = 23 or less) studies used a cross-over design (<LINK REF="STD-Blin-1989" TYPE="STUDY">Blin 1989</LINK>; <LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>; <LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>), and two of them a parallel group design (<LINK REF="STD-Norris-1979" TYPE="STUDY">Norris 1979</LINK>; <LINK REF="STD-Blin-1992" TYPE="STUDY">Blin 1992</LINK>). All other studies used a parallel group design. The washout periods in the cross-over trials (<LINK REF="STD-Blin-1989" TYPE="STUDY">Blin 1989</LINK>; <LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>; <LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>) were 7, 8 and 14 days, respectively.</P>
<P>Five studies were short term with an observational period of eight weeks or less. Fifteen studies were long term with an observational period of six months or more. Consequently, (cramp) assessment interval varied from once every week in the short-term studies to once in six months in the long-term trials. Assessment intervals are given for each study in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Eight studies applied interventions that were used in multiple trials: three trials (<LINK REF="STD-Bensimon-1994" TYPE="STUDY">Bensimon 1994</LINK>; <LINK REF="STD-Bensimon-2002" TYPE="STUDY">Bensimon 2002</LINK>; <LINK REF="STD-Lacomblez-1996" TYPE="STUDY">Lacomblez 1996</LINK>) studied riluzole 100 mg per day, one trial <LINK REF="STD-Lacomblez-1996" TYPE="STUDY">Lacomblez 1996</LINK> studied 50 mg and 200 mg riluzole per day, three trials (<LINK REF="STD-Blin-1989" TYPE="STUDY">Blin 1989</LINK>; <LINK REF="STD-Blin-1992" TYPE="STUDY">Blin 1992</LINK>; <LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>) used L-threonine (all 2 g per day), two trials (<LINK REF="STD-Meininger-2004" TYPE="STUDY">Meininger 2004</LINK>, published as one study) investigated xaliproden. Five trials (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>; <LINK REF="STD-Miller-2001" TYPE="STUDY">Miller 2001</LINK>; <LINK REF="STD-Norris-1979" TYPE="STUDY">Norris 1979</LINK>; <LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>; <LINK REF="STD-De-Carvalho-2010" TYPE="STUDY">De Carvalho 2010</LINK>) used medications not used in other trials (vitamin E, gabapentin, baclofen, THC, and lithium).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-03-13 19:30:21 +0000" MODIFIED_BY="[Empty name]">
<P>The review authors graded each individual quality criterion for each study as set out in the methods section and tabulated individual scores (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). The quality of the trials varied considerably. Newer trials and trials conducted by professional pharmaceutical investigators were of better design, incorporating more appropriate statistical analysis, applying intention-to-treat analysis and taking into consideration baseline differences.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-03-13 19:32:59 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome measure (reduction of impression of cramp burden over time rated by VAS)</HEADING>
<P>The interventions comprised vitamin E, baclofen, riluzole, L-threonine, xaliproden, indinavir, memantine, and THC. All 14 studies reported statistically nonsignificant differences between the intervention and control groups. One ongoing study identified by personal communication is assessing the effect of vitamin E on muscle cramps as a primary outcome measure (<LINK REF="STD-Strong-ongoing" TYPE="STUDY">Strong ongoing</LINK>).</P>
<P>A meta-analysis could be performed for L-threonine (<LINK REF="STD-Blin-1992" TYPE="STUDY">Blin 1992;</LINK> <LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>). The combined mean change of the cramp intensity was -12.61 on a VAS (95% CI - 26.94 to 1.72) and the difference was statistically nonsignificant (P = 0.08) (see <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Data for the interventions vitamin E and THC were also reported allowing reanalysis (<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>; <LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>) (see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> and <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>, respectively). One author (<LINK REF="STD-De-Carvalho-2010" TYPE="STUDY">De Carvalho 2010</LINK>) provided unpublished data about memantine (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcome measures (intensity of cramps by VAS in the last 24 hours, number of cramps in the last 24 hours, cramps as adverse events)</HEADING>
<P>One study assessed intensity of cramps by VAS in the last 24 hours and number of cramps in the last 24 hours (<LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>) and a statistically nonsignificant difference was found.</P>
<P>All six studies assessing cramps as adverse events (<LINK REF="STD-Brooks-2004" TYPE="STUDY">Brooks 2004</LINK>; <LINK REF="STD-Chi_x00f2_-2010" TYPE="STUDY">Chiò 2010</LINK>; <LINK REF="STD-Groeneveld-2003" TYPE="STUDY">Groeneveld 2003</LINK>; <LINK REF="STD-Miller-1996" TYPE="STUDY">Miller 1996</LINK>; <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>; <LINK REF="STD-Scelsa-2005" TYPE="STUDY">Scelsa 2005</LINK>) reported statistically nonsignificant differences. Only <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK> (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>) and <LINK REF="STD-Scelsa-2005" TYPE="STUDY">Scelsa 2005</LINK> (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>) reported the data (as a proportion of participants experiencing cramps). The interventions comprised dextromethorphan/quinidine, lithium, creatine, gabapentin, and indinavir.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-03-14 13:38:38 +0000" MODIFIED_BY="[Empty name]">
<P>The aim of this review was to assess the evidence for the treatment of cramps in ALS/MND. So far there is a lack of interventional studies targeted at treating cramps in ALS/MND. Treatment of cramps in ALS has been the primary endpoint in only one completed (<LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>) and one ongoing (<LINK REF="STD-Strong-ongoing" TYPE="STUDY">Strong ongoing</LINK>) RCT. The former trial, investigating the drug THC, did not find any treatment benefit (see <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>). Thus, we also included studies assessing cramps as secondary outcome measures, as side effects (for example <LINK REF="STD-Scelsa-2005" TYPE="STUDY">Scelsa 2005</LINK>, see <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>) or simply as part of the study protocol without specification as a primary or secondary outcome measure. Most of the identified studies were large-scale ALS/MND trials investigating disease-modifying interventions without any indication about the usefulness of the intervention for the treatment of muscle cramps in people with ALS/MND. It is therefore not surprising that all included studies that assessed muscle cramps found statistically nonsignificant differences between the intervention and control group.</P>
<P>However, some trials were identified in this review that used medications in ALS/MND as disease-modifying treatment which have also been used in non-ALS populations for the treatment of cramps. They include vitamin E, creatine, gabapentin, dextromethorphan and quinidine. Data from the gabapentin trial and dextromethorphan/quinidine trial were not available.</P>
<P>The analysis of single trial data suggests that vitamin E and creatine, which have shown to be effective in other conditions (<LINK REF="REF-Khajehdehi-2001" TYPE="REFERENCE">Khajehdehi 2001</LINK>), do not affect cramps in people with ALS/MND (see <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK> and <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>). However, these studies were not powered for treatment effects on cramps so no conclusions can be drawn with respect to their effectiveness. This points to another fundamental problem of cramp trials in ALS/MND, which is that no formal studies exist about the natural course (for example prevalence, duration, frequency, and intensity).</P>
<P>One of the inherent difficulties was the assessment of the symptom of interest itself, that is muscle cramps. Total muscle cramp burden can be subdivided into number, duration and intensity (or severity, the two terms were used interchangeably in this review) of muscle cramps. As muscle cramps are in most part constituted by pain, a patient has to rate this solely subjective symptom on a scale between zero and maximal symptom burden. As in pain, this was assessed with a VAS. Of the large scale, high quality ALS/MND intervention trials, all assessed muscle cramps by VAS only at every study visit. Since no indication was given that muscle cramps were assessed at a higher frequency outside the visits (for example with a daily log), the assessments probably reflect a global impression of cramp burden over the weeks to months since the previous visit, which implements a high recall bias. To reach a more firm conclusion, future intervention trials need to assess cramp number, duration and intensity on a daily basis.</P>
<P>Another difficulty was that data on muscle cramps were not reported. Of the 20 trials assessing cramps, only five reported the data. Unpublished data could be retrieved only from one trial (<LINK REF="STD-De-Carvalho-2010" TYPE="STUDY">De Carvalho 2010</LINK>) (see <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>). The latter and the published data were re-analysed in this review. Only two trials (<LINK REF="STD-Blin-1992" TYPE="STUDY">Blin 1992</LINK>; <LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>) reported on the same intervention (L-threonine) and a meta-analysis resulted in a statistically nonsignificant difference (see <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>). In no other instance were data on cramps reported twice or more and thus we were not able to pool the data.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-03-14 16:01:23 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="Ruth Brassington">
<P>Based on results of this review, there is no evidence to support the use of any intervention for muscle cramps in people with ALS/MND.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-03-14 16:01:23 +0000" MODIFIED_BY="[Empty name]">
<P>More trials aimed to investigate the treatment of cramps in ALS/MND are needed. Studies directly addressing muscle cramps in ALS should assess number and duration of muscle cramps as well as intensity of muscle cramps on a VAS.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-01-25 13:05:22 +0000" MODIFIED_BY="Ruth Brassington">
<P>We would like to thank Angela Gunn for designing the search strategy and performing the searches, Kate Jewitt, Ruth Brassington and Dr Ros Quinlivan for editorial support and Dr AV Swan for statistical assistance.</P>
<P>The Cochrane Neuromuscular Disease Group editorial base is supported by the Motor Neurone Disease Association and the MRC Centre for Neuromuscular Diseases.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-03-13 19:34:42 +0000" MODIFIED_BY="Ruth Brassington">
<P>MW designed and conducted the study on THC for the treatment of cramps in ALS. He has not received any financial support or honoraria from the manufacturer. RB and HDK declare no known conflicts of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-03-13 19:34:40 +0000" MODIFIED_BY="Reto Baldinger">
<P>MW drafted the protocol. RB performed data handling. All authors screened abstracts and articles meeting the inclusion criteria. RB drafted the final manuscript. All authors agreed on the risk of bias assessments for the included studies. MW and HK edited the final version and all authors agreed on the final version.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-03-14 16:30:44 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>The first search included the search terms "motor neuron disease", "cramp" and "clinical trial". After updating the first search a number of relevant studies which were retrieved during the first search were no longer identified. After omitting "cramp" as a search term, relevant studies from the first search were again identified but at the cost of expanding the search to all (randomised controlled) intervention trials (in ALS).</LI>
<LI>Primary outcome measure: we changed "absolute change in analogue rating scale of cramps one month after initiation of the intervention" to "reduction in the (patient's) global impression of muscle cramp burden over a period of time rated with a visual analogue scale (VAS)" since the vast majority of studies used this global measure and did not assess number, duration and intensity (or severity) of muscle cramps. Furthermore, no studies used a four-week intervention period.</LI>
<LI>Secondary outcome measures: because the outcomes "duration of cramps" and "number of days/nights per week during which the participants had muscle cramps (cramp days)" were not used in any of the trials, we eliminated them. Since one study assessed the "cramp intensity in the last 24 hours" and "number of cramps in the last 24 hours", these outcome measures were included. Since quality of life and adverse effects are also important outcome measures likely to be assessed in studies primarily designed to treat cramps, we also included these.</LI>
<LI>After it became apparent that only few data could be retrieved from existing trials, we included studies using subcutaneous and intravenous medications (in addition to oral medication and physical therapy).</LI>
<LI>Change in authorship: Reto Baldinger and Hans Dieter Katzberg included; Daniel Feinberg withdrew.</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-03-14 16:15:32 +0000" MODIFIED_BY="Ruth Brassington">
<STUDIES MODIFIED="2012-03-14 10:02:58 +0000" MODIFIED_BY="Ruth Brassington">
<INCLUDED_STUDIES MODIFIED="2012-03-14 10:02:40 +0000" MODIFIED_BY="Reto Baldinger">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Bensimon-1994" MODIFIED="2011-02-14 15:42:42 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bensimon 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-14 15:42:42 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;03A controlled trial of riluzole in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:42:42 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bensimon G, Lacomblez L, Meininger V</AU>
<TI>A controlled trial of riluzole in amyotrophic lateral sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>9</NO>
<PG>585-91</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:42:42 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:42:42 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8302340"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Bensimon-2002" MODIFIED="2011-02-14 15:42:59 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bensimon 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-02-14 15:42:59 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:42:59 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bensimon G, Lacomblez L, Delumeau J C, Bejuit R, Truffinet P, Meininger V</AU>
<TI>A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>2002</YR>
<VL>249</VL>
<NO>5</NO>
<PG>609-15</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:42:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:42:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="12021952"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Blin-1989" MODIFIED="2011-02-14 15:43:31 +0000" MODIFIED_BY="Kate Jewitt" NAME="Blin 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-02-14 15:43:31 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Short-term double-blind drug versus placebo trial of L-threonine in amyotrophic lateral sclerosis. [French]&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:43:31 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blin O, Serratrice G, Pouget J, Aubrespy G, Guelton C, Crevat A</AU>
<TI>Short-term double-blind drug vs placebo trial of L-threonine in amyotrophic lateral sclerosis. [French]</TI>
<SO>Presse Medicale</SO>
<YR>1989</YR>
<VL>18</VL>
<NO>30</NO>
<PG>1469-70</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:43:29 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:43:29 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2534171"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Blin-1992" MODIFIED="2011-02-14 15:43:52 +0000" MODIFIED_BY="Kate Jewitt" NAME="Blin 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-02-14 15:43:52 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:43:52 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blin O, Pouget J, Aubrespy G, Guelton C, Crevat A, Serratrice G</AU>
<TI>A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1992</YR>
<VL>239</VL>
<NO>2</NO>
<PG>79-81</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:43:52 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:43:52 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="1313078"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Brooks-2004" MODIFIED="2011-02-14 15:44:28 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brooks 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-14 15:44:28 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;26Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:44:28 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al</AU>
<TI>Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: A randomized trial</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>8</NO>
<PG>1364-70</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:44:12 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:44:12 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15505150"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Chi_x00f2_-2010" MODIFIED="2012-03-13 20:11:06 +0000" MODIFIED_BY="Reto Baldinger" NAME="Chiò 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-13 20:11:06 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chiò A, Borghero G, Calvo A, Capasso M, Caponnetto C, Corbo M et al; LITALS Study Group</AU>
<TI>Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial</TI>
<SO>Neurology</SO>
<YR>2010</YR>
<VL>75</VL>
<NO>7</NO>
<PG>619-25</PG>
<IDENTIFIERS MODIFIED="2012-03-12 22:21:29 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2012-03-12 22:21:29 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="20702794"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-De-Carvalho-2010" MODIFIED="2012-03-13 20:12:37 +0000" MODIFIED_BY="Reto Baldinger" NAME="De Carvalho 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-13 20:12:37 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>De Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A</AU>
<TI>A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>5</NO>
<PG>456&#8211;60</PG>
<IDENTIFIERS MODIFIED="2012-03-12 22:21:06 +0000" MODIFIED_BY="Ruth Brassington">
<IDENTIFIER MODIFIED="2012-03-12 22:21:06 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="20565333"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-04-13 16:28:21 +0100" MODIFIED_BY="Reto Baldinger"/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Desnuelle-2001" MODIFIED="2011-02-14 15:44:57 +0000" MODIFIED_BY="Kate Jewitt" NAME="Desnuelle 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-14 15:44:57 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MarA double-blind, placeho-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:44:57 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desnuelle C, Dib M, Garrel C, Favier A</AU>
<TI>A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2001</YR>
<VL>2</VL>
<NO>1</NO>
<PG>9-18</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:44:54 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:44:54 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11465936"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Gil-1992" MODIFIED="2011-02-15 15:49:48 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gil 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-02-15 15:49:48 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A double-blind placebo-controlled study of branched chain amino acids and L-threonine for the short-term treatment of signs and symptoms of amyotrophic lateral sclerosis. [French]&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:49:48 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gil R, Neau JP, Courtois P, Gaucher C, Jonveaux T, Rosolacci T, et al</AU>
<TI>A double-blind placebo-controlled study of branched chain amino acids and L-threonine for the short-term treatment of signs and symptoms of amyotrophic lateral sclerosis. [French]</TI>
<SO>Semaine des Hopitaux</SO>
<YR>1992</YR>
<VL>68</VL>
<NO>42</NO>
<PG>1472-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:49:48 +0000" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Groeneveld-2003" MODIFIED="2011-02-14 15:45:44 +0000" MODIFIED_BY="Kate Jewitt" NAME="Groeneveld 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-14 15:45:44 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;01A randomized sequential trial of creatine in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:45:44 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groeneveld GJ, Veldink JH, Van der Tweel I, Kalmijn S, Beijer C, De Visser M, et al</AU>
<TI>A randomized sequential trial of creatine in amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2003</YR>
<VL>53</VL>
<NO>4</NO>
<PG>437-45</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:45:40 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:45:40 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="12666111"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Lacomblez-1996" MODIFIED="2011-02-14 15:46:12 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lacomblez 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-14 15:46:12 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;25Dose-ranging study of riluzole in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:46:12 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V</AU>
<TI>Dose-ranging study of riluzole in amyotrophic lateral sclerosis</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<NO>9013</NO>
<PG>1425-31</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:46:11 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:46:10 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8676624"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-11-01 14:37:59 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Lacomblez-1996a" MODIFIED="2011-02-14 15:46:30 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lacomblez 1996a" YEAR="1996">
<REFERENCE MODIFIED="2011-02-14 15:46:30 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;DecA confirmatory dose-ranging study of riluzole in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:46:30 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al</AU>
<TI>A confirmatory dose-ranging study of riluzole in ALS</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>6 SUPPL 4</NO>
<PG>S242-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Meininger-2004" MODIFIED="2011-02-14 15:47:09 +0000" MODIFIED_BY="Kate Jewitt" NAME="Meininger 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-14 15:47:09 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;JunEfficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:47:09 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meininger V, Bensimon G, Bradley WG, Brooks BR, Douillet P, Eisen A A, et al</AU>
<TI>Efficacy and safety of xaliproden in amyotrophic lateral sclerosis: Results of two phase III trials</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>2</NO>
<PG>107-17</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:47:05 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:47:05 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15204012"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Miller-1996" MODIFIED="2012-03-14 10:02:40 +0000" MODIFIED_BY="Reto Baldinger" NAME="Miller 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-03-14 10:02:40 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;DecPlacebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2012-03-14 10:02:40 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Moore D, Young LA, Armon C, Barohn RJ, Bromberg MB, et al; Western Amyotrophic Lateral Sclerosis (WALS) Study Group</AU>
<TI>Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis.</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>6</NO>
<PG>1383-8</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:47:35 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:47:35 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8960715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Miller-2001" MODIFIED="2011-02-14 15:48:33 +0000" MODIFIED_BY="Kate Jewitt" NAME="Miller 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-14 15:48:33 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;10Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:48:33 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller R G, Moore DH 2nd, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, et al</AU>
<TI>Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>56</VL>
<NO>7</NO>
<PG>843-8</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:48:33 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:48:33 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11294919"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Norris-1979" MODIFIED="2011-02-14 15:49:21 +0000" MODIFIED_BY="Kate Jewitt" NAME="Norris 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-02-14 15:49:21 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Trial of baclofen in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:49:21 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norris FH Jr, Sang UK, Sachais B, Carey M</AU>
<TI>Trial of baclofen in amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1979</YR>
<VL>36</VL>
<NO>11</NO>
<PG>715-6</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:49:21 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:49:21 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="508132"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Rosenfeld-2008" MODIFIED="2011-02-14 15:50:25 +0000" MODIFIED_BY="Kate Jewitt" NAME="Rosenfeld 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-14 15:50:25 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;OctMulticenter Study&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, N.I.H., Extramural&lt;br&gt;Research Support, Non-U.S. Gov't18608103&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:50:25 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn R, Dick A, et al</AU>
<TI>Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>5</NO>
<PG>266-72</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:50:25 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:50:25 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE=" 18608103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Scelsa-2005" MODIFIED="2011-02-14 15:50:58 +0000" MODIFIED_BY="Kate Jewitt" NAME="Scelsa 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-14 15:50:58 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;12A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:50:58 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scelsa SN, MacGowan DJL, Mitsumoto H, Imperato T, LeValley AJ, Liu MH, et al</AU>
<TI>A pilot, double-blind, placebo-controlled trial of indinavir in patients with ALS</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>7</NO>
<PG>1298-300</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:50:50 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:50:50 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15824372"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Weber-2010" MODIFIED="2011-02-14 15:51:53 +0000" MODIFIED_BY="Kate Jewitt" NAME="Weber 2010" YEAR="2009">
<REFERENCE MODIFIED="2011-02-14 15:51:53 +0000" MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weber M, Goldman B, Truniger S</AU>
<TI>Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>2010</YR>
<VL>81</VL>
<NO>10</NO>
<PG>1135-40</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:51:53 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:51:53 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="20498181"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-03-14 10:02:58 +0000" MODIFIED_BY="Ruth Brassington">
<STUDY DATA_SOURCE="PUB" ID="STD-Aggarwal-2010" MODIFIED="2012-03-13 20:20:30 +0000" MODIFIED_BY="Reto Baldinger" NAME="Aggarwal 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-13 20:20:30 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Aggarwal SP, Zinman L, Simpson E, McKinley J, Jackson KE, Pinto H, et al</AU>
<TI>Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>5</NO>
<PG>481-8</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00742644"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aisen-1995" MODIFIED="2011-02-14 15:52:16 +0000" MODIFIED_BY="Kate Jewitt" NAME="Aisen 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-14 15:52:16 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;3,4-Diaminopyridine as a treatment for amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:52:16 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aisen ML, Sevilla D, Gibson G, Kutt H, Blau A, Edelstein L, et al</AU>
<TI>3,4-Diaminopyridine as a treatment for amyotrophic lateral sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1995</YR>
<VL>129</VL>
<NO>1</NO>
<PG>21-4</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:52:15 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:52:15 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8791245"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aksu-2002" MODIFIED="2010-01-19 12:12:53 +0000" MODIFIED_BY="[Empty name]" NAME="Aksu 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-19 12:12:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DecThe effects of exercise therapy in amyotrophic lateral sclerosis patients&lt;/p&gt;" NOTES_MODIFIED="2010-01-19 12:12:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aksu S, Karaduman A, Yakut Y, Tan E</AU>
<TI>The effects of exercise therapy in amyotrophic lateral sclerosis patients</TI>
<SO>Fizyoterapi Rehabilitasyon</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>3</NO>
<PG>105-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aksu-2002a" MODIFIED="2010-01-19 12:13:46 +0000" MODIFIED_BY="[Empty name]" NAME="Aksu 2002a" YEAR="2002">
<REFERENCE MODIFIED="2010-01-19 12:13:46 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CN-00419466&lt;/p&gt;" NOTES_MODIFIED="2010-01-19 12:13:46 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Aksu S, Kurne A, Tan E</AU>
<TI>The effects of exercises on fatigue and muscle cramp in amyotrophic lateral sclerosis</TI>
<SO>3rd World Congress in Neurological Rehabilitation; 2002 April 2-6; Venice</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ALSCNTF-1996" MODIFIED="2011-02-14 15:52:54 +0000" MODIFIED_BY="Kate Jewitt" NAME="ALSCNTF 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-14 15:52:54 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00124548Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;s.c. not oral&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:52:54 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ALSCNTF (Brooks et al.)</AU>
<TI>A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>5</VL>
<NO>4</NO>
<PG>1244-9</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:52:53 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:52:53 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8628460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apostolski-1998" MODIFIED="2012-03-13 20:19:10 +0000" MODIFIED_BY="Kate Jewitt" NAME="Apostolski 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-03-13 20:19:10 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00154498Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:19:10 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Apostolski S, Marinkovi&#263; Z, Nikoli&#263; A, Blagojevi&#263; D, Spasi&#263; MB, Michelson AM</AU>
<TI>Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation</TI>
<SO>Journal of Environmental Pathology, Toxicology and Oncology</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>3-4</NO>
<PG>325-9</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:53:32 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:53:32 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9726810"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Appel-1988" MODIFIED="2011-02-14 15:53:44 +0000" MODIFIED_BY="Kate Jewitt" NAME="Appel 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-02-14 15:53:44 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:53:44 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Appel SH, Stewart SS, Appel V, Harati Y, Mietlowski W, Weiss W, et al</AU>
<TI>A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1988</YR>
<VL>45</VL>
<NO>4</NO>
<PG>381-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aquilonius-1986" MODIFIED="2011-02-14 15:54:15 +0000" MODIFIED_BY="Kate Jewitt" NAME="Aquilonius 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-14 15:54:15 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:54:15 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aquilonius SM, Askmark H, Eckernas SA</AU>
<TI>Cholinesterase inhibitors lack therapeutic effect in amyotrophic lateral sclerosis. A controlled study of physostigmine versus neostigmine</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1986</YR>
<VL>73</VL>
<NO>6</NO>
<PG>628-32</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:54:15 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:54:15 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3529799"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Armon-1997" MODIFIED="2012-03-13 00:34:30 +0000" MODIFIED_BY="Kate Jewitt" NAME="Armon 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-03-13 00:34:30 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00138246Clinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 00:34:30 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Armon C, Brandstater M E, Peterson G W</AU>
<TI>Motor unit number estimates and quantitative muscle strength measurements of distal muscles in patients with amyotrophic lateral sclerosis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1997</YR>
<NO>4</NO>
<PG>499-501</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:54:36 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:54:36 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9121509"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Askmark-1993" MODIFIED="2011-02-14 15:55:16 +0000" MODIFIED_BY="Kate Jewitt" NAME="Askmark 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-14 15:55:16 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A pilot trial of dextromethorphan in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:55:16 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Askmark H, Aquilonius SM, Gillberg PG, Liedholm LJ, Stalberg E, Wuopio R</AU>
<TI>A pilot trial of dextromethorphan in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1993</YR>
<VL>56</VL>
<NO>2</NO>
<PG>197-200</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:55:16 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:55:16 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8437010"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-BDNF-1999" MODIFIED="2011-04-16 20:21:32 +0100" MODIFIED_BY="Reto Baldinger" NAME="BDNF 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-04-16 20:21:32 +0100" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;22A controlled trial of recombinant methionyl human BDNF in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-04-16 20:21:32 +0100" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The BDNF Study Group</AU>
<TI>A controlled trial of recombinant methionyl human BDNF in ALS</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>7</NO>
<PG>1427-33</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:13:52 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:13:52 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10227630"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beghi-1993" MODIFIED="2011-02-14 15:55:57 +0000" MODIFIED_BY="Kate Jewitt" NAME="Beghi 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-14 15:55:57 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure?&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 15:55:57 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beghi E, Fiordelli E, Mora G, Mazzini L, Poloni M, Pinelli P, et al</AU>
<TI>Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure? The Italian ALS Study Group</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>12</NO>
<PG>2466-70</PG>
<IDENTIFIERS MODIFIED="2011-02-14 15:55:43 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:55:43 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8255440"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beghi-2000" MODIFIED="2011-02-14 16:07:31 +0000" MODIFIED_BY="Kate Jewitt" NAME="Beghi 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-02-14 16:07:31 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;25A randomized controlled trial of recombinant interferon beta-1a in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:07:31 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beghi E, Chio A, Inghilleri M, Mazzini L, Micheli A, Mora G, et al</AU>
<TI>A randomized controlled trial of recombinant interferon beta-1a in ALS</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>2</NO>
<PG>469-74</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:07:31 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:07:31 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10668716"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bello_x002d_Haas-2007" MODIFIED="2011-02-14 16:08:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bello-Haas 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-14 16:08:38 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;JunA randomized controlled trial of resistance exercise in individuals with ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:08:38 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bello-Haas VD, Florence JM, Kloos AD, Scheirbecker J, Lopate G, Hayes SM, et al</AU>
<TI>A randomized controlled trial of resistance exercise in individuals with ALS</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>23</NO>
<PG>2003-7</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:08:38 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:08:38 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="17548549"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berto-2007" MODIFIED="2011-02-14 16:09:27 +0000" MODIFIED_BY="Kate Jewitt" NAME="Berto 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-14 16:09:27 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MayAcute action of aminophylline in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:09:27 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berto MC, Filha SC, Camelier A, Rosa FW, de Souza Bulle Oliveira A, Jardim JR</AU>
<TI>Acute action of aminophylline in patients with amyotrophic lateral sclerosis</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2007</YR>
<VL>115</VL>
<NO>5</NO>
<PG>301-5</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:09:27 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:09:27 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="17489939"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Biletch-1989" MODIFIED="2011-02-14 16:09:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Biletch 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-02-14 16:09:38 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Increased fiber density after subcutaneous TRH in amyotrophic lateral sclerosis (ALS) patients. A placebo and low-dose controlled study&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:09:38 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Biletch M, Eichman P, Sufit R, Turner J, Brooks BR</AU>
<TI>Increased fiber density after subcutaneous TRH in amyotrophic lateral sclerosis (ALS) patients. A placebo and low-dose controlled study</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>1989</YR>
<VL>553</VL>
<PG>614-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blin-1991" MODIFIED="2011-02-14 16:10:26 +0000" MODIFIED_BY="Kate Jewitt" NAME="Blin 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-02-14 16:10:26 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00228028&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:10:26 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Blin O, Desnuelle C, Guelton C, Aubrespy G, Ardissone JP, Crevat A et al</AU>
<TI>[Anomaly in the neurotransmitter amino acids in amyotrophic lateral sclerosis: a therapeutic application]</TI>
<SO>Revue Neurologique</SO>
<YR>1991</YR>
<VL>147</VL>
<NO>5</NO>
<PG>392-4</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:10:26 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:10:26 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="1677212"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blin-1996" MODIFIED="2011-02-14 16:10:54 +0000" MODIFIED_BY="Kate Jewitt" NAME="Blin 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-14 16:10:54 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:10:54 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blin O, Azulay JP, Desnuelle C, Bille-Turc F, Braguer D, Besse D, et al</AU>
<TI>A controlled one-year trial of dextromethorphan in amyotrophic lateral sclerosis</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>2</NO>
<PG>189-92</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:10:52 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:10:52 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8777774"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borasio-1996" MODIFIED="2012-03-13 20:20:57 +0000" MODIFIED_BY="Reto Baldinger" NAME="Borasio 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-03-13 20:20:57 +0000" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;CN-00227862&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:20:57 +0000" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Borasio GD, De Jong JM, Emile J, Guiloff R, Jerusalem F, Leigh N, et al</AU>
<TI>Insulin-like growth factor I in the treatment of amyotrophic lateral sclerosis: results of the European multicentre, double blind, placebo controlled trial</TI>
<SO>Journal of Neurology</SO>
<YR>1996</YR>
<VL>243</VL>
<PG>S26</PG>
<IDENTIFIERS MODIFIED="2012-03-12 22:45:14 +0000" MODIFIED_BY="Reto Baldinger"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Borasio-1998" MODIFIED="2011-02-14 16:12:06 +0000" MODIFIED_BY="Kate Jewitt" NAME="Borasio 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-14 16:12:06 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;AugA placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:12:06 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F, et al</AU>
<TI>A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>2</NO>
<PG>583-6</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:12:06 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:12:06 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9710040"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bourke-2006" MODIFIED="2011-02-14 16:12:37 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bourke 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-14 16:12:37 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;FebEffects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomised controlled trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:12:37 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ</AU>
<TI>Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomised controlled trial</TI>
<SO>Lancet Neurology</SO>
<YR>2006</YR>
<VL>5</VL>
<NO>2</NO>
<PG>140-7</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:12:37 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:12:37 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16426990"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradley-1984" MODIFIED="2011-02-14 16:13:02 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bradley 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-02-14 16:13:02 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:13:02 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley WG, Hedlund W, Cooper C</AU>
<TI>A double-blind controlled trial of bovine brain gangliosides in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>8</NO>
<PG>1079-82</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:13:02 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:13:02 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="6379506"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brody-1974" MODIFIED="2011-02-14 16:14:35 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brody 1974" YEAR="1974">
<REFERENCE MODIFIED="2011-02-14 16:14:35 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00009936Clinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:14:35 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Brody JA, Chen KM, Yase Y, Holden EM, Morris CE</AU>
<TI>Inosiplex and amyotrophic lateral sclerosis. Therapeutic trial in patients on Guam</TI>
<SO>Archives of Neurology</SO>
<YR>1974</YR>
<NO>4</NO>
<PG>322-3</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:14:35 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:14:35 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="4593550"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooke-1986" MODIFIED="2011-02-14 16:20:10 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brooke 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-14 16:20:10 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:20:10 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooke MH, Florence JM, Heller SL</AU>
<TI>Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<NO>2</NO>
<PG>146-51</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:20:10 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:20:10 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3080694"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-1985" MODIFIED="2011-04-03 15:56:46 +0100" MODIFIED_BY="Reto Baldinger" NAME="Brooks 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-04-03 15:56:46 +0100" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;CN-00227958&lt;/p&gt;" NOTES_MODIFIED="2011-04-03 15:56:46 +0100" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Brooks BR, Sufit RL, Beaulieu DA, Erickson LM, Montgomery GK, Peters HA, et al</AU>
<TI>Intravenous (10 mg/kg) thyrotropin releasing hormone (TRH) administration in amyotrophic lateral sclerosis (ALS): decreased loss of muscle strength in TRH-treated patients during parallel-placebo controlled pilot study</TI>
<SO>Journal of Neurology</SO>
<YR>1985</YR>
<VL>232</VL>
<PG>264</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-1987" MODIFIED="2011-02-14 16:21:28 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brooks 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-02-14 16:21:28 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:21:28 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR, Sufit RL, Montgomery GK</AU>
<TI>Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies</TI>
<SO>Neurologic Clinics</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>1</NO>
<PG>143-58</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:21:28 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:21:28 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3104750"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-1995" MODIFIED="2010-01-19 12:27:17 +0000" MODIFIED_BY="[Empty name]" NAME="Brooks 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-01-19 12:27:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CN-00271617&lt;/p&gt;" NOTES_MODIFIED="2010-01-19 12:27:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Brooks B R, Madison W I</AU>
<TI>Phase II-III double blind, placebo controlled clinical trial of subcutaneous administration of recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<NO>Suppl 4</NO>
<PG>A448</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brooks-2001" MODIFIED="2012-03-13 20:22:09 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brooks 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-03-13 20:22:09 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00387114&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:22:09 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Brooks BR, Sanjak M, Belden DS, Roelke KA, Parnell JH</AU>
<TI>Delayed early loss of arm computerized isometric muscle strength (CIMS) in amyotrophic lateral sclerosis (ALS): a randomized, placebo-controlled ancillary study to the phase 3 clinical trials of SR57746A-xaliproden in patients treated and not-treated with riluzole conducted by the SR57746A-Xaliproden International ALS Study Group</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<NO>8 Suppl 3</NO>
<PG>A156</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caroscio-1986" MODIFIED="2011-02-14 16:22:59 +0000" MODIFIED_BY="Kate Jewitt" NAME="Caroscio 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-14 16:22:59 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:22:59 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caroscio JT, Cohen JA, Zawodniak J, Takai V, Shapiro A, Blaustein S et al</AU>
<TI>A double-blind, placebo-controlled trial of TRH in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<NO>2</NO>
<PG>141-5</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:22:39 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:22:39 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3080693"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carter-2005" MODIFIED="2012-03-13 20:22:41 +0000" MODIFIED_BY="Kate Jewitt" NAME="Carter 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-03-13 20:22:41 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:22:41 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carter GT, Weiss MD, Lou JS, Jensen MP, Abresch RT, Martin TK, et al</AU>
<TI>Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study</TI>
<SO>The American Journal of Hospice &amp; Palliative Care</SO>
<YR>2005</YR>
<VL>22</VL>
<NO>1</NO>
<PG>55-9</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:24:13 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:24:13 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15736608"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cedarbaum-1997" MODIFIED="2011-02-14 16:28:21 +0000" MODIFIED_BY="Kate Jewitt" NAME="Cedarbaum 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-14 16:28:21 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;01Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:28:21 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cedarbaum JM, Stambler N</AU>
<TI>Performance of the amyotrophic lateral sclerosis functional rating scale (ALSFRS) in multicenter clinical trials</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1997</YR>
<VL>152</VL>
<NO>SUPPL. 1</NO>
<PG>S1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chi_x00f2_-1998" MODIFIED="2011-02-14 16:28:56 +0000" MODIFIED_BY="Kate Jewitt" NAME="Chiò 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-14 16:28:56 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00298816Clinical Trial; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:28:56 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Chiò A, Cucatto A, Terreni AA, Schiffer D</AU>
<TI>Reduced glutathione in amyotrophic lateral sclerosis: an open, crossover, randomized trial</TI>
<SO>Italian Journal of Neurological Sciences</SO>
<YR>1998</YR>
<NO>6</NO>
<PG>363-6</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:28:56 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:28:56 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10935831"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Civardi-1994" MODIFIED="2011-02-14 16:29:21 +0000" MODIFIED_BY="Kate Jewitt" NAME="Civardi 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-14 16:29:21 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Protirelin tartrate (TRH-T) in upper motoneuron syndrome: A controlled neurophysiological and clinical study&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:29:21 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Civardi C, Naldi P, Cantello R, Gianelli M, Mutani R</AU>
<TI>Protirelin tartrate (TRH-T) in upper motoneuron syndrome: A controlled neurophysiological and clinical study</TI>
<SO>Italian Journal of Neurological Sciences</SO>
<YR>1994</YR>
<VL>15</VL>
<NO>8</NO>
<PG>395-406</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:29:21 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:29:21 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7875957"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Conrad-1985" MODIFIED="2010-12-15 13:36:34 +0000" MODIFIED_BY="Reto Baldinger" NAME="Conrad 1985" YEAR="1985">
<REFERENCE MODIFIED="2010-12-15 13:36:34 +0000" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;CN-00444897&lt;/p&gt;" NOTES_MODIFIED="2010-12-15 13:36:34 +0000" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Conrad J, Clough J, Sufit R L, Brooks B R</AU>
<TI>Isokinetic Assessment of muscle torque in amyotrophic lateral sclerosis (ALS) patients after administration of saline and thyrotropin-releasing hormone (trh)</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<NO>4</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cudkowicz-2003" MODIFIED="2011-02-14 16:30:22 +0000" MODIFIED_BY="Kate Jewitt" NAME="Cudkowicz 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-14 16:30:22 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;26A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:30:22 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cudkowicz ME, Shefner JM, Schoenfeld DA, Brown RH Jr, Johnson H, Qureshi M, et al</AU>
<TI>A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>4</NO>
<PG>456-64</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:30:22 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:30:22 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="18551622"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cudkowicz-2006" MODIFIED="2009-12-23 17:00:24 +0000" MODIFIED_BY="[Empty name]" NAME="Cudkowicz 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-12-23 17:00:24 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;JulTrial of celecoxib in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2009-12-23 17:00:24 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cudkowicz M E, Shefner J M, Schoenfeld D A, Zhang H, Andreasson K I, Rothstein J D, et al</AU>
<TI>Trial of celecoxib in amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2006</YR>
<VL>60</VL>
<NO>1</NO>
<PG>22-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cudkowicz-2008" MODIFIED="2012-03-13 00:36:10 +0000" MODIFIED_BY="[Empty name]" NAME="Cudkowicz 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-03-13 00:36:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;JulyArimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 00:36:10 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cudkowicz M E, Shefner J M, Simpson E, Grasso D, Yu H, Zhang H, et al</AU>
<TI>Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2008</YR>
<VL>38</VL>
<NO>1</NO>
<PG>837-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Desai-1998" MODIFIED="2011-02-14 16:30:44 +0000" MODIFIED_BY="Kate Jewitt" NAME="Desai 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-14 16:30:44 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;01Riluzole has no acute effect on motor unit parameters in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:30:44 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Desai J, Sharief M, Swash M</AU>
<TI>Riluzole has no acute effect on motor unit parameters in ALS</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1998</YR>
<VL>160</VL>
<NO>SUPPL. 1</NO>
<PG>S69-72</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:30:44 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:30:44 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9851653"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Di-2006" MODIFIED="2011-02-14 16:31:06 +0000" MODIFIED_BY="Kate Jewitt" NAME="Di 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-14 16:31:06 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;13Repetitive transcranial magnetic stimulation for ALS. A preliminary controlled study&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:31:06 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Lazzaro V, Dileone M, Pilato F, Profice P, Ranieri F, Musumeci G, et al</AU>
<TI>Repetitive transcranial magnetic stimulation for ALS. A preliminary controlled study</TI>
<SO>Neuroscience Letters</SO>
<YR>2006</YR>
<VL>408</VL>
<NO>2</NO>
<PG>135-40</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:31:06 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:31:06 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16979292"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drachman-1994" MODIFIED="2011-02-14 16:31:34 +0000" MODIFIED_BY="Kate Jewitt" NAME="Drachman 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-14 16:31:34 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;FebTrial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:31:34 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drachman DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk A, Clawson L, et al</AU>
<TI>Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation</TI>
<SO>Annals of Neurology</SO>
<YR>1994</YR>
<VL>35</VL>
<NO>2</NO>
<PG>142-50</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:31:34 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:31:34 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8109895"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drory-2001" MODIFIED="2011-02-14 16:33:48 +0000" MODIFIED_BY="Kate Jewitt" NAME="Drory 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-14 16:33:48 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;15The value of muscle exercise in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:33:48 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drory V E, Goltsman E, Reznik JG, Mosek A, Korczyn AD</AU>
<TI>The value of muscle exercise in patients with amyotrophic lateral sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>133-7</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:33:48 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:33:48 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11677004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drory-2002" MODIFIED="2012-03-13 20:23:12 +0000" MODIFIED_BY="Kate Jewitt" NAME="Drory 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-03-13 20:23:12 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00408877Clinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:23:12 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Drory VE, Gross D</AU>
<TI>No effect of creatine on respiratory distress in amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>1</NO>
<PG>43-6</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:34:22 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:34:22 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="12061948"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eckland-1986" MODIFIED="2011-04-03 16:04:19 +0100" MODIFIED_BY="Reto Baldinger" NAME="Eckland 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-04-03 16:04:19 +0100" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;CN-00257588&lt;/p&gt;" NOTES_MODIFIED="2011-04-03 16:04:19 +0100" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Eckland DJ, Lightman S, Nagendaen K, Guiloff R</AU>
<TI>The endocrine manifestations of high doses of a thyrotrophin releasing hormone (TRH) analogue, RX77368, in patients with motor neurone disease (MND) [abstract]</TI>
<SO>Clinical Science</SO>
<YR>1986</YR>
<VL>70</VL>
<NO>13</NO>
<PG>15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eisen-1993" MODIFIED="2011-02-14 16:34:52 +0000" MODIFIED_BY="Kate Jewitt" NAME="Eisen 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-14 16:34:52 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Anti-glutamate therapy in amyotrophic lateral sclerosis: A trial using lamotrigine&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:34:52 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eisen A, Stewart H, Schulzer M, Cameron D</AU>
<TI>Anti-glutamate therapy in amyotrophic lateral sclerosis: A trial using lamotrigine</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1993</YR>
<VL>20</VL>
<NO>4</NO>
<PG>297-301</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:34:52 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:34:52 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7906190"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ellis-1997" MODIFIED="2011-02-14 16:35:29 +0000" MODIFIED_BY="Kate Jewitt" NAME="Ellis 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-14 16:35:29 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00227770&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:35:29 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Ellis T, Cudkowicz ME, McKenna-Yasek D, Eggelston PM, Brown RH, Cros D</AU>
<TI>Combination antioxidant therapy in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<NO>3</NO>
<PG>A127</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fareed-1971" MODIFIED="2011-02-14 16:35:55 +0000" MODIFIED_BY="Kate Jewitt" NAME="Fareed 1971" YEAR="1971">
<REFERENCE MODIFIED="2011-02-14 16:35:55 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00006202Clinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:35:55 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Fareed GC, Tyler HR</AU>
<TI>The use of isoprinosine in patients with amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1971</YR>
<NO>9</NO>
<PG>937-40</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:35:55 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:35:55 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="4936827"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farkkila-1990" MODIFIED="2011-02-14 16:36:20 +0000" MODIFIED_BY="Kate Jewitt" NAME="Farkkila 1990" YEAR="1990">
<REFERENCE MODIFIED="2011-02-14 16:36:20 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Disturbance of the water and electrolyte balance during high-dose interferon treatment&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:36:20 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farkkila AM, Iivanainen MV, Farkkila MA</AU>
<TI>Disturbance of the water and electrolyte balance during high-dose interferon treatment</TI>
<SO>Journal of Interferon Research</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>2</NO>
<PG>221-7</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:36:20 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:36:20 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2341751"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farkkila-1996" MODIFIED="2010-12-15 20:41:15 +0000" MODIFIED_BY="Reto Baldinger" NAME="Farkkila 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-12-15 20:41:15 +0000" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;High-dose alpha-interferon treatment in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2010-12-15 20:41:15 +0000" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farkkila M, Laaksovirta H, Hokkanen L, Cantell K</AU>
<TI>High-dose alpha-interferon treatment in amyotrophic lateral sclerosis</TI>
<SO>Botechnologia Aplicada</SO>
<YR>1996</YR>
<VL>13</VL>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Finsterer-1999" MODIFIED="2011-02-14 16:36:47 +0000" MODIFIED_BY="Kate Jewitt" NAME="Finsterer 1999" YEAR="1999">
<REFERENCE MODIFIED="2011-02-14 16:36:47 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Cerebrospinal fluid filtration in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:36:47 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Finsterer J, Mamoli B</AU>
<TI>Cerebrospinal fluid filtration in amyotrophic lateral sclerosis</TI>
<SO>European Journal of Neurology</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>5</NO>
<PG>597-600</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:36:47 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:36:47 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10457394"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Gelinas-2001" MODIFIED="2012-03-13 20:23:51 +0000" MODIFIED_BY="Reto Baldinger" NAME="Gelinas 2001" YEAR="2001">
<REFERENCE MODIFIED="2012-03-13 20:23:51 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Gelinas D, et al</AU>
<TI>Individual patient data (as supplied February 22 2009)</TI>
<SO>Data on file</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goonetilleke-1995" MODIFIED="2011-02-14 16:37:55 +0000" MODIFIED_BY="Kate Jewitt" NAME="Goonetilleke 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-14 16:37:55 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Continuous response variable trial design in motor neuron disease: Long term treatment with a TRH analogue (RX77368)&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:37:55 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goonetilleke A, Guiloff RJ</AU>
<TI>Continuous response variable trial design in motor neuron disease: Long term treatment with a TRH analogue (RX77368)</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1995</YR>
<VL>58</VL>
<NO>2</NO>
<PG>201-8</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:37:55 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:37:55 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7876852"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2004" MODIFIED="2011-02-14 16:38:24 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gordon 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-14 16:38:24 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;25Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:38:24 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J, et al</AU>
<TI>Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1845-7</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:38:24 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:38:24 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15159491"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2006" MODIFIED="2011-02-14 16:38:42 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gordon 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-14 16:38:42 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Early phase trials of minocycline in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:38:42 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon PH, Choi J Moore DH, Miller RG</AU>
<TI>Early phase trials of minocycline in amyotrophic lateral sclerosis</TI>
<SO>Progress in Neurotherapeutics and Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>1</VL>
<NO>1</NO>
<PG>63-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2006a" MODIFIED="2011-02-14 16:39:09 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gordon 2006a" YEAR="2006">
<REFERENCE MODIFIED="2011-02-14 16:39:09 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Randomized controlled trial of glatiramer acetate in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:39:09 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon PH, Doorish C, Montes J, Mosely RL, Diamond B, MacArthur R B, et al</AU>
<TI>Randomized controlled trial of glatiramer acetate in ALS</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<PG>1117-9</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:39:05 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:39:05 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16606934"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2007" MODIFIED="2011-02-14 16:39:48 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gordon 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-14 16:39:48 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;DecEfficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:39:48 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, et al</AU>
<TI>Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial</TI>
<SO>Lancet Neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>12</NO>
<PG>1045-53</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:39:48 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:39:48 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="17980667"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gordon-2008" MODIFIED="2011-02-14 16:40:17 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gordon 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-14 16:40:17 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:40:17 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gordon PH, Cheung YK, Levin B, Andrews H, Doorish C, MacArthur R B, et al</AU>
<TI>A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>4</NO>
<PG>212-22</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:40:17 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:40:17 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="18608093"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graf-2005" MODIFIED="2011-02-14 16:40:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Graf 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-14 16:40:38 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MayHigh dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:40:38 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al</AU>
<TI>High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: Results of a placebo-controlled double-blind study</TI>
<SO>Journal of Neural Transmission</SO>
<YR>2005</YR>
<VL>112</VL>
<NO>5</NO>
<PG>649-60</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:40:38 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:40:38 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15517433"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gredal-1996" MODIFIED="2011-02-14 16:41:06 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gredal 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-14 16:41:06 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00407977&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:41:06 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Gredal O, Werdelin L, Bak S, Christensen PB, Bosen G, Kristenses MO, et al</AU>
<TI>A clinical trial of dextromethorphan in amyotrophic lateral sclerosis [abstract]</TI>
<SO>European Journal of Neurology</SO>
<YR>1996</YR>
<NO>Suppl 5</NO>
<PG>132</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gredal-1997" MODIFIED="2011-02-14 16:42:16 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gredal 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-14 16:42:16 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A clinical trial of dextromethorphan in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:42:16 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gredal O, Werdelin L, Bak S, Christensen PB, Boysen G, Kristensen M O, et al</AU>
<TI>A clinical trial of dextromethorphan in amyotrophic lateral sclerosis</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1997</YR>
<VL>96</VL>
<NO>1</NO>
<PG>8-13</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:42:16 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:42:16 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9262126"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Groeneveld-2005" MODIFIED="2011-02-14 16:43:23 +0000" MODIFIED_BY="Kate Jewitt" NAME="Groeneveld 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-14 16:43:23 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MayFew adverse effects of long-term creatine supplementation in a placebo-controlled trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:43:23 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Groeneveld GJ, Beijer C, Veldink JH, Kalmijn S, Wokke JHJ, Van Den Berg LH</AU>
<TI>Few adverse effects of long-term creatine supplementation in a placebo-controlled trial</TI>
<SO>International Journal of Sports Medicine</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>4</NO>
<PG>307-13</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:43:23 +0000" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guiloff-1987" MODIFIED="2011-02-14 16:43:16 +0000" MODIFIED_BY="Kate Jewitt" NAME="Guiloff 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-02-14 16:43:16 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:43:16 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guiloff RJ, Eckland DJA, Demaine C, Hoare RC, Macrae KD, Lightman SL</AU>
<TI>Controlled acute trial of a thyrotrophin releasing hormone analogue (RX77368) in motor neuron disease</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1987</YR>
<VL>50</VL>
<NO>10</NO>
<PG>1359-70</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:43:03 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:43:03 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3119776"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Guiloff-1987a" MODIFIED="2011-02-14 16:43:43 +0000" MODIFIED_BY="Kate Jewitt" NAME="Guiloff 1987a" YEAR="1987">
<REFERENCE MODIFIED="2011-02-14 16:43:43 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00317387&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:43:43 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Guiloff RJ, Stalberg E, Eckland DJ, Lightman SL</AU>
<TI>Electrophysiological observations in patients with motor neuron disease receiving a thyrotropin releasing hormone analogue (RX77368)</TI>
<SO>Journal of Neurology, Neurosurgery &amp; Psychiatry</SO>
<YR>1987</YR>
<PG>1633-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hallett-1984" MODIFIED="2011-02-14 16:44:13 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hallett 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-02-14 16:44:13 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00035011Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:44:13 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Hallett M, Harrington H, Tyler HR, Flood T, Slater N</AU>
<TI>Trials of ganglioside therapy for amyotrophic lateral sclerosis and diabetic neuropathy</TI>
<SO>Advances in Experimental Medicine and Biology</SO>
<YR>1984</YR>
<PG>575-9</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:44:13 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:44:13 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="6377851"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harrington-1984" MODIFIED="2011-02-14 16:44:36 +0000" MODIFIED_BY="Kate Jewitt" NAME="Harrington 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-02-14 16:44:36 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Ganglioside therapy for amyotrophic lateral sclerosis: A double-blind controlled trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:44:36 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harrington H, Hallett M, Tyler HR</AU>
<TI>Ganglioside therapy for amyotrophic lateral sclerosis: A double-blind controlled trial</TI>
<SO>Neurology</SO>
<YR>1984</YR>
<VL>34</VL>
<NO>8</NO>
<PG>1083-5</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:44:34 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:44:34 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="6379507"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hawley-1987" MODIFIED="2011-02-14 16:45:05 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hawley 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-02-14 16:45:05 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:45:05 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hawley RJ, Kratz R, Goodman RR</AU>
<TI>Treatment of amyotrophic lateral sclerosis with the TRH analog DN-1417</TI>
<SO>Neurology</SO>
<YR>1987</YR>
<VL>37</VL>
<NO>4</NO>
<PG>715-7</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:45:05 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:45:05 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3104820"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hesselmans-1993" MODIFIED="2011-02-14 16:45:49 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hesselmans 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-14 16:45:49 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:45:49 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hesselmans LFGM, Wieneke GH, Oey PL, Groenhout DM, van der Graaf Y, Gispen WH, et al</AU>
<TI>Evaluation of electrophysiological and clinical tests in an exploratory trial of Org 2766 in motor neuron disease</TI>
<SO>Neuromuscular Disorders</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>4</NO>
<PG>319-25</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:45:47 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:45:47 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8268729"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hoagland-1997" MODIFIED="2012-03-13 00:35:15 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hoagland 1997" YEAR="1997">
<REFERENCE MODIFIED="2012-03-13 00:35:15 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00139523Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 00:35:15 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Hoagland RJ, Mendoza M, Armon C, Barohn RJ, Bryan WW, Goodpasture JC, et al</AU>
<TI>Reliability of maximal voluntary isometric contraction testing in a multicenter study of patients with amyotrophic lateral sclerosis. Syntex/Synergen Neuroscience Joint Venture rhCNTF ALS Study Group</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1997</YR>
<NO>6</NO>
<PG>691-5</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:46:32 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:46:32 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9149075"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hubbard-1992" MODIFIED="2011-02-14 16:47:03 +0000" MODIFIED_BY="Kate Jewitt" NAME="Hubbard 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-02-14 16:47:03 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Elevated plasma glucagon in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:47:03 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hubbard RW, Will AD, Peterson GW, Sanchez A, Gillan WW, Tan SA</AU>
<TI>Elevated plasma glucagon in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>8</NO>
<PG>1532-4</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:46:53 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:46:53 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="1641148"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Imoto-1984" MODIFIED="2011-02-14 16:47:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Imoto 1984" YEAR="1984">
<REFERENCE MODIFIED="2011-02-14 16:47:38 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Amyotrophic lateral sclerosis: A double-blind crossover trial of thyrotropin-releasing hormone&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:47:38 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Imoto K, Saida K, Iwamura K</AU>
<TI>Amyotrophic lateral sclerosis: A double-blind crossover trial of thyrotropin-releasing hormone</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1984</YR>
<VL>47</VL>
<NO>12</NO>
<PG>1332-4</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:47:38 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:47:38 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="6439824"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jackson-2001" MODIFIED="2011-02-14 16:48:07 +0000" MODIFIED_BY="Kate Jewitt" NAME="Jackson 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-02-14 16:48:07 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;15A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:48:07 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jackson CE, Rosenfeld J, Moore DH, Bryan WW, Barohn RJ, Wrench M, et al</AU>
<TI>A preliminary evaluation of a prospective study of pulmonary function studies and symptoms of hypoventilation in ALS/MND patients</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2001</YR>
<VL>191</VL>
<NO>1-2</NO>
<PG>75-8</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:48:07 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:48:07 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11676995"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janik-1996" MODIFIED="2009-12-23 17:00:24 +0000" MODIFIED_BY="[Empty name]" NAME="Janik 1996" YEAR="1996">
<REFERENCE MODIFIED="2009-12-23 17:00:24 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CN-00227824&lt;/p&gt;" NOTES_MODIFIED="2009-12-23 17:00:24 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Janik P, Kwiecinski H, Jamrozik Z, Czyzewski K, Opuchlik A</AU>
<TI>A randomised trial of antioxidative therapy in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1996</YR>
<PG>S25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jossan-1994" MODIFIED="2011-02-14 16:48:33 +0000" MODIFIED_BY="Kate Jewitt" NAME="Jossan 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-14 16:48:33 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:48:33 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jossan SS, Ekblom J, Gudjonsson O, Hagbarth KE, Aquilonius SM</AU>
<TI>Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neural Transmission, Supplement</SO>
<YR>1994</YR>
<VL>41</VL>
<PG>237-41</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:48:33 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:48:33 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7931231"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaji-1998" MODIFIED="2012-03-13 00:35:33 +0000" MODIFIED_BY="Kate Jewitt" NAME="Kaji 1998" YEAR="1998">
<REFERENCE MODIFIED="2012-03-13 00:35:33 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: A double-blind controlled study&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 00:35:33 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaji R, Kodama M, Imamura A, Hashida T, Kohara N, Ishizu M, et al</AU>
<TI>Effect of ultrahigh-dose methylcobalamin on compound muscle action potentials in amyotrophic lateral sclerosis: a double-blind controlled study</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1998</YR>
<VL>21</VL>
<NO>12</NO>
<PG>1775-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kalra-2003" MODIFIED="2011-02-14 16:49:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Kalra 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-14 16:49:38 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;AprA prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: Feasibility and results&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:49:38 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kalra S, Genge A, Arnold DL</AU>
<TI>A prospective, randomized, placebo-controlled evaluation of corticoneuronal response to intrathecal BDNF therapy in ALS using magnetic resonance spectroscopy: feasibility and results</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>1</NO>
<PG>22-6</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:49:36 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:49:36 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="12745614"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karageorgiou-2004" MODIFIED="2010-01-19 12:37:00 +0000" MODIFIED_BY="[Empty name]" NAME="Karageorgiou 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-19 12:37:00 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;A comparative study of the i.v. Ig therapeutic effect in the course of ALS&lt;/p&gt;" NOTES_MODIFIED="2010-01-19 12:37:00 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karageorgiou C E, Korakaki D, Sakkou V, Giannoulis C, Karageorgiou E</AU>
<TI>A comparative study of the i.v. Ig therapeutic effect in the course of ALS</TI>
<SO>European Journal of Neurology</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>Suppl 2</NO>
<PG>144</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaufmann-2009" MODIFIED="2012-03-14 10:02:58 +0000" MODIFIED_BY="Reto Baldinger" NAME="Kaufmann 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-14 10:02:58 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al</AU>
<TI>Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III</TI>
<SO>Annals of Neurology</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>2</NO>
<PG>235-44</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00722838"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelly-2008" MODIFIED="2010-02-23 13:48:47 +0000" MODIFIED_BY="[Empty name]" NAME="Kelly 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-02-23 13:48:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17Failure of a minocycline trial in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2010-02-23 13:48:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelly J S</AU>
<TI>Failure of a minocycline trial in patients with amyotrophic lateral sclerosis</TI>
<SO>Journal of the Royal College of Physicians of Edinburgh</SO>
<YR>2008</YR>
<VL>38</VL>
<NO>1</NO>
<PG>35-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kodama-2000" MODIFIED="2011-02-14 16:50:00 +0000" MODIFIED_BY="Kate Jewitt" NAME="Kodama 2000" YEAR="2000">
<REFERENCE MODIFIED="2011-02-14 16:50:00 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00295211&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:50:00 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Kodama M, Kaji R, Kohara N, Imamura A, Inui K, Kimura J, et al</AU>
<TI>Double-blind controlled crossover trial of ultra-high dose methylcobalamin for amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<NO>Suppl 3</NO>
<PG>A255</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kwiecinski-2001" MODIFIED="2011-07-20 19:54:12 +0100" MODIFIED_BY="Ruth Brassington" NAME="Kwiecinski 2001" YEAR="2001">
<REFERENCE MODIFIED="2011-07-20 19:54:12 +0100" MODIFIED_BY="Ruth Brassington" NOTES="&lt;p&gt;CN-00375901Clinical Trial; English Abstract; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-07-20 19:54:12 +0100" NOTES_MODIFIED_BY="Ruth Brassington" PRIMARY="NO" TYPE="OTHER">
<AU>Kwiecinski H, Janik P, Jamrozik Z, Opuchlik A</AU>
<TI>[The effect of selegiline and vitamin E in the treatment of ALS: an open randomized clinical trials]</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>2001</YR>
<NO>1 Suppl</NO>
<PG>101-6</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:50:26 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:50:26 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11732275"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacomblez-1989" MODIFIED="2010-02-23 13:48:51 +0000" MODIFIED_BY="[Empty name]" NAME="Lacomblez 1989" YEAR="1989">
<REFERENCE MODIFIED="2010-02-23 13:48:51 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;CN-00307217&lt;/p&gt;" NOTES_MODIFIED="2010-02-23 13:48:51 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lacomblez L, Bensimon G, Bouche P, Meininger V</AU>
<TI>Ganglioside therapy for amyotrophic lateral sclerosis: a double-blind controlled trial</TI>
<SO>Fundamental &amp; Clinical Pharmacology</SO>
<YR>1989</YR>
<NO>4</NO>
<PG>467</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacomblez-1989a" MODIFIED="2011-02-14 16:50:48 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lacomblez 1989a" YEAR="1989">
<REFERENCE MODIFIED="2011-02-14 16:50:48 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:50:48 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacomblez L, Bouche P, Bensimon G, Meininger V</AU>
<TI>A double-blind, placebo-controlled trial of high doses of gangliosides in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39</VL>
<NO>12</NO>
<PG>1635-7</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:50:48 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:50:48 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2685660"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacomblez-2002" MODIFIED="2011-02-14 16:51:16 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lacomblez 2002" YEAR="2002">
<REFERENCE MODIFIED="2011-02-14 16:51:16 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Long-term safety of riluzole in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:51:16 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacomblez L, Bensimon G, Leigh PN, Debove C, Bejuit P, Truffinet P, et al</AU>
<TI>Long-term safety of riluzole in amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2002</YR>
<VL>3</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:51:16 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:51:16 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="12061945"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacomblez-2004" MODIFIED="2011-02-14 16:51:49 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lacomblez 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-14 16:51:49 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;JunXaliproden in amyotrophic lateral sclerosis: Early clinical trials&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:51:49 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacomblez L, Bensimon G, Douillet P, Doppler V, Salachas F, Meininger V</AU>
<TI>Xaliproden in amyotrophic lateral sclerosis: early clinical trials</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>2</NO>
<PG>99-106</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:51:49 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:51:49 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15204011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lai-1997" MODIFIED="2011-02-14 16:52:22 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lai 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-02-14 16:52:22 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;DecEffect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:52:22 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lai EC, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al</AU>
<TI>Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>6</NO>
<PG>1621-30</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:52:22 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:52:22 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9409357"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange-1996" MODIFIED="2011-02-14 16:52:43 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lange 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-14 16:52:43 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;OctRecombinant human insulin-like growth factor-I in ALS: Description of a double-blind, placebo-controlled study&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:52:43 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange DJ, Felice KJ, Festoff BW, Gawel MJ, Gelinas DF, Kratz R, et al</AU>
<TI>Recombinant human insulin-like growth factor-I in ALS: Description of a double-blind, placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>4 SUPPL.</NO>
<PG>S93-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange-1998" MODIFIED="2011-02-15 13:43:32 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lange 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-15 13:43:32 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Selegiline is ineffective in a collaborative double-blind, placebo- controlled trial for treatment of amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:43:32 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, et al</AU>
<TI>Selegiline is ineffective in a collaborative double-blind, placebo- controlled trial for treatment of amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>1</NO>
<PG>93-6</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:43:32 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:43:29 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9443715"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lange-2006" MODIFIED="2011-02-15 13:44:04 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lange 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-15 13:44:04 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;SepHigh-frequency chest wall oscillation in ALS: An exploratory randomized, controlled trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:44:04 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lange DJ, Lechtzin N, Davey C, David W, Heiman-Patterson T, Gelinas D, et al</AU>
<TI>High-frequency chest wall oscillation in ALS: An exploratory randomized, controlled trial</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>67</VL>
<NO>6</NO>
<PG>991-7</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:44:04 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:44:04 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="17000967"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lauria-2009" MODIFIED="2012-03-13 20:25:05 +0000" MODIFIED_BY="Reto Baldinger" NAME="Lauria 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-13 20:25:05 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Lauria G, Campanella A, Filippini G, Martini A, Penza P, Maggi L, et al</AU>
<TI>Erythropoietin in amyotrophic lateral sclerosis: a pilot, randomized, double-blind, placebo-controlled study of safety and tolerability</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>5-6</NO>
<PG>410-5</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00731482"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levin-2006" MODIFIED="2011-02-15 13:44:50 +0000" MODIFIED_BY="Kate Jewitt" NAME="Levin 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-15 13:44:50 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;JunPentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial [5]&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:44:50 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levin B, Thompson JLP, Levy H, Mitsumoto LH, Kaufmann P</AU>
<TI>Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>11</NO>
<PG>1786</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:44:50 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:44:50 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16769973"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-2006" MODIFIED="2011-02-15 13:45:11 +0000" MODIFIED_BY="Kate Jewitt" NAME="Levy 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-15 13:45:11 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MarA two-stage design for a phase II clinical trial of coenzyme Q10 in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:45:11 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, et al</AU>
<TI>A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>5</NO>
<PG>660-3</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:45:11 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:45:11 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16534103"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lipp-2003" MODIFIED="2011-02-15 13:45:43 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lipp 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-15 13:45:43 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Nov 11Clinical Trial&lt;br&gt;Randomized Controlled Trial&lt;br&gt;Research Support, Non-U.S. Gov't14610139&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:45:43 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G</AU>
<TI>A randomized trial of botulinum toxin A for treatment of drooling</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>9</NO>
<PG>1279-81</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:45:43 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:45:43 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="14610139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liversedge-1956" MODIFIED="2011-02-15 13:46:12 +0000" MODIFIED_BY="Kate Jewitt" NAME="Liversedge 1956" YEAR="1956">
<REFERENCE MODIFIED="2011-02-15 13:46:12 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00228017&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:46:12 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Liversedge L A</AU>
<TI>Glycocyamine and betaine in motor-neurone disease</TI>
<SO>Lancet</SO>
<YR>1956</YR>
<VL>271</VL>
<NO>6953</NO>
<PG>1136-8</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:46:12 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:46:12 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="13377693"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lomen_x002d_Hoerth-2007" MODIFIED="2010-10-24 14:41:57 +0100" MODIFIED_BY="[Empty name]" NAME="Lomen-Hoerth 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-24 14:41:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Double-blind, placebo controlled safety study of ritonavir and hydroxyurea in patients with ALS&lt;/p&gt;" NOTES_MODIFIED="2010-10-24 14:41:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lomen-Hoerth C, Scott S, Ramasubbu J, Vieira F, Olney R K</AU>
<TI>Double-blind, placebo controlled safety study of ritonavir and hydroxyurea in patients with ALS</TI>
<SO>Annals of Neurology</SO>
<YR>2007</YR>
<VL>62</VL>
<NO>Suppl 11</NO>
<PG>S63, Abstract no: T-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Louwerse-1995" MODIFIED="2011-02-15 13:47:25 +0000" MODIFIED_BY="Kate Jewitt" NAME="Louwerse 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-15 13:47:25 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:47:25 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Louwerse ES, Weverling GJ, Bossuyt PMM, Meyjes FEP, De Jong JM</AU>
<TI>Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis</TI>
<SO>Archives of Neurology</SO>
<YR>1995</YR>
<VL>52</VL>
<NO>6</NO>
<PG>559-64</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:46:52 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:46:52 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7763202"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Markland-1997" MODIFIED="2011-04-09 10:33:47 +0100" MODIFIED_BY="Reto Baldinger" NAME="Markland 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-04-09 10:33:47 +0100" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;CN-00227763&lt;/p&gt;" NOTES_MODIFIED="2011-04-09 10:33:47 +0100" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Markland C</AU>
<TI>An evaluation of the efficacy of recombinant human insulin-like growth factor (rhIGF-I) in the treatment of amyotrophic lateral sclerosis (ALS) (Abstract)</TI>
<SO>Journal of Neurology</SO>
<YR>1997</YR>
<VL>244</VL>
<PG>93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazzini-1994" MODIFIED="2011-02-15 13:47:52 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mazzini 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-15 13:47:52 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:47:52 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazzini L, Testa D, Balzarini C, Mora G</AU>
<TI>An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1994</YR>
<VL>241</VL>
<NO>4</NO>
<PG>223-7</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:47:52 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:47:52 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8195821"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mazzini-1998" MODIFIED="2011-02-15 13:48:15 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mazzini 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-15 13:48:15 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;01The natural history and the effects of gabapentin in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:48:15 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mazzini L, Mora G, Balzarini C, Brigatti M, Pirali I, Comazzi F, et al</AU>
<TI>The natural history and the effects of gabapentin in amyotrophic lateral sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1998</YR>
<VL>160</VL>
<NO>SUPPL. 1</NO>
<PG>S57-63</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:48:15 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:48:15 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9851651"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meininger-1995" MODIFIED="2010-12-15 20:43:15 +0000" MODIFIED_BY="Reto Baldinger" NAME="Meininger 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-12-15 20:42:55 +0000" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;Unpublished report: Controlled trial of riluzole in patients with advanced ALS&lt;/p&gt;" NOTES_MODIFIED="2010-12-15 20:42:55 +0000" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meininger V, Lacomblez L, Bensimon G</AU>
<TI>Unpublished report: Controlled trial of riluzole in patients with advanced ALS</TI>
<SO>RP 54272-302</SO>
<YR>1995</YR>
<VL>54272</VL>
<PG>302</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meininger-2006" MODIFIED="2011-02-15 13:49:02 +0000" MODIFIED_BY="Kate Jewitt" NAME="Meininger 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-15 13:49:02 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;JanPentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:49:02 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meininger V, Asselain B, Guillet P, Leigh PN, Ludolph A, Lacomblez L, et al</AU>
<TI>Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>1</NO>
<PG>88-92</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:49:02 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:49:02 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16401582"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meininger-2009" MODIFIED="2012-03-13 20:25:39 +0000" MODIFIED_BY="Reto Baldinger" NAME="Meininger 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-13 20:25:39 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V</AU>
<TI>Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: a double- blind, randomized, multicentre, placebo-controlled trial</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>5-6</NO>
<PG>378-83</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00730046"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer-2008" MODIFIED="2011-02-15 13:49:31 +0000" MODIFIED_BY="Kate Jewitt" NAME="Meyer 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-15 13:49:31 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;AprThalidomide causes sinus bradycardia in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:49:31 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meyer T, Maier A, Borisow N, Dullinger JS, Splettstosser G, Ohlraun S, et al</AU>
<TI>Thalidomide causes sinus bradycardia in ALS</TI>
<SO>Journal of Neurology</SO>
<YR>2008</YR>
<VL>255</VL>
<NO>4</NO>
<PG>587-91</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:49:31 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:49:31 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="18425621"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1996a" MODIFIED="2011-04-09 09:44:27 +0100" MODIFIED_BY="Reto Baldinger" NAME="Miller 1996a" YEAR="1996">
<REFERENCE MODIFIED="2011-02-15 13:50:10 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;NovToxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:50:10 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Bryan WW, Dietz MA, Munsat TL, Petajan JH, Smith SA, et al</AU>
<TI>Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>5</NO>
<PG>1329-31</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:50:10 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:50:10 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8909453"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1996b" MODIFIED="2011-02-15 13:50:43 +0000" MODIFIED_BY="Kate Jewitt" NAME="Miller 1996b" YEAR="1996">
<REFERENCE MODIFIED="2011-02-15 13:50:43 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:50:43 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture J C, et al</AU>
<TI>A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>2</NO>
<PG>256-60</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:50:43 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:50:43 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8967757"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1996c" MODIFIED="2011-02-15 13:51:51 +0000" MODIFIED_BY="Kate Jewitt" NAME="Miller 1996c" YEAR="1996">
<REFERENCE MODIFIED="2011-02-15 13:51:51 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MarControlled trial of nimodipine in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:51:51 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Shepherd R, Dao H, Khramstov A, Mendoza M, Graves J, et al</AU>
<TI>Controlled trial of nimodipine in amyotrophic lateral sclerosis</TI>
<SO>Neuromuscular Disorders</SO>
<YR>1996</YR>
<VL>6</VL>
<NO>2</NO>
<PG>101-4</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:51:51 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:51:51 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8664560"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1996d" MODIFIED="2012-03-13 00:36:29 +0000" MODIFIED_BY="Kate Jewitt" NAME="Miller 1996d" YEAR="1996">
<REFERENCE MODIFIED="2012-03-13 00:36:29 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;AprA clinical trial of verapamil in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 00:36:29 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Smith SA, Murphy JR, Brinkmann JR, Graves J, Mendoza M, et al</AU>
<TI>A clinical trial of verapamil in amyotrophic lateral sclerosis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>4</NO>
<PG>511-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:51:27 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:51:27 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8622731"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-2007" MODIFIED="2011-02-15 13:52:23 +0000" MODIFIED_BY="Kate Jewitt" NAME="Miller 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-15 13:52:23 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;AugPhase II/III randomized trial of TCH346 in patients with ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:52:23 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller R, Bradley W, Cudkowicz M, Hubble J, Meininger V, Mitsumoto H, et al</AU>
<TI>Phase II/III randomized trial of TCH346 in patients with ALS</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>69</VL>
<NO>8</NO>
<PG>776-84</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:52:23 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:52:23 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="17709710"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitchell-1995" MODIFIED="2011-02-15 13:52:58 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mitchell 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-15 13:52:58 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Serial studies of free radical and antioxidant activity in motor neurone disease and the effect of selegiline [1]&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 13:52:58 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitchell JD, Houghton E, Rostron G, Wignall C, Gatt JA, Phillips TM, et al</AU>
<TI>Serial studies of free radical and antioxidant activity in motor neurone disease and the effect of selegiline</TI>
<SO>Neurodegeneration</SO>
<YR>1995</YR>
<VL>4</VL>
<NO>2</NO>
<PG>233-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 13:52:58 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 13:52:58 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7583688"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mitsumoto-1986" MODIFIED="2011-02-15 14:11:07 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mitsumoto 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-15 14:11:07 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Amyotrophic lateral sclerosis: Effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:11:07 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mitsumoto H, Salgado ED, Negroski D</AU>
<TI>Amyotrophic lateral sclerosis: Effects of acute intravenous and chronic subcutaneous administration of thyrotropin-releasing hormone in controlled trials</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<NO>2</NO>
<PG>152-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:11:07 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:11:07 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3080695"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munsat-1981" MODIFIED="2011-02-15 14:11:32 +0000" MODIFIED_BY="Kate Jewitt" NAME="Munsat 1981" YEAR="1981">
<REFERENCE MODIFIED="2011-02-15 14:11:32 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Amantadine and guanidine are ineffective in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:11:32 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munsat TL, Easterday CS, Levy S</AU>
<TI>Amantadine and guanidine are ineffective in ALS</TI>
<SO>Neurology</SO>
<YR>1981</YR>
<VL>31</VL>
<NO>8</NO>
<PG>1054-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:11:32 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:11:32 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7022258"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munsat-1987" MODIFIED="2011-02-15 14:11:54 +0000" MODIFIED_BY="Kate Jewitt" NAME="Munsat 1987" YEAR="1987">
<REFERENCE MODIFIED="2011-02-15 14:11:54 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Intrathecal thyrotropin-releasing hormone in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:11:54 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munsat TL, Taft J, Kasdon D</AU>
<TI>Intrathecal thyrotropin-releasing hormone in amyotrophic lateral sclerosis</TI>
<SO>Neurologic Clinics</SO>
<YR>1987</YR>
<VL>5</VL>
<NO>1</NO>
<PG>159-70</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:11:54 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:11:54 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3104751"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Munsat-1992" MODIFIED="2011-02-15 14:12:26 +0000" MODIFIED_BY="Kate Jewitt" NAME="Munsat 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-02-15 14:12:26 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: Experience with an intrathecal drug delivery system&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:12:26 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Munsat TL, Taft J, Jackson IMD, Andres PL, Hollander D, Skerry L, et al</AU>
<TI>Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: Experience with an intrathecal drug delivery system</TI>
<SO>Neurology</SO>
<YR>1992</YR>
<VL>42</VL>
<NO>5</NO>
<PG>1049-53</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:12:26 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:12:26 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="1579228"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1995" MODIFIED="2011-04-03 16:33:49 +0100" MODIFIED_BY="Reto Baldinger" NAME="Murphy 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-04-03 16:33:49 +0100" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;CN-00227870&lt;/p&gt;" NOTES_MODIFIED="2011-04-03 16:33:49 +0100" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Murphy MF, Felice K, Gawel M, Gelinas D, Kratz R, Lai E, et al</AU>
<TI>A double blind placebo controlled study of myotrophin (CEP 151) in the treatment of amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>2</NO>
<PG>335</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagano-2005" MODIFIED="2011-02-15 14:13:03 +0000" MODIFIED_BY="Kate Jewitt" NAME="Nagano 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-15 14:13:03 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;OctBeneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:13:03 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagano I, Shiote M, Murakami T, Kamada H, Hamakawa Y, Matsubara E, et al</AU>
<TI>Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis</TI>
<SO>Neurological Research</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>7</NO>
<PG>768-72</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:13:03 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:13:03 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16197815"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nefussy-2010" MODIFIED="2012-03-13 20:26:47 +0000" MODIFIED_BY="Reto Baldinger" NAME="Nefussy 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-13 20:26:47 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Nefussy B, Artamonov I, Deutsch V, Naparstek E, Nagler A, Drory VE</AU>
<TI>Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: a pilot study</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>1-2</NO>
<PG>187-93</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00749460"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norris-1974" MODIFIED="2011-02-15 14:13:34 +0000" MODIFIED_BY="Kate Jewitt" NAME="Norris 1974" YEAR="1974">
<REFERENCE MODIFIED="2011-02-15 14:13:34 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;AugClinical Trial&lt;br&gt;Randomized Controlled Trial4858705&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:13:34 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norris FH Jr, Calanchini PR, Fallat RJ, Panchari S, Jewett B</AU>
<TI>The administration of guanidine in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1974</YR>
<VL>24</VL>
<NO>8</NO>
<PG>721-8</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:13:34 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:13:34 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="4858705"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norris-1986" MODIFIED="2011-02-15 14:14:22 +0000" MODIFIED_BY="Kate Jewitt" NAME="Norris 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-15 14:14:22 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Trial of octacosanol in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:14:22 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norris FH, Denys EH, Fallat RJ</AU>
<TI>Trial of octacosanol in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<NO>9</NO>
<PG>1263-4</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:14:22 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:14:22 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="3528918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Norris-1993" MODIFIED="2011-02-15 14:15:00 +0000" MODIFIED_BY="Kate Jewitt" NAME="Norris 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-15 14:15:00 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;DecTrial of oral physostigmine in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:15:00 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Norris FH, Tan Y, Fallat RJ, Elias L</AU>
<TI>Trial of oral physostigmine in amyotrophic lateral sclerosis</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>6</NO>
<PG>680-2</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:15:00 +0000" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ochs-2000" MODIFIED="2012-03-13 20:27:03 +0000" MODIFIED_BY="Kate Jewitt" NAME="Ochs 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-03-13 20:27:03 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00349563Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't&lt;br&gt;Comment in: Amyotroph Lateral Scler Other Motor Neuron Disord. 2000 Jun;1(3):141. PMID: 11464948.&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:27:03 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Ochs G, Penn RD, York M, Giess R, Beck M, Tonn J, et al</AU>
<TI>A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</SO>
<YR>2000</YR>
<NO>3</NO>
<PG>201-6</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:15:28 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:15:28 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11464953"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oda-1996" MODIFIED="2011-02-15 14:16:06 +0000" MODIFIED_BY="Kate Jewitt" NAME="Oda 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-15 14:16:06 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. [Japanese]&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:16:06 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oda E, Ohashi Y, Tashiro K, Mizuno Y, Kowa H, Yanagisawa N</AU>
<TI>Reliability and factorial structure of a rating scale for amyotrophic lateral sclerosis. [Japanese]</TI>
<SO>No To Shinkei</SO>
<YR>1996</YR>
<VL>48</VL>
<NO>11</NO>
<PG>999-1007</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:16:06 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:16:06 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8951891"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olarte-1979" MODIFIED="2011-02-15 14:16:32 +0000" MODIFIED_BY="Kate Jewitt" NAME="Olarte 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-02-15 14:16:32 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00020424Clinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:16:32 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Olarte MR, Gersten JC, Zabriskie J, Rowland LP</AU>
<TI>Transfer factor is ineffective in amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>1979</YR>
<NO>4</NO>
<PG>385-8</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:16:32 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:16:32 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="4010949"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olarte-1985" MODIFIED="2011-02-15 14:16:55 +0000" MODIFIED_BY="Kate Jewitt" NAME="Olarte 1985" YEAR="1985">
<REFERENCE MODIFIED="2011-02-15 14:16:55 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:16:55 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olarte MR, Shafer SQ</AU>
<TI>Levamisole is ineffective in the treatment of amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1985</YR>
<VL>35</VL>
<NO>7</NO>
<PG>1063-6</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:16:55 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:16:55 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="4010949"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Olson-1978" MODIFIED="2011-02-15 14:17:20 +0000" MODIFIED_BY="Kate Jewitt" NAME="Olson 1978" YEAR="1978">
<REFERENCE MODIFIED="2011-02-15 14:17:20 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;DecClinical Trial&lt;br&gt;Controlled Clinical Trial366454&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:17:20 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Olson WH, Simons JA, Halaas GW</AU>
<TI>Therapeutic trial of tilorone in ALS: lack of benefit in a double-blind, placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<VL>28</VL>
<NO>12</NO>
<PG>1293-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:17:20 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:17:20 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="366454"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-On-2005" MODIFIED="2011-02-15 14:17:49 +0000" MODIFIED_BY="Kate Jewitt" NAME="On 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-15 14:17:49 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00554170Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:17:49 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>On AY, Oncu J, Uludag B, Ertekin C</AU>
<TI>Effects of lamotrigine on the symptoms and life qualities of patients with post polio syndrome: a randomized, controlled study</TI>
<SO>Neurorehabilitation</SO>
<YR>2005</YR>
<NO>4</NO>
<PG>245-51</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:17:49 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:17:49 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16403993"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Panitch-2006" MODIFIED="2011-02-15 14:18:26 +0000" MODIFIED_BY="Kate Jewitt" NAME="Panitch 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-15 14:18:26 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MayRandomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:18:26 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, et al</AU>
<TI>Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>5</NO>
<PG>780-7</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:18:26 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:18:26 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16634036"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pascuzzi-2010" MODIFIED="2012-03-13 20:28:23 +0000" MODIFIED_BY="Reto Baldinger" NAME="Pascuzzi 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-13 20:28:23 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Pascuzzi RM, Shefner J, Chappell AS, Bjerke JS, Tamura R, Chaudhry V, et al</AU>
<TI>A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>3</NO>
<PG>266-71</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00749001"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Percy-1971" MODIFIED="2011-02-15 14:18:59 +0000" MODIFIED_BY="Kate Jewitt" NAME="Percy 1971" YEAR="1971">
<REFERENCE MODIFIED="2011-02-15 14:18:59 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00006050Clinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:18:59 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Percy AK, Davis LE, Johnston DM, Drachman DB</AU>
<TI>Failure of isoprinosine in amyotrophic lateral sclerosis</TI>
<SO>The New England journal of medicine</SO>
<YR>1971</YR>
<NO>12</NO>
<PG>689</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:18:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:18:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="4935228"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piepers-2008" MODIFIED="2011-02-15 14:31:31 +0000" MODIFIED_BY="Kate Jewitt" NAME="Piepers 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-15 14:31:31 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A randomized, placebo-controlled, sequential trial of valproic acid in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:31:31 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piepers S, De Jong S, Veldink JH, Van der Tweel I, Van der Pol WL, Groeneveld GJG, et al</AU>
<TI>A randomized, placebo-controlled, sequential trial of valproic acid in ALS</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>70</VL>
<NO>11 Suppl 1</NO>
<PG>A192, Abstract no: P04.085</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piepers-2009" MODIFIED="2012-03-13 20:28:41 +0000" MODIFIED_BY="Reto Baldinger" NAME="Piepers 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-13 20:28:41 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Piepers S, Veldink JH, De Jong SW, Van der Tweel I, Van der Pol WL, Uijtendaal EV, et al</AU>
<TI>Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2009</YR>
<VL>66</VL>
<NO>2</NO>
<PG>227-34</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00722837"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pioro-2010" MODIFIED="2012-03-13 20:30:29 +0000" MODIFIED_BY="Reto Baldinger" NAME="Pioro 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-13 20:30:29 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al</AU>
<TI>Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect</TI>
<SO>Annnals of Neurology</SO>
<YR>2010</YR>
<VL>68</VL>
<NO>5</NO>
<PG>693&#8211;702</PG>
<IDENTIFIERS MODIFIED="2011-04-03 13:37:54 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER MODIFIED="2011-04-03 13:37:54 +0100" MODIFIED_BY="Reto Baldinger" TYPE="PUBMED" VALUE="20839238"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Plaitakis-1988" MODIFIED="2011-05-26 19:28:23 +0100" MODIFIED_BY="Reto Baldinger" NAME="Plaitakis 1988" YEAR="1988">
<REFERENCE MODIFIED="2011-05-26 19:28:23 +0100" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-05-26 19:28:23 +0100" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Plaitakis A, Smith J, Mandeli J, Yahr MD</AU>
<TI>Pilot trial of branched-chain amino acids in amyotrophic lateral sclerosis</TI>
<SO>Lancet</SO>
<YR>1988</YR>
<VL>1</VL>
<NO>8593</NO>
<PG>1015-8</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:32:12 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:32:12 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2896868"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pontieri-2005" MODIFIED="2011-02-15 14:32:39 +0000" MODIFIED_BY="Kate Jewitt" NAME="Pontieri 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-15 14:32:39 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;OctMinocycline in amyotrophic lateral sclerosis: A pilot study&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:32:39 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pontieri FE, Ricci A, Pellicano C, Benincasa D, Buttarelli FR</AU>
<TI>Minocycline in amyotrophic lateral sclerosis: A pilot study</TI>
<SO>Neurological Sciences</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>4</NO>
<PG>285-7</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:32:39 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:32:39 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16193258"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Poutiainen-1994" MODIFIED="2011-02-15 14:32:59 +0000" MODIFIED_BY="Kate Jewitt" NAME="Poutiainen 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-15 14:32:59 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Reversible cognitive decline during high-dose alpha-interferon treatment&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:32:59 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poutiainen E, Hokkanen L, Niemi M L, Farkkila M</AU>
<TI>Reversible cognitive decline during high-dose alpha-interferon treatment</TI>
<SO>Pharmacology Biochemistry and Behavior</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>4</NO>
<PG>901-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:32:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:32:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8029260"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rabkin-2009" MODIFIED="2011-02-15 14:33:51 +0000" MODIFIED_BY="Kate Jewitt" NAME="Rabkin 2009" YEAR="2009">
<REFERENCE MODIFIED="2011-02-15 14:33:51 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;MarchModafinil treatment of fatigue in patients with ALS: A placebo-controlled study&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:33:51 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H</AU>
<TI>Modafinil treatment of fatigue in patients with ALS: A placebo-controlled study</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2009</YR>
<VL>39</VL>
<NO>3</NO>
<PG>297-303</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:33:25 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:33:25 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="19208464"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-rHCNTF-1995" MODIFIED="2011-02-14 16:27:54 +0000" MODIFIED_BY="Kate Jewitt" NAME="rHCNTF 1995" YEAR="1995">
<REFERENCE MODIFIED="2011-02-14 16:25:48 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-14 16:25:48 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cedarbaum J M, Chapman C, Charatan M, Stambler N, Andrews L, Zhan C, et al</AU>
<TI>A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis, ALS CNTF Treatment Study Group</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>6</NO>
<PG>515-32</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:25:10 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:25:10 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8681312"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-rHCNTF-1996" MODIFIED="2012-03-13 20:37:42 +0000" MODIFIED_BY="Reto Baldinger" NAME="rHCNTF 1996" YEAR="1996">
<REFERENCE MODIFIED="2012-03-13 20:37:42 +0000" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;MayA double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:37:42 +0000" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>ALS CNTF Treatment Study Group</AU>
<TI>A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>46</VL>
<NO>5</NO>
<PG>1244-9</PG>
<IDENTIFIERS MODIFIED="2011-02-14 16:26:49 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 16:26:49 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8628466"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rivera-1979" MODIFIED="2011-02-15 14:37:40 +0000" MODIFIED_BY="Kate Jewitt" NAME="Rivera 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-02-15 14:37:40 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00447417&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:37:40 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Rivera VM, Grabois M, Deathon W, Breitbach W, Hines M</AU>
<TI>Modified snake venoms in amyotrophic lateral sclerosis (ALS): a controlled study using objective parameters</TI>
<SO>Neurology</SO>
<YR>1979</YR>
<NO>4</NO>
<PG>612</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:37:40 +0000" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rivera-1980" MODIFIED="2011-02-15 14:37:33 +0000" MODIFIED_BY="Kate Jewitt" NAME="Rivera 1980" YEAR="1980">
<REFERENCE MODIFIED="2011-02-15 14:37:33 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:37:33 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rivera VM, Grabois M, Deaton W</AU>
<TI>Modified snake venom in amyotrophic lateral sclerosis. Lack of clinical effectiveness</TI>
<SO>Archives of Neurology</SO>
<YR>1980</YR>
<VL>37</VL>
<NO>4</NO>
<PG>201-3</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:37:33 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:37:33 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7362484"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roufs-1991" MODIFIED="2012-03-13 20:31:02 +0000" MODIFIED_BY="Kate Jewitt" NAME="Roufs 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-03-13 20:31:02 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;L-threnonine as a symptomatic treatment for amyotrophic lateral sclerosis (ALS)&lt;/p&gt;" NOTES_MODIFIED="2012-03-13 20:31:02 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roufs JB</AU>
<TI>L-threonine as a symptomatic treatment for amyotrophic lateral sclerosis (ALS)</TI>
<SO>Medical Hypotheses</SO>
<YR>1991</YR>
<VL>34</VL>
<NO>1</NO>
<PG>20-3</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:38:28 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:38:28 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="1905383"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ryberg-2003" MODIFIED="2011-02-15 14:38:56 +0000" MODIFIED_BY="Kate Jewitt" NAME="Ryberg 2003" YEAR="2003">
<REFERENCE MODIFIED="2011-02-15 14:38:56 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;01A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: Effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:38:56 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ryberg H, Askmark H, Persson L I</AU>
<TI>A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2003</YR>
<VL>108</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:38:56 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:38:56 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="12807386"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sacca-2009" MODIFIED="2012-03-13 20:29:46 +0000" MODIFIED_BY="Reto Baldinger" NAME="Sacca 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-03-13 20:29:46 +0000" MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="OTHER">
<AU>Sacca F, Quarantelli M, Rinaldi C, Tucci T, Piro R, Carotenuto B, et al</AU>
<TI>A double-blind, placebo-controlled, randomized trial of growth hormone as add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: preliminary MRS, hormonal, and population analysis</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>11 Suppl 3</NO>
<PG>A36, Abstract no: P07.164</PG>
<IDENTIFIERS MODIFIED="2011-04-09 10:07:45 +0100" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER TYPE="OTHER" VALUE="CN-00747130"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sato-2006" MODIFIED="2011-02-15 14:39:18 +0000" MODIFIED_BY="Kate Jewitt" NAME="Sato 2006" YEAR="2006">
<REFERENCE MODIFIED="2011-02-15 14:39:18 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;NovEtidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:39:18 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sato Y, Honda Y, Iwamoto J</AU>
<TI>Etidronate for fracture prevention in amyotrophic lateral sclerosis: A randomized controlled trial</TI>
<SO>Bone</SO>
<YR>2006</YR>
<VL>39</VL>
<NO>5</NO>
<PG>1080-6</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:39:18 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:39:18 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16777503"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shefner-2004" MODIFIED="2011-02-15 14:39:42 +0000" MODIFIED_BY="Kate Jewitt" NAME="Shefner 2004" YEAR="2004">
<REFERENCE MODIFIED="2011-02-15 14:39:42 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;09A clinical trial of creatine in ALS&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:39:42 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, et al</AU>
<TI>A clinical trial of creatine in ALS</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>9</NO>
<PG>1656-61</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:39:42 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:39:42 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="15534251"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1986" MODIFIED="2011-02-15 14:40:04 +0000" MODIFIED_BY="Kate Jewitt" NAME="Smith 1986" YEAR="1986">
<REFERENCE MODIFIED="2011-02-15 14:40:04 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Treatment of ALS with bromocriptine does not improve muscle strength&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:40:04 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith SA, Roelofs RI, Matthews D, Loewenson RB, Gardner M</AU>
<TI>Treatment of ALS with bromocriptine does not improve muscle strength</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>Suppl 5</NO>
<PG>108</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:40:04 +0000" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Smith-1993" MODIFIED="2011-02-15 14:40:34 +0000" MODIFIED_BY="Kate Jewitt" NAME="Smith 1993" YEAR="1993">
<REFERENCE MODIFIED="2011-02-15 14:40:34 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00093508Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:40:34 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Smith RA, Melmed S, Sherman B, Frane J, Munsat TL, Festoff BW</AU>
<TI>Recombinant growth hormone treatment of amyotrophic lateral sclerosis</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1993</YR>
<NO>6</NO>
<PG>624-33</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:40:34 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:40:34 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8502260"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sofuoglu-2008" MODIFIED="2011-02-15 14:41:08 +0000" MODIFIED_BY="Kate Jewitt" NAME="Sofuoglu 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-15 14:41:08 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;01Riluzole and d-amphetamine interactions in humans&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:41:08 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sofuoglu M, Waters AJ, Mooney M, Kosten T</AU>
<TI>Riluzole and d-amphetamine interactions in humans</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:41:08 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:41:08 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="17714844"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sorenson-2008" MODIFIED="2011-02-15 14:41:45 +0000" MODIFIED_BY="Kate Jewitt" NAME="Sorenson 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-02-15 14:41:45 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;25Subcutaneous IGF-1 is not beneficial in 2-year ALS trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:41:45 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sorenson EJ, Windbank AJ, Mandrekar JN, Bamlet WR, Appel SH, Armon C, et al</AU>
<TI>Subcutaneous IGF-1 is not beneficial in 2-year ALS trial</TI>
<SO>Neurology</SO>
<YR>2008</YR>
<VL>71</VL>
<NO>22</NO>
<PG>1770-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:41:45 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:41:45 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="19029516"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Steele-2007" MODIFIED="2011-02-15 14:42:10 +0000" MODIFIED_BY="Kate Jewitt" NAME="Steele 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-15 14:42:10 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis [1]&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:42:10 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Steele J, Zutshi D, Bradley WG</AU>
<TI>Negative results of a phase II study of hyperbaric oxygen therapy for amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>5</NO>
<PG>274-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:42:10 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:42:10 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="17852024"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strevic-1998" MODIFIED="2011-02-15 14:42:23 +0000" MODIFIED_BY="Kate Jewitt" NAME="Strevic 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-15 14:42:23 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;A controlled trial of combination of methionine and antioxidans in amyotrophic lateral sclerosis&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:42:23 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Strevic Z, Nicolic A, Blagjevic D, Saicia ZS, Apostolski S, Spasic M</AU>
<TI>A controlled trial of combination of methionine and antioxidants in amyotrophic lateral sclerosis</TI>
<SO>Proceedings ALS/MND International Alliance Meeting, Munich, Germany</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Szczudlik-1998" MODIFIED="2011-02-15 14:42:52 +0000" MODIFIED_BY="Kate Jewitt" NAME="Szczudlik 1998" YEAR="1998">
<REFERENCE MODIFIED="2011-02-15 14:42:52 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00158318Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 14:42:52 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Szczudlik A, Tomik B, Slowik A, Kasprzyk K</AU>
<TI>[Assessment of the efficacy of treatment with pimozide in patients with amyotrophic lateral sclerosis. Introductory notes]</TI>
<SO>Neurologia i Neurochirurgia Polska</SO>
<YR>1998</YR>
<NO>4</NO>
<PG>821-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 14:42:52 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 14:42:52 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9864711"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tandan-1996" MODIFIED="2011-02-15 15:50:38 +0000" MODIFIED_BY="Kate Jewitt" NAME="Tandan 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-02-15 15:50:38 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;NovA controlled trial of amine acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:50:38 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tandan R, Bromberg MB, Forshew D, Fries TJ, Badger GJ, Carpenter J, et al</AU>
<TI>A controlled trial of amine acid therapy in amyotrophic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data</TI>
<SO>Neurology</SO>
<YR>1996</YR>
<VL>47</VL>
<NO>5</NO>
<PG>1220-6</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:50:38 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:50:38 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8909433"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Testa-1989" MODIFIED="2011-02-15 15:51:00 +0000" MODIFIED_BY="Kate Jewitt" NAME="Testa 1989" YEAR="1989">
<REFERENCE MODIFIED="2011-02-15 15:51:00 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00228031&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:51:00 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Testa D, Caraceni T, Fetoni V</AU>
<TI>Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis</TI>
<SO>Journal of Neurology</SO>
<YR>1989</YR>
<NO>8</NO>
<PG>445-7</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:51:00 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:51:00 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2614487"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Testa-1992" MODIFIED="2011-02-15 15:51:27 +0000" MODIFIED_BY="Kate Jewitt" NAME="Testa 1992" YEAR="1992">
<REFERENCE MODIFIED="2011-02-15 15:51:27 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:51:27 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Testa D, Caraceni T, Fetoni V, Girotti F</AU>
<TI>Chronic treatment with L-threonine in amyotrophic lateral sclerosis: a pilot study</TI>
<SO>Clinical Neurology and Neurosurgery</SO>
<YR>1992</YR>
<VL>94</VL>
<NO>1</NO>
<PG>7-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:51:27 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:51:27 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="1353011"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyler-1978" MODIFIED="2011-02-15 15:51:47 +0000" MODIFIED_BY="Kate Jewitt" NAME="Tyler 1978" YEAR="1978">
<REFERENCE MODIFIED="2011-02-15 15:51:47 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00448085&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:51:47 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Tyler HR</AU>
<TI>Modified snake venom therapy in motor neuron disease: a double-blind study</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<NO>4</NO>
<PG>372</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tyler-1979" MODIFIED="2011-02-15 15:52:28 +0000" MODIFIED_BY="Kate Jewitt" NAME="Tyler 1979" YEAR="1979">
<REFERENCE MODIFIED="2011-02-15 15:52:28 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;CN-00019940Clinical Trial; Controlled Clinical Trial; Journal Article&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:52:28 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="OTHER">
<AU>Tyler HR</AU>
<TI>Double-blind study of modified neurotoxin in motor neuron disease</TI>
<SO>Neurology</SO>
<YR>1979</YR>
<NO>1</NO>
<PG>77-81</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:52:28 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:52:28 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="370685"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yanagisawa-1997" MODIFIED="2010-12-15 13:43:12 +0000" MODIFIED_BY="Reto Baldinger" NAME="Yanagisawa 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-12-15 13:43:12 +0000" MODIFIED_BY="Reto Baldinger" NOTES="&lt;p&gt;Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis.:double-bline placebo-controlled study in Japan&lt;/p&gt;" NOTES_MODIFIED="2010-12-15 13:43:12 +0000" NOTES_MODIFIED_BY="Reto Baldinger" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yanagisawa N, Tashiro K, Tohgi H, Mizuno Y, Kowa H, Kimuma J</AU>
<TI>Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo-controlled study in Japan</TI>
<SO>Igakuno Ayumi</SO>
<YR>1997</YR>
<VL>182</VL>
<PG>851-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2011-02-15 15:52:52 +0000" MODIFIED_BY="Kate Jewitt" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2011-02-15 15:52:52 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;AprThe randomized open clinical trial on a novel free radical scavenger edaravone in amyotrophic lateral sclerosis. [Chinese]&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:52:52 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YJ, Zhang J, Zhang N, Zhang HG, Wang LP, Lu M, et al</AU>
<TI>The randomized open clinical trial on a novel free radical scavenger edaravone in amyotrophic lateral sclerosis. [Chinese]</TI>
<SO>Chinese Journal of Contemporary Neurology and Neurosurgery</SO>
<YR>2007</YR>
<VL>7</VL>
<NO>2</NO>
<PG>161-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ziv-1994" MODIFIED="2011-02-15 15:53:17 +0000" MODIFIED_BY="Kate Jewitt" NAME="Ziv 1994" YEAR="1994">
<REFERENCE MODIFIED="2011-02-15 15:53:17 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;Can nimodipine affect progression of motor neuron disease? A double-blind pilot study&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:53:17 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ziv I, Achiron A, Djaldetti R, Abraham M, Melamed E</AU>
<TI>Can nimodipine affect progression of motor neuron disease? A double-blind pilot study</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>5</NO>
<PG>423-8</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:53:17 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:53:17 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9316691"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zoccolella-2005" MODIFIED="2011-02-15 15:53:36 +0000" MODIFIED_BY="Kate Jewitt" NAME="Zoccolella 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-02-15 15:53:36 +0000" MODIFIED_BY="Kate Jewitt" NOTES="&lt;p&gt;DecClassification of amyotrophic lateral sclerosis cases at presentation in epidemiological studies&lt;/p&gt;" NOTES_MODIFIED="2011-02-15 15:53:36 +0000" NOTES_MODIFIED_BY="Kate Jewitt" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zoccolella S, Beghi E, Serlenga L, Logroscino G</AU>
<TI>Classification of amyotrophic lateral sclerosis cases at presentation in epidemiological studies</TI>
<SO>Neurological Sciences</SO>
<YR>2005</YR>
<VL>26</VL>
<NO>5</NO>
<PG>330-3</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:53:36 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:53:36 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="16388367"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2010-03-06 04:47:37 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2012-03-12 19:59:33 +0000" MODIFIED_BY="Reto Baldinger">
<STUDY DATA_SOURCE="SOUGHT" ID="STD-Strong-ongoing" MODIFIED="2012-03-12 19:59:33 +0000" MODIFIED_BY="Reto Baldinger" NAME="Strong ongoing" YEAR="">
<IDENTIFIERS MODIFIED="2012-01-18 14:58:32 +0000" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER MODIFIED="2012-01-18 14:58:32 +0000" MODIFIED_BY="Reto Baldinger" TYPE="CTG" VALUE="NCT00372879"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-03-14 16:15:32 +0000" MODIFIED_BY="Ruth Brassington">
<ADDITIONAL_REFERENCES MODIFIED="2012-03-14 16:15:32 +0000" MODIFIED_BY="Ruth Brassington">
<REFERENCE ID="REF-Ahmad-1990" MODIFIED="2012-03-12 19:59:48 +0000" MODIFIED_BY="Kate Jewitt" NAME="Ahmad 1990" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad S, Robertson HT, Golper TA, Wolfson M, Kurtin P, Katz LA et al</AU>
<TI>Multicenter trial of L-carnitine in maintenance hemodialysis patients. II. Clinical and biochemical effects</TI>
<SO>Kidney International</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>5</NO>
<PG>912-18</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:53:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:53:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2266675"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Baldissera-1994" MODIFIED="2011-02-15 15:54:24 +0000" MODIFIED_BY="Kate Jewitt" NAME="Baldissera 1994" TYPE="JOURNAL_ARTICLE">
<AU>Baldissera F, Cavallari P, Dworzak F</AU>
<TI>Motor neuron 'bistability'. A pathogenetic mechanism for cramps and myokymia</TI>
<SO>Brain</SO>
<YR>1994</YR>
<VL>117</VL>
<NO>Pt 5</NO>
<PG>929-39</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:54:24 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:54:24 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7953602"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bedlack-2009" MODIFIED="2012-03-13 20:32:15 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bedlack 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bedlack RS, Pastula DM, Hawes J, Heydt D</AU>
<TI>Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease</TI>
<SO>Amyotrophic Lateral Sclerosis</SO>
<YR>2009</YR>
<VL>10</VL>
<NO>4</NO>
<PG>210-5</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:55:03 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:55:03 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="18821142"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bertolasi-1993" MODIFIED="2011-02-15 15:55:33 +0000" MODIFIED_BY="Kate Jewitt" NAME="Bertolasi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bertolasi L, De Grandis D, Bongiovanni LG, Zanette GP, Gasperini M</AU>
<TI>The influence of muscular lengthening on cramps</TI>
<SO>Annals of Neurology</SO>
<YR>1993</YR>
<VL>33</VL>
<NO>2</NO>
<PG>176-80</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:55:33 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:55:33 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8434879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brooks-1994" MODIFIED="2011-02-15 15:56:41 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brooks 1994" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR</AU>
<TI>El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1994</YR>
<VL>124 Suppl</VL>
<PG>96-107</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:56:02 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:56:02 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7807156"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brooks-2000" MODIFIED="2011-02-15 15:56:32 +0000" MODIFIED_BY="Kate Jewitt" NAME="Brooks 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brooks BR, Miller RG, Swash M, Munsat TL</AU>
<TI>El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</SO>
<YR>2000</YR>
<VL>1</VL>
<NO>5</NO>
<PG>293-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:56:32 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:56:32 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11464847"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-1998" MODIFIED="2011-02-15 15:57:14 +0000" MODIFIED_BY="Kate Jewitt" NAME="Chan 1998" TYPE="JOURNAL_ARTICLE">
<AU>Chan P, Huang TY, Chen YJ, Huang WP, Liu YC</AU>
<TI>Randomized, double-blind, placebo-controlled study of the safety and efficacy of vitamin B complex in the treatment of nocturnal leg cramps in elderly patients with hypertension</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1998</YR>
<VL>38</VL>
<NO>12</NO>
<PG>1151-4</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:57:11 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:57:11 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11301568"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Connolly-1992" MODIFIED="2011-02-15 15:57:57 +0000" MODIFIED_BY="Kate Jewitt" NAME="Connolly 1992" TYPE="JOURNAL_ARTICLE">
<AU>Connolly PS, Shirley EA, Wasson JH, Nierenberg DW</AU>
<TI>Treatment of nocturnal leg cramps. A crossover trial of quinine vs vitamin E</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1992</YR>
<VL>152</VL>
<NO>9</NO>
<PG>1877-80</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:57:57 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:57:57 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="1520054"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Denny_x002d_Brown-1953" MODIFIED="2011-02-15 15:58:14 +0000" MODIFIED_BY="Kate Jewitt" NAME="Denny-Brown 1953" TYPE="JOURNAL_ARTICLE">
<AU>Denny-Brown D</AU>
<TI>Clinical problems in neuromuscular physiology</TI>
<SO>American Journal of Medicine</SO>
<YR>1953</YR>
<VL>15</VL>
<PG>368-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El_x002d_Tawil-2010" MODIFIED="2012-03-14 16:15:32 +0000" MODIFIED_BY="Reto Baldinger" NAME="El-Tawil 2010" TYPE="COCHRANE_REVIEW">
<AU>El-Tawil S, Al Musa T, Valli H, Lunn MP, El-Tawil T, Weber M</AU>
<TI>Quinine for muscle cramps</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2012-03-12 23:29:22 +0000" MODIFIED_BY="Reto Baldinger">
<IDENTIFIER MODIFIED="2012-03-12 23:29:22 +0000" MODIFIED_BY="Ruth Brassington" TYPE="DOI" VALUE="10.1002/14651858.CD005044"/>
<IDENTIFIER MODIFIED="2012-03-12 23:29:06 +0000" MODIFIED_BY="Ruth Brassington" TYPE="PUBMED" VALUE="21154358"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2006" MODIFIED="2011-07-20 19:57:45 +0100" MODIFIED_BY="Ruth Brassington" NAME="FDA 2006" TYPE="OTHER">
<AU>Food and Drug Administration (FDA)</AU>
<TI>FDA orders unapproved quinine drugs from the market and cautions consumers about &#8216;off-label&#8217; use of quinine to treat leg cramps</TI>
<SO>http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108799.htm</SO>
<YR>2006</YR>
<PG>website accessed 31 Oct 2010</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2010" MODIFIED="2012-03-13 20:33:23 +0000" MODIFIED_BY="Ruth Brassington" NAME="FDA 2010" TYPE="OTHER">
<AU>Food and Drug Administration (FDA)</AU>
<TI>New risk management plan and patient medication guide for Qualaquin (quinine sulfate)</TI>
<SO>http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218202.htm</SO>
<YR>2010</YR>
<PG>website last accessed 29 February 2012, website last edited by the FDA 7 August 2010</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Forshew-2003" MODIFIED="2012-03-13 20:33:50 +0000" MODIFIED_BY="Kate Jewitt" NAME="Forshew 2003" TYPE="JOURNAL_ARTICLE">
<AU>Forshew DA, Bromberg MB</AU>
<TI>A survey of clinicians' practice in the symptomatic treatment of ALS</TI>
<SO>Amyotrophic Lateral Slerosis and Other Motor Neuron Disorders: official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>4</NO>
<PG>258-63</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:58:53 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:58:53 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="14753660"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fowler-1997" MODIFIED="2011-02-15 15:59:19 +0000" MODIFIED_BY="Kate Jewitt" NAME="Fowler 1997" TYPE="JOURNAL_ARTICLE">
<AU>Fowler AW</AU>
<TI>Randomised controlled trial of hydroquinine in muscle cramps</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9061</NO>
<PG>1325-6</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:59:17 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:59:17 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9142089"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Frusso-1999" MODIFIED="2011-02-15 15:59:51 +0000" MODIFIED_BY="Kate Jewitt" NAME="Frusso 1999" TYPE="JOURNAL_ARTICLE">
<AU>Frusso R, Zarate M, Augustovski F, Rubinstein A</AU>
<TI>Magnesium for the treatment of nocturnal leg cramps: a crossover randomized trial</TI>
<SO>Journal of Family Practice</SO>
<YR>1999</YR>
<VL>48</VL>
<NO>11</NO>
<PG>868-71</PG>
<IDENTIFIERS MODIFIED="2011-02-15 15:59:51 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 15:59:51 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10907623"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fung-1989" MODIFIED="2011-02-15 16:00:18 +0000" MODIFIED_BY="Kate Jewitt" NAME="Fung 1989" TYPE="JOURNAL_ARTICLE">
<AU>Fung MC, Holbrook JH</AU>
<TI>Placebo-controlled trial of quinine therapy for nocturnal leg cramps</TI>
<SO>Western Journal of Medicine</SO>
<YR>1989</YR>
<VL>151</VL>
<NO>1</NO>
<PG>42-4</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:00:18 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:00:18 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2669340"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gorlich-1991" MODIFIED="2011-02-15 16:00:39 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gorlich 1991" TYPE="JOURNAL_ARTICLE">
<AU>Gorlich HD, von Gablenz E, Steinberg HW</AU>
<TI>[Treatment of nocturnal leg cramps. A multicenter, double blind, placebo controlled comparison between the combination of quinine and theophylline ethylene diamine with quinine]</TI>
<SO>Arzneimittelforschung</SO>
<YR>1991</YR>
<VL>41</VL>
<PG>167-75</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:00:38 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:00:38 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2043179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Gubbay-1985" MODIFIED="2011-02-15 16:01:21 +0000" MODIFIED_BY="Kate Jewitt" NAME="Gubbay 1985" TYPE="JOURNAL_ARTICLE">
<AU>Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y</AU>
<TI>Amyotrophic lateral sclerosis. A study of its presentation and prognosis</TI>
<SO>Journal of Neurology</SO>
<YR>1985</YR>
<VL>232</VL>
<NO>5</NO>
<PG>295-300</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:01:21 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:01:21 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="4056836"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Heiman_x002d_Patterson-2000" MODIFIED="2011-04-03 16:51:28 +0100" MODIFIED_BY="Reto Baldinger" NAME="Heiman-Patterson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Heiman-Patterson TD, Rampal N, Brannagan TH, Acosta T, Forshew D, Bromberg MB</AU>
<TI>The spectrum of patient symptoms in ALS and symptom management</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>8, Suppl 3</NO>
<PG>A199</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-03-13 20:34:22 +0000" MODIFIED_BY="Ruth Brassington" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jansen-1994" MODIFIED="2011-02-15 16:01:48 +0000" MODIFIED_BY="Kate Jewitt" NAME="Jansen 1994" TYPE="JOURNAL_ARTICLE">
<AU>Jansen PH, Veenhuizen KC, Verbeek AL, Straatman H</AU>
<TI>Efficacy of hydroquinine in preventing frequent ordinary muscle cramp outlasts actual administration</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1994</YR>
<VL>122</VL>
<NO>2</NO>
<PG>157-61</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:01:46 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:01:46 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8021700"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jansen-1997" MODIFIED="2011-02-15 16:02:17 +0000" MODIFIED_BY="Kate Jewitt" NAME="Jansen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jansen PH, Veenhuizen KC, Wesseling AI, de Boo T, Verbeek AL</AU>
<TI>Randomised controlled trial of hydroquinine in muscle cramps</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<NO>9051</NO>
<PG>528-32</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:02:17 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:02:17 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9048790"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Khajehdehi-2001" MODIFIED="2011-02-15 16:02:39 +0000" MODIFIED_BY="Kate Jewitt" NAME="Khajehdehi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Khajehdehi P, Mojerlou M, Behzadi S, Rais-Jalali GA</AU>
<TI>A randomized, double-blind, placebo-controlled trial of supplementary vitamins E, C and their combination for treatment of haemodialysis cramps</TI>
<SO>Nephrology, Dialysis, Transplantation: official publication of the European Dialysis and Transplant Association</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>7</NO>
<PG>1448-51</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:02:37 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:02:37 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11427639"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kiernan-2001" MODIFIED="2011-02-15 16:03:08 +0000" MODIFIED_BY="Kate Jewitt" NAME="Kiernan 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kiernan MC, Hart KI, Bostock H</AU>
<TI>Excitability properties of motor axons in patients with spontaneous motor unit activity</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>2001</YR>
<VL>70</VL>
<NO>1</NO>
<PG>56-64</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:03:08 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:03:08 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11118248"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Layzer-1982" MODIFIED="2011-02-15 16:03:36 +0000" MODIFIED_BY="Kate Jewitt" NAME="Layzer 1982" TYPE="JOURNAL_ARTICLE">
<AU>Layzer RB</AU>
<TI>Diagnostic implications of clinical fasciculation and cramps</TI>
<SO>Advances in Neurology</SO>
<YR>1982</YR>
<VL>36</VL>
<PG>23-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:03:35 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:03:35 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7180684"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Layzer-1994" MODIFIED="2011-02-15 16:04:59 +0000" MODIFIED_BY="Kate Jewitt" NAME="Layzer 1994" TYPE="JOURNAL_ARTICLE">
<AU>Layzer RB</AU>
<TI>The origin of muscle fasciculations and cramps</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>11</NO>
<PG>1243-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:04:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:04:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7935546"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lee-1991" MODIFIED="2011-02-15 16:05:36 +0000" MODIFIED_BY="Kate Jewitt" NAME="Lee 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lee FY, Lee SD, Tsai YT, Lai KH, Chao Y, Lin HC, et al</AU>
<TI>A randomized controlled trial of quinidine in the treatment of cirrhotic patients with muscle cramps</TI>
<SO>Journal of Hepatology</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>2</NO>
<PG>236-40</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:05:36 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:05:36 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2051002"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Man_x002d_Son_x002d_Hing-1998" MODIFIED="2011-02-15 16:06:01 +0000" MODIFIED_BY="Kate Jewitt" NAME="Man-Son-Hing 1998" TYPE="JOURNAL_ARTICLE">
<AU>Man-Son-Hing M, Wells G, Lau A</AU>
<TI>Quinine for nocturnal leg cramps: a meta-analysis including unpublished data</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>1998</YR>
<VL>13</VL>
<NO>9</NO>
<PG>600-6</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:06:01 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:06:01 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9754515"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Miller-2009" MODIFIED="2012-03-13 20:34:40 +0000" MODIFIED_BY="Reto Baldinger" NAME="Miller 2009" TYPE="JOURNAL_ARTICLE">
<AU>Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W, et al</AU>
<TI>Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>73</VL>
<NO>15</NO>
<PG>1227-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mueller-1997" MODIFIED="2011-02-15 16:06:32 +0000" MODIFIED_BY="Kate Jewitt" NAME="Mueller 1997" TYPE="JOURNAL_ARTICLE">
<AU>Mueller ME, Gruenthal M, Olson WL, Olson WH</AU>
<TI>Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1997</YR>
<VL>78</VL>
<NO>5</NO>
<PG>521-4</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:06:30 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:06:30 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="9161373"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Norris-1957" MODIFIED="2011-02-15 16:06:59 +0000" MODIFIED_BY="Kate Jewitt" NAME="Norris 1957" TYPE="JOURNAL_ARTICLE">
<AU>Norris FH, Gasteiger EL, Chatfield PO</AU>
<TI>An electromyographic study of induced and spontaneous muscle cramps</TI>
<SO>Electroencephalography and Clinical Neurophysiology</SO>
<YR>1957</YR>
<VL>9</VL>
<NO>1</NO>
<PG>139-47</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:06:59 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:06:59 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="13404940"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Obi-1993" MODIFIED="2011-02-15 16:07:31 +0000" MODIFIED_BY="Kate Jewitt" NAME="Obi 1993" TYPE="JOURNAL_ARTICLE">
<AU>Obi T, Mizoguchi K, Matsuoka H, Takatsu M, Nishimura Y</AU>
<TI>Muscle cramp as the result of impaired GABA function--an electrophysiological and pharmacological observation</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>1993</YR>
<VL>16</VL>
<NO>11</NO>
<PG>1228-31</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:07:29 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:07:29 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="8413375"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parisi-2000" MODIFIED="2011-02-15 16:07:55 +0000" MODIFIED_BY="Kate Jewitt" NAME="Parisi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Parisi L, Serrao M, Rossi P, Valente G, Fattapposta F, Pierelli F, Amabile G</AU>
<TI>Afterdischarge activity in neuropathic patients with frequent muscle cramps</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>2000</YR>
<VL>102</VL>
<NO>6</NO>
<PG>359-62</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:07:54 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:07:54 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="11125756"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Piergies-1990" MODIFIED="2011-02-15 16:08:26 +0000" MODIFIED_BY="Kate Jewitt" NAME="Piergies 1990" TYPE="JOURNAL_ARTICLE">
<AU>Piergies AA, Atkinson AJ Jr, Hubler GL, del Greco F</AU>
<TI>Activation of renin-angiotensin system does not cause skeletal muscle cramps during hemodialysis</TI>
<SO>International Journal of Clinical Pharmacology, Therapy and Toxicology</SO>
<YR>1990</YR>
<VL>28</VL>
<NO>10</NO>
<PG>405-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:08:26 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:08:26 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="2258248"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Roeleveld-2000" MODIFIED="2011-02-15 16:08:53 +0000" MODIFIED_BY="Kate Jewitt" NAME="Roeleveld 2000" TYPE="JOURNAL_ARTICLE">
<AU>Roeleveld K, van Engelen BG, Stegeman DF</AU>
<TI>Possible mechanisms of muscle cramp from temporal and spatial surface EMG characteristics</TI>
<SO>Journal of Applied Physiology</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>5</NO>
<PG>1698-1706</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:08:53 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:08:53 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10797132"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ross-1995" MODIFIED="2011-02-15 16:09:34 +0000" MODIFIED_BY="Kate Jewitt" NAME="Ross 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ross BH, Thomas CK</AU>
<TI>Human motor unit activity during induced muscle cramp</TI>
<SO>Brain</SO>
<YR>1995</YR>
<VL>118 ( Pt 4)</VL>
<PG>983-93</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:09:31 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:09:31 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7655893"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Serrao-2000" MODIFIED="2011-02-15 16:10:05 +0000" MODIFIED_BY="Kate Jewitt" NAME="Serrao 2000" TYPE="JOURNAL_ARTICLE">
<AU>Serrao M, Rossi P, Cardinali P, Valente G, Parisi L, Pierelli F</AU>
<TI>Gabapentin treatment for muscle cramps: an open-label trial</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2000</YR>
<VL>23</VL>
<NO>1</NO>
<PG>45-9</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:10:05 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:10:05 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="10682230"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sidhom-1994" MODIFIED="2011-02-15 16:10:40 +0000" MODIFIED_BY="Kate Jewitt" NAME="Sidhom 1994" TYPE="JOURNAL_ARTICLE">
<AU>Sidhom OA, Odeh YK, Krumlovsky FA, Budris WA, Wang Z, Pospisil PA, Atkinson AJ Jr</AU>
<TI>Low-dose prazosin in patients with muscle cramps during hemodialysis</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1994</YR>
<VL>56</VL>
<NO>4</NO>
<PG>445-51</PG>
<IDENTIFIERS MODIFIED="2011-02-15 16:10:40 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-15 16:10:40 +0000" MODIFIED_BY="Kate Jewitt" TYPE="PUBMED" VALUE="7955806"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Swash-2000" MODIFIED="2011-02-15 16:10:46 +0000" MODIFIED_BY="Kate Jewitt" NAME="Swash 2000" TYPE="BOOK_SECTION">
<AU>Swash M</AU>
<TI>Clinical features and diagnosis of amyotrophic lateral sclerosis</TI>
<SO>Amyotrophic lateral sclerosis</SO>
<YR>2000</YR>
<PG>3-30</PG>
<EN>1st</EN>
<ED>Brown HR, Meininger V, Swash M</ED>
<PB>Martin Dunitz Ltd.</PB>
<CY>London</CY>
<IDENTIFIERS MODIFIED="2011-02-15 16:10:46 +0000" MODIFIED_BY="Kate Jewitt"/>
</REFERENCE>
<REFERENCE ID="REF-Young-2002" MODIFIED="2011-02-14 15:42:01 +0000" MODIFIED_BY="Kate Jewitt" NAME="Young 2002" TYPE="COCHRANE_REVIEW">
<AU>Young GL, Jewell D</AU>
<TI>Interventions for leg cramps in pregnancy (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2011-02-14 15:42:01 +0000" MODIFIED_BY="Kate Jewitt">
<IDENTIFIER MODIFIED="2011-02-14 15:42:01 +0000" MODIFIED_BY="Kate Jewitt" TYPE="DOI" VALUE="10.1002/14651858.CD000121"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-06-23 15:55:36 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2009-08-04 15:23:28 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-03-14 16:04:38 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-03-14 16:04:38 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-03-13 19:35:31 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Bensimon-1994">
<CHAR_METHODS MODIFIED="2012-03-13 19:35:26 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0, 8,16, 24, 32, 40, 48</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:50:27 +0000" MODIFIED_BY="Reto Baldinger">
<P>155 participants (64 female, 91 male), aged 20 to 75 years with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:35:29 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Riluzole 100 mg/day</LI>
<LI>Placebo</LI>
</UL>
<P>Identical-appearing tablets taken twice daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:35:31 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: death or tracheostomy after 12 months</P>
<P>Secondary outcomes: among others, cramps expressed on 100 mm VAS. Cramps assessment was not statistically different among the 2 groups, data were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-09 16:25:21 +0100" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:35:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bensimon-2002">
<CHAR_METHODS MODIFIED="2012-03-13 19:35:36 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0, 24, 48, 72</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-12 12:34:10 +0000" MODIFIED_BY="Reto Baldinger">
<P>168 participants (86 female, 82 male) with probable or definite ALS comprising one of three inclusion criteria:</P>
<OL>
<LI>age over 75 years; or</LI>
<LI>disease duration over 5 years since first symptoms; or</LI>
<LI>forced vital ventilatory capacity below 60% of the theoretical maximum value or not assessable</LI>
</OL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:35:38 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Riluzole 100 mg/day</LI>
<LI>Placebo</LI>
</UL>
<P>Tablets taken twice daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:35:41 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: death or tracheostomy after 18 months</P>
<P>Secondary outcomes: cramps expressed on a 100 mm VAS. Cramps were not significantly different among the two groups, data were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-09 16:25:32 +0100" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:36:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blin-1989">
<CHAR_METHODS MODIFIED="2012-03-13 19:35:58 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled cross-over trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0, 1, 3</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 13:00:31 +0000" MODIFIED_BY="Reto Baldinger">
<P>12 participants (gender not reported) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:36:01 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>L-Threonine 2 g/day for 7 days</LI>
<LI>Placebo for 7 days</LI>
</UL>
<P>One capsule once daily with a washout period of 7 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:36:07 +0000" MODIFIED_BY="Ruth Brassington">
<P>Outcome measures (primary outcome measure not stated): manual muscle strength, hand grip dynamometry, Tufts bulbar score and...cramps expressed on a 100 mm VAS. Cramps assessment was not significantly different among the 2 groups, data were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-02-23 08:50:40 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:36:20 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Blin-1992">
<CHAR_METHODS MODIFIED="2012-03-13 19:36:18 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0,12, 24, 36, 48</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:52:05 +0000" MODIFIED_BY="Reto Baldinger">
<P>23 participants (10 female, 13 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:36:20 +0000" MODIFIED_BY="Ruth Brassington">
<UL>
<LI>L-threonine 2 g/day</LI>
<LI>Placebo</LI>
</UL>
<P>Powder taken orally once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-01-18 15:53:17 +0000" MODIFIED_BY="Ruth Brassington">
<P>Outcome measures (primary outcome measure not stated): manual muscle strength, hand grip dynamometry, and ... cramps expressed on a 100-mm VAS. Cramps assessment was not significantly different among the two groups, data were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-14 10:43:08 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Brooks-2004">
<CHAR_METHODS MODIFIED="2012-01-18 15:54:08 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, parallel trial</P>
<P>Assessment of cramps (as adverse effects) at week 0, 2, 4</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:52:24 +0000" MODIFIED_BY="Reto Baldinger">
<P>129 participants (49 female, 80 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-14 10:43:08 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Quinidine (Q) 60 mg/d</LI>
<LI>Dextromethorphan (D) 60 mg/d</LI>
<LI>Q + D (60 mg/d each)</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-23 14:49:57 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: change in a pseudobulbar affect score</P>
<P>Secondary outcomes: number of laughing or crying episodes per week, quality of life and quality of relationship scores</P>
<P>Cramps were assessed as adverse effects. Adverse effects were not significantly different between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 17:07:20 +0000" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:47:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chi_x00f2_-2010">
<CHAR_METHODS MODIFIED="2012-01-11 15:01:34 +0000" MODIFIED_BY="Reto Baldinger">
<P>Single-blind, randomised, controlled parallel dose-finding trial</P>
<P>Cramps were not assessed prospectively. Study visits were at week 12, 24, 36, 48, and 60.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-13 19:47:12 +0000" MODIFIED_BY="Reto Baldinger">
<P>171 participants (71 female, 100 male) with probable or definite ALS, all taking 50mg riluzole twice daily</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:47:14 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Group 1 was targeted at a therapeutic lithium serum level</LI>
<LI>Group 2 was targeted at a subtherapeutic lithium serum level</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:47:21 +0000" MODIFIED_BY="Reto Baldinger">
<P>The composite primary outcome measure was survival or severe loss of autonomy, defined as the time from inclusion to death/tracheostomy or at least 2 of the following ALSFRS-R scores: 1 for swallowing, 1 for walking, or 2 for respiratory insufficiency</P>
<P>Secondary endpoints were the mean monthly variation of 1) the ALSFRS-R total score and 2) the FVC% value; 3) the number of therapeutic failures (treatment stops for ineffectiveness, adverse events, or both); and 4) quality of life score</P>
<P>Cramps were assessed as adverse effects, number of participants was not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-03-13 19:47:26 +0000" MODIFIED_BY="[Empty name]">
<P>117 participants (68%) discontinued due to adverse effects and the trial was stopped prematurely. The vast majority of adverse effects were attributed to the lithium therapy and comprised tremor, thyroid disturbances including thyroiditis, polyuria, deep venous thrombosis, gastrointestinal disturbances, cardiac disturbances (1 fatal and 1 non-fatal arrhythmia, 1 myocardial infarction), muscle pain, and severe cramps (number of participants not given)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:47:48 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-De-Carvalho-2010">
<CHAR_METHODS MODIFIED="2012-03-13 19:47:29 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 12, 24, 36, and 48</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-13 19:47:32 +0000" MODIFIED_BY="Reto Baldinger">
<P>63 participants (21 female, 42 male) with probable or definite ALS, all taking 50mg riluzole twice daily</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:47:37 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Memantine 10 mg twice daily</LI>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:47:48 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>The primary outcome was change in the ALSFRS (40-point rating scale) from baseline to 12 months</LI>
</UL>
<UL>
<LI>Secondary outcomes were: predicted value of FVC; manual muscle testing (32 muscle groups as classified on the MRC scale, maximal score 160); patient 100 mm VAS (for fasciculations, cramps, fatigue and stiffness); medical 100 mm VAS (global: worse, stable, improved); quality of life (SF-36); motor unit number estimation of both ADM (incremental technique); and neurophysiological index (NI) of both ADM. For the neurophysiological measurements the mean value from both hands was calculated and its value used in the analysis</LI>
</UL>
<P>Quote: "There was no significant difference between memantine and placebo groups."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:48:06 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Desnuelle-2001">
<CHAR_METHODS MODIFIED="2012-03-13 19:48:02 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0,12, 24, 36, 48</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:54:20 +0000" MODIFIED_BY="Reto Baldinger">
<P>289 participants (130 female, 158 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:48:04 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Vitamin E 1000 mg/day + riluzole 100 mg/day</LI>
<LI>Placebo + riluzole 100 mg/day</LI>
</UL>
<P>two identically appearing capsules (vitamin E versus placebo) twice daily and Riluzole tablets twice daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:48:06 +0000" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome: change in functional status of each participant using the modified Norris limb scale</P>
<P>Secondary outcomes: survival (the time to death or tracheostomy), bulbar function assessed with the Norris bulbar scale and manual muscle testing. Fatigue, limb stiffness, cramps and fasciculations were assessed with VAS</P>
<P>Cramps were not significantly different among the two groups, data were not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 16:17:22 +0000" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:48:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gil-1992">
<CHAR_METHODS MODIFIED="2012-03-13 19:48:25 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, quasi-randomised, placebo-controlled cross-over trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0, 1, 3, 5</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:54:38 +0000" MODIFIED_BY="Reto Baldinger">
<P>20 participants (11 female, 9 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:48:38 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>A: L-threonine 2 g/day for 8 days</LI>
<LI>B: L-leucine 12 g/day + L-isoleucine 8 g/day + L-valine 6,4 g/day for 8 days</LI>
<LI>C: placebo for 8 days</LI>
</UL>
<P>Between phase A to B and B to C was a washout period of 8 days, respectively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:48:50 +0000" MODIFIED_BY="Ruth Brassington">
<P>Outcome measures (primary outcome measure not stated): manual muscle strength, a clinical severity score, a bulbar function score, and fatigue and cramps assessed on a VAS. Comment: cramp assessment by VAS was not further specified (i.e. not specified whether cramp intensity or number of cramp days were assessed)</P>
<P>Quote: "Pour ce qui concerne les chelles d'auto-evaluation, la fatigue, les fasciculations, le handicap ne sont pas modifies; toutefois, les crampes, stables sous acides amines branches et sous L-threonine, s'aggravent sous placebo (P = 0,038)." Translation: "Concerning visual analogue scale of fatigue and fasciculation, the result remained unchanged. But cramps, stable under therapy with branched amino acids and L-threonine, increased under placebo (P = 0.038)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-01 15:14:12 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:48:58 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Groeneveld-2003">
<CHAR_METHODS MODIFIED="2011-03-23 14:50:33 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps at week 0, 4, 8, 24, 40, 56</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:54:57 +0000" MODIFIED_BY="Reto Baldinger">
<P>175 participants (57 female, 118 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-20 19:53:39 +0100" MODIFIED_BY="Ruth Brassington">
<UL>
<LI>Creatine 10 g/day</LI>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:48:58 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: death, tracheostomy, or persistent assisted ventilation after 16 months</P>
<P>Secondary outcomes: rate of decline in muscle strength, rate of decline of lung VC, rate of decline of ALSFRS, and rate of decline of the physical and mental summary scores of the SF-36</P>
<P>Cramps were assessed as adverse effects. Adverse effects were not significantly different between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 17:07:21 +0000" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:49:04 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lacomblez-1996">
<CHAR_METHODS MODIFIED="2012-03-13 19:49:01 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0, 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 96, 104</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:55:19 +0000" MODIFIED_BY="Reto Baldinger">
<P>959 participants (384 female, 575 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-23 14:50:48 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Riluzole 50 mg/day</LI>
<LI>Riluzole 100 mg/day</LI>
<LI>Riluzole 200 mg/day</LI>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:49:04 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: death or tracheostomy</P>
<P>Secondary outcomes: rates of change in functional measures (muscle strength, functional status, respiratory function, and patient&#8217;s assessments of fasciculation, cramps, stiffness, and<BR/>tiredness. Cramps expressed on 100 mm VAS</P>
<P>Quote: "No other treatment effect was detectable with the other secondary variables (respiratory function test, visual analogue scales, or clinician general impression of severity)." No specific results concerning cramps were presented in the article</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-09 16:26:00 +0100" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:49:22 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lacomblez-1996a">
<CHAR_METHODS MODIFIED="2012-03-13 19:49:12 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0, 8,16, 24, 32, 40, 48, 56, 64, 72 ,80, 96, 104</P>
<P>"... Rates of functional deterioration were secondary efficacy criteria. Disease progression was assessed with use of functional evaluations (muscle testing, modified Norris limb and bulbar scales) and symptom assessments for fasciculations, cramps, stiffness, and tiredness were based on the patients&#8217; subjective evaluation using 100-mm visual-analog scales ..."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:55:39 +0000" MODIFIED_BY="Reto Baldinger">
<P>959 participants (384 female, 575 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-23 14:51:54 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Riluzole 50 mg/day</LI>
<LI>Riluzole 100 mg/day</LI>
<LI>Riluzole 200 mg/day</LI>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:49:22 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: death, tracheostomy, or mechanical ventilation after 18 months</P>
<P>Secondary outcomes: muscle strength, modified Norris limb and bulbar scales, change of CGI, lung VC, and subjective symptom assessments for fasciculations, cramps, stiffness, and tiredness (using 100 mm VAS)</P>
<P>Data concerning cramps were not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-03-23 14:51:58 +0000" MODIFIED_BY="Reto Baldinger">
<P>Subgroup analysis of the study by <LINK REF="STD-Lacomblez-1996" TYPE="STUDY">Lacomblez 1996</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:53:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Meininger-2004">
<CHAR_METHODS MODIFIED="2012-03-13 19:49:34 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 4, 8, 16, 32, 40, 48, 56, 64, 72</P>
<P>Quote: "The secondary efficacy outcome variables were VC, manual muscle testing, ALSFRS, Norris limb and bulbar scales, VAS (for fasciculations, cramps, stiffness, fatigability, and breathing),"... etc</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-13 19:52:30 +0000" MODIFIED_BY="Reto Baldinger">
<P>867 participants (338 female, 529 male) with probable or definite ALS in the first, 1210 (448 female, 762 male) participants with probable or definite ALS in the second of the 2 studies reported in this article.</P>
<P>"Patient characteristics at baseline...were similar between ... groups..."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:52:44 +0000" MODIFIED_BY="Reto Baldinger">
<P>Study 1:</P>
<UL>
<LI>xaliproden 1 mg/day</LI>
<LI>xaliproden 2 mg/day</LI>
<LI>placebo</LI>
</UL>
<P>Identical-appearing capsules once daily</P>
<P>Study 2:</P>
<UL>
<LI>xaliproden 1 mg/day + riluzole 100 mg/day</LI>
<LI>xaliproden 2 mg/day + riluzole 100 mg/day</LI>
<LI>placebo + riluzole 100 mg/day</LI>
</UL>
<P>In addition to riluzole, participants were given identical-appearing capsules once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:53:07 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: time to death, tracheostomy, or permanent assisted ventilation (DTP), and 2. Time to lung VC 50% or DTP
<BR/>

</P>
<P>Secondary outcomes: lung VC, muscle strength, ALSFRS, Norris limb and bulbar scales, VAS (using 100 mm VAS) for fasciculations, cramps, stiffness, fatigability, and breathing, spasticity scale, CGI (severity of illness, impression of change), and SIP. Results concerning cramps were not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-09 16:26:10 +0100" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:53:15 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Miller-1996">
<CHAR_METHODS MODIFIED="2012-01-18 15:57:09 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps at week 0, 4, 8, 12, 16, 20, 24</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 12:58:02 +0000" MODIFIED_BY="Reto Baldinger">
<P>149 participants (47 female, 102 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:53:12 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>gabapentin 2400 mg/day</LI>
<LI>placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:53:15 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: slope of arm strength megascore</P>
<P>Secondary outcomes: rates of decline of lung functional VC and arm megascore slope for the completer population (those who had completed all 6 monthly visits)</P>
<P>Cramps were assessed as adverse effects. Adverse effects were not significantly different between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 16:54:18 +0000" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-14 10:01:47 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Miller-2001">
<CHAR_METHODS MODIFIED="2012-03-14 10:01:47 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps (patient's global impression of muscle cramp burden over the time between study visits as rated by VAS) at week 0, 4, 8, 12, 16, 20, 24, 28, 32, 36</P>
<P>Quote: "...as well as a symptom survey (cramps, fasciculations, stiffness, sleeping and emotionality, in which patients rated the severity of symptoms on an analogue scale of 0 to 10), were all measured every 4 weeks."</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-13 19:53:32 +0000" MODIFIED_BY="Reto Baldinger">
<P>204 participants (79 female, 125 male) with probable or definite ALS</P>
<P>Quote: "The baseline characteristics of the patients were...well matched for age, sex, height, weight, initial FVC, MVC (% predicted), and initial mean megascore. However, treated patients had a shorter duration of symptoms prior to study entry...compared with the placebo group suggesting a more rapid rate of progression in the treated group."</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-05-15 15:35:42 +0100" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Gabapentin 3600 mg/day</LI>
<LI>Placebo</LI>
</UL>
<P>Quote: "Eligible patients were randomly assigned in a double blinded fashion to receive either gabapentin 1,200 mg or placebo three times daily for 9 months."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:53:46 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: slope of arm strength megascore</P>
<P>Secondary outcomes: lung VC, ALSFRS, timed walking, rapid foot taps, a health status survey, SF-12 quality of life scale, as well as symptom surveys (cramps, fasciculations, stiffness, sleeping and emotionality, in which participants rated the severity of symptoms on an analogue scale of 0 to 10)</P>
<P>Quote: "...there was no difference between the treatment and placebo groups with respect to...symptomatic benefit of...cramps..."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-11 22:14:55 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Norris-1979">
<CHAR_METHODS MODIFIED="2012-03-11 22:14:55 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps at week 0, 1, 2, 3, 4, 5, 6, 7</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-18 15:57:50 +0000" MODIFIED_BY="Reto Baldinger">
<P>20 participants (gender not reported) with probable or definite ALS</P>
<P>Participant characteristics were not reported.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-23 14:54:11 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Baclofen 15 to 80 mg/day</LI>
<LI>Placebo</LI>
</UL>
<P>Quote: "23 consecutive patients with ALS ... who manifested major problems with spasticity were randomly assigned to treatment with either baclofen or placebo."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-03-23 14:54:12 +0000" MODIFIED_BY="Reto Baldinger">
<P>Outcome measures (primary outcome measure not stated): an ALS clinical score, subjective impression of spasticity and cramps</P>
<P>Quote: "Several patients in the baclofen treated group noted ... diminution of painful cramps, but such benefit also occurred in the placebo-treated patients."</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-14 16:04:38 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Rosenfeld-2008">
<CHAR_METHODS MODIFIED="2011-03-23 14:54:40 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps at week 0, 1, 2, 3, 8, 12, 16, 20, 28, 36</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 13:00:56 +0000" MODIFIED_BY="Reto Baldinger">
<P>107 participants (45 female, 62 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-07-20 19:53:49 +0100" MODIFIED_BY="Ruth Brassington">
<UL>
<LI>Creatine monohydrate 5 g/day</LI>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-14 16:04:38 +0000" MODIFIED_BY="Reto Baldinger">
<P>Primary outcome: MVIC</P>
<P>Secondary outcomes: FVC, ALSFRS, SF-12 quality of life scale and muscle fatigue</P>
<P>Cramps were assessed as adverse effects. Adverse effects were not significantly different between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 17:07:23 +0000" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:54:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scelsa-2005">
<CHAR_METHODS MODIFIED="2011-03-23 14:55:10 +0000" MODIFIED_BY="Reto Baldinger">
<P>Double-blind, randomised, placebo-controlled parallel trial</P>
<P>Assessment of cramps at week 0, 12, 24, 36</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 13:01:14 +0000" MODIFIED_BY="Reto Baldinger">
<P>46 participants (13 female, 33 male) with probable or definite ALS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-03-23 14:55:20 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>Indinavir 800 mg/day</LI>
<LI>Placebo</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:54:09 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: slope of decline of the ALSFRS score</P>
<P>Secondary outcomes: slope of decline of the Manual Muscle Testing Composite Scale score, lung VC, and the SF-36 quality of life scale</P>
<P>Cramps were assessed as adverse effects: the number of participants reporting leg muscle cramp as a side effect was (2/23, 8.7%) in the treatment group and (1/23, 4.4%) in the placebo group for the whole observation period. Adverse effects were not significantly different between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-06 17:07:23 +0000" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-03-13 19:54:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weber-2010">
<CHAR_METHODS MODIFIED="2012-03-13 19:54:18 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind, randomised, placebo-controlled cross-over trial</P>
<P>Assessment of cramps at week 0, 4, 8</P>
<P>Quote: "The primary outcome measure was the average cramp intensity during the preceding 24 hours rated every morning on a VAS with a scale of 0 to 10 (zero to maximal burden, i.e. 0% to 100%).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-01-14 13:02:43 +0000" MODIFIED_BY="Reto Baldinger">
<P>22 participants (5 female, 17 male) with probable or definite ALS</P>
<P>Due to the cross-over study design, mean baseline participant characteristics were not compared between the placebo-verum and the verum-placebo group</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:54:22 +0000" MODIFIED_BY="Reto Baldinger">
<UL>
<LI>THC 10 mg/day for 2 weeks</LI>
<LI>Placebo for 2 weeks</LI>
</UL>
<P>Washout period of 2 weeks</P>
<P>Quote: "The active study medication consisted of sesame oil containing D9-THC (dronabinol) 2.5 mg. The placebo medication contained only sesame oil..."</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:54:25 +0000" MODIFIED_BY="[Empty name]">
<P>Primary outcome: average cramp intensity during the preceding 24 hours rated every morning on a VAS</P>
<P>Secondary outcomes: number of cramps during the preceding 24 hours, and severity of fasciculations on a VAS</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-04-16 14:29:29 +0100" MODIFIED_BY="Reto Baldinger"/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALS/MND: amyotrophic lateral sclerosis/motor neuron disease</P>
<P>ALSFRS-R: amyotrophic lateral sclerosis functional rating scale - revised</P>
<P>CGI: clinical global impression</P>
<P>FVC%: forced vital capacity as a percentage of predicted</P>
<P>MRC: Medical Research Council</P>
<P>MVIC: maximum voluntary isometric contraction</P>
<P>SF-12: Short Form-12 Health Survey</P>
<P>SF-36: Short Form-36 Health Survey</P>
<P>THC: tetrahydrocannabinol</P>
<P>VAS: visual analogue scale</P>
<P>VC: vital capacity</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-03-14 10:03:17 +0000" MODIFIED_BY="Reto Baldinger" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:48:25 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Aggarwal-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:48:25 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:50:22 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Aisen-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:50:22 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:50:26 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Aksu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:50:26 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:50:32 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Aksu-2002a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:50:32 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:50:36 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-ALSCNTF-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:50:36 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 22:00:18 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Apostolski-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 22:00:18 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 22:00:16 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Appel-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 22:00:16 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 22:00:13 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Aquilonius-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 22:00:13 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 22:00:11 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Armon-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 22:00:11 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 22:00:07 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Askmark-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 22:00:07 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 22:00:05 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-BDNF-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 22:00:05 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 22:00:02 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Beghi-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 22:00:02 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:59 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Beghi-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:59 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:57 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Bello_x002d_Haas-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:57 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:54 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Berto-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:54 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:51 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Biletch-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:51 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:48 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Blin-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:48 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:45 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Blin-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:45 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:43 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Borasio-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:42 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:40 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Borasio-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:40 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:58:58 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Bourke-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:58:58 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:04 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Bradley-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:04 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:06 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Brody-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:06 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:08 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Brooke-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:08 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:11 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Brooks-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:11 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:13 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Brooks-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:13 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:16 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Brooks-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:16 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:18 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Brooks-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:18 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:20 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Caroscio-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:20 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:22 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Carter-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:22 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:25 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Cedarbaum-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:25 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:59:27 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Chi_x00f2_-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:59:27 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:00 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Civardi-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:00 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:04 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Conrad-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:04 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:08 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Cudkowicz-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:08 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:15 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Cudkowicz-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:15 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:23 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Cudkowicz-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:23 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:34 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Desai-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:34 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:44 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Di-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:44 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:48 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Drachman-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:48 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:51:56 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Drory-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:51:56 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:05 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Drory-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:05 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:10 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Eckland-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:10 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:21 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Eisen-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:21 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:17 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Ellis-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:17 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:24 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Fareed-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:24 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:27 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Farkkila-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:27 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:29 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Farkkila-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:29 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:32 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Finsterer-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:32 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:34 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gelinas-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:34 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:38 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Goonetilleke-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:38 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:41 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gordon-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:41 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:45 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gordon-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:45 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:47 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gordon-2006a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:47 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:51 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gordon-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:51 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:54 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gordon-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:54 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:56 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Graf-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:56 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:52:58 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gredal-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:52:58 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:01 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Gredal-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:01 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:03 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Groeneveld-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:03 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:06 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Guiloff-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:06 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:08 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Guiloff-1987a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:08 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:10 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Hallett-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:10 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:12 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Harrington-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:12 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:14 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Hawley-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:14 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:16 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Hesselmans-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:16 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:18 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Hoagland-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:18 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:20 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Hubbard-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:20 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:23 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Imoto-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:23 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:25 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Jackson-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:25 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:28 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Janik-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:28 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:29 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Jossan-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:29 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:31 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Kaji-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:31 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:33 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Kalra-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:33 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:35 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Karageorgiou-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:35 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:46 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Kaufmann-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:46 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:54 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Kelly-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:54 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:57 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Kodama-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:57 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:53:59 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Kwiecinski-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:53:59 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:01 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lacomblez-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:01 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:03 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lacomblez-1989a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:03 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-14 10:03:17 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Lacomblez-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-14 10:03:17 +0000" MODIFIED_BY="Kate Jewitt">
<P>Open label extension study (i.e. not randomized) of <LINK REF="STD-Bensimon-1994" TYPE="STUDY">Bensimon 1994</LINK> and <LINK REF="STD-Lacomblez-1996" TYPE="STUDY">Lacomblez 1996</LINK> to assess long-term safety of riluzole 100 mg/day.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:16 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lacomblez-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:16 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:20 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lai-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:20 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:22 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lange-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:22 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:24 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lange-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:24 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:26 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lange-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:26 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:58:29 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lauria-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:58:29 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:30 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Levin-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:30 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:32 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Levy-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:32 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:34 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lipp-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:34 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:36 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Liversedge-1956">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:36 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:38 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Lomen_x002d_Hoerth-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:38 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:40 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Louwerse-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:40 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:44 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Markland-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:44 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:46 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Mazzini-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:46 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:48 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Mazzini-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:48 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:50 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Meininger-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:50 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:52 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Meininger-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:52 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:57:59 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Meininger-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:57:59 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:56 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Meyer-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:56 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:54:58 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Miller-1996a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:54:58 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:00 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Miller-1996b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:00 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:01 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Miller-1996c">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:01 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:03 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Miller-1996d">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:03 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:05 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Miller-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:05 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:06 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Mitchell-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:06 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:08 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Mitsumoto-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:08 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:10 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Munsat-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:10 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:11 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Munsat-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:11 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:13 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Munsat-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:13 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:14 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Murphy-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:14 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:18 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Nagano-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:18 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:57:50 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Nefussy-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:57:50 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:21 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Norris-1974">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:21 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:24 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Norris-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:24 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:25 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Norris-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:25 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:27 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Ochs-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:27 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:30 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Oda-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:30 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:31 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Olarte-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:31 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:34 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Olarte-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:34 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:36 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Olson-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:36 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:39 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-On-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:39 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:40 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Panitch-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:40 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:57:42 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Pascuzzi-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:57:42 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:45 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Percy-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:45 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:47 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Piepers-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:47 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:57:31 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Piepers-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:57:31 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:57:31 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Pioro-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:57:31 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:53 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Plaitakis-1988">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:53 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:54 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Pontieri-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:54 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:56 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Poutiainen-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:56 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:55:59 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Rabkin-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:55:59 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:01 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-rHCNTF-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:01 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:03 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-rHCNTF-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:03 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:04 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Rivera-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:04 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:06 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Rivera-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:06 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:08 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Roufs-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:08 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:10 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Ryberg-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:10 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:57:23 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Sacca-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:57:23 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:15 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Sato-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:15 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:17 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Shefner-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:17 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:19 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Smith-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:19 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:21 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Smith-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:21 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:23 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Sofuoglu-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:23 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:24 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Sorenson-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:24 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:26 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Steele-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:26 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:29 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Strevic-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:29 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:31 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Szczudlik-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:31 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:32 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Tandan-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:32 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:34 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Testa-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:34 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:36 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Testa-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:36 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:38 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Tyler-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:38 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:57:08 +0000" MODIFIED_BY="Kate Jewitt" STUDY_ID="STD-Tyler-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:57:08 +0000" MODIFIED_BY="Kate Jewitt">
<P>Neurotoxin was given intramuscularly</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:46 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Yanagisawa-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:46 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:49 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Zhang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:49 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:52 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Ziv-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:52 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-12 21:56:54 +0000" MODIFIED_BY="Reto Baldinger" STUDY_ID="STD-Zoccolella-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-12 21:56:54 +0000" MODIFIED_BY="Reto Baldinger">
<P>The study did not meet the selection criteria. "Cramp" or "cramps" was not mentioned in the full text paper.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2010-03-06 04:47:37 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-03-14 15:52:13 +0000" MODIFIED_BY="Ruth Brassington" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-03-14 15:52:13 +0000" MODIFIED_BY="Ruth Brassington" STUDY_ID="STD-Strong-ongoing">
<CHAR_STUDY_NAME MODIFIED="2012-03-14 15:52:10 +0000" MODIFIED_BY="Ruth Brassington">
<P>Randomised crossover design trial of vitamin E vs placebo for treatment of cramps in amyotrophic lateral sclerosis</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-03-14 15:52:13 +0000" MODIFIED_BY="Ruth Brassington">
<P>Double-blind, placebo-controlled, randomised, cross-over trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-13 19:55:11 +0000" MODIFIED_BY="Ruth Brassington">
<P>People with ALS/MND</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-13 19:55:16 +0000" MODIFIED_BY="Ruth Brassington">
<P>800 IE vitamin E twice daily vs placebo (cross-over)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-13 19:55:59 +0000" MODIFIED_BY="Ruth Brassington">
<P>Primary outcome measure: reduction of cramp number in a 2-week period (time frame: 4 weeks)</P>
<P>Secondary outcome measure: reduction of cramp duration and severity in a 2-week period (time frame: 4 weeks)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2011-07-20 19:53:59 +0100" MODIFIED_BY="Ruth Brassington">
<P>December 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2011-07-20 19:54:00 +0100" MODIFIED_BY="Ruth Brassington">
<P>Principal Investigator: Michael J Strong, MD, FRCPC. Sub-Investigator: Christen L Shoesmith, MD, FRCPC. Contact: Ann Rowe, RN, 1-519-663-3934 <A HREF="mailto:annm.rowe%40lhsc.on.ca?subject=NCT00372879, R-06-451, Clinical Trial of Vitamin E to Treat Muscular Cramps in Patients With ALS">annm.rowe@lhsc.on.ca</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2011-06-19 19:34:19 +0100" MODIFIED_BY="Reto Baldinger"/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ALS/MND: amyotrophic lateral sclerosis/motor neuron disease</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-03-14 10:01:26 +0000" MODIFIED_BY="Reto Baldinger" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:35:35 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Bensimon-1994">
<DESCRIPTION>
<P>Quote: " ...We conducted a prospective, randomised, double-blind, placebo-controlled, stratified trial... Randomisation was stratified according to the centre where the patient was treated (one of seven centres) and the site of the onset of disease (a limb or the bulbar region)..."Comment: the specific randomisation method is not reported, but randomisation was done centrally. Sequence generation probably adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 20:27:15 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Bensimon-2002">
<DESCRIPTION>
<P>Quote: "Patients were randomly assigned to one of the two treatment groups...according to a randomisation list balanced by centre...No information on the previously allocated double-blind treatment was given to the investigator or to the patient"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:49:34 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Blin-1989">
<DESCRIPTION>
<P>Quote: "Le plan experimental etait un essai randomise en cross over, en double aveugle contre placebo ... " Translation: "The study was planned as a randomised placebo-controlled cross-over trial ..." Comment: insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:36:22 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Blin-1992">
<DESCRIPTION>
<P>Quote: "...patients were...randomised..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:16:55 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Brooks-2004">
<DESCRIPTION>
<P>Quote: "The study was randomised by centre. Randomisation was blocked to ensure approximately equal representation within treatment centres using a computer algorithm."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-16 19:41:01 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Chi_x00f2_-2010">
<DESCRIPTION>
<P>Quote: "Randomization was performed separately for each centre, according to predetermined lists. Patients were stratified according to FVC% at enrolment (50%&#8211;79% vs 80%)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:47:58 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-De-Carvalho-2010">
<DESCRIPTION>
<P>Quote: "Randomization was independently performed by the clinical research unit of our department, although a computer-generated list and randomisation codes were kept blinded to the study investigators and statisticians." Strati&#64257;cation by region of onset (limb vs bulbar) within each treatment arm was undertaken, and a block of 4 was used in each stratum. Participants were assigned (ratio of 1:1) to placebo or memantine</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:48:08 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Quote: "...The randomisation was balanced by centre... "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-16 22:26:37 +0100" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Gil-1992">
<DESCRIPTION>
<P>Allocation generation to cross-over sequence was not done by random but by sequential entry into the study: 1. participant to ABC, 2. to BCA, 3. to CAB, 4. again to ABC, etc. No comparison of baseline characteristics was given to document an even distribution among the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:28:16 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>Quote: "Randomization was performed by an independent physician according to the minimization method of Pocock and Zelen."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:49:07 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996">
<DESCRIPTION>
<P>Quote: "...Randomisation was stratified by centre..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 10:01:26 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996a">
<DESCRIPTION>
<P>Quote: "... Randomisation was stratified by centre...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:53:08 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Meininger-2004">
<DESCRIPTION>
<P>Quote: "...A computer-generated list was used to randomly assign patients to the three treatment arms..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:53:21 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1996">
<DESCRIPTION>
<P>Quote: "...patients were randomly assigned, ...". Comment: insufficient information to permit "Yes" or "No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:29:01 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Miller-2001">
<DESCRIPTION>
<P>Quote: "The randomisation was accomplished by the research pharmacist at the coordinating site and the allocation of patients was known only to her."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:54:13 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Norris-1979">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:29:04 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Quote: "Patients were randomised in a 1:1 ratio..." and "Randomisation was organized in blocks and stratified by clinic to ensure treatment group balance at each site."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:29:05 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Scelsa-2005">
<DESCRIPTION>
<P>Quote: "Patients were randomised 1:1 to placebo or indinavir treatment by the Beth Israel Pharmacy Department, using a random chart assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-05 14:09:25 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Weber-2010">
<DESCRIPTION>
<P>Quote: "A computer-generated blockwise random sequence was provided by the study statistician."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="Reto Baldinger" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 12:33:51 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Bensimon-1994">
<DESCRIPTION>
<P>Quote: "treatment assignments were made separately in each centre and were based on randomisation codes established by blocking"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 20:27:12 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Bensimon-2002">
<DESCRIPTION>
<P>Comment: randomisation was done centrally</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:36:10 +0000" MODIFIED_BY="Kate Jewitt" RESULT="UNKNOWN" STUDY_ID="STD-Blin-1989">
<DESCRIPTION>
<P>Quote: "Le plan experimental etait un essai randomise en cross over, en double aveugle contre placebo ... " Translation: "The study was planned as a randomised placebo-controlled cross-over trial ..." Comment: insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-11 21:45:12 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Blin-1992">
<DESCRIPTION>
<P>Quote: "...patients were entered sequentially..." Comment: insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Brooks-2004">
<DESCRIPTION>
<P>Study drug was randomised by Sharp Clinicals (Conshohocken, PA) and shipped directly to the clinical study sites. The sponsor and investigators were blinded to treatment allocation. Investigators were shipped Q + D, D, and Q in identical blister-pack cards that were dispensed in strict sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-16 19:41:03 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Chi_x00f2_-2010">
<DESCRIPTION>
<P>Quote: "Randomization was performed separately for each centre, according to predetermined lists. Patients were stratified according to FVC% at enrolment (50%&#8211;79% vs 80%)."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 14:45:49 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-De-Carvalho-2010">
<DESCRIPTION>
<P>Quote: "Masked study medication was supplied for dispensation in blister packs at each visit. Drug and placebo tablets were visually identical."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:48:09 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Quote: "...Patients were randomly assigned to one of the two treatment groups according to a randomisation schedule... "</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:50:28 +0000" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Gil-1992">
<DESCRIPTION>
<P>No information concerning allocation concealment is provided. Comment: probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:28:17 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>Quote: "After having allocated a trial patient to one of two treatment groups, Groups A or B, the independent physician, ignorant to whether A or B was creatine, would instruct the research pharmacist to prepare trial medication A or B. The research pharmacist was the only person who knew the trial code of A or B. Trial medication was packed in blank containers and handed out ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:49:09 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996">
<DESCRIPTION>
<P>Quote: "...Randomisation was stratified by centre..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 10:01:29 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996a">
<DESCRIPTION>
<P>Quote: "... Randomisation was stratified by centre...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:29:00 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Meininger-2004">
<DESCRIPTION>
<P>Quote: "A double-blind randomised parallel group design was used... At all sites consecutively enrolled individuals who satisfied all entry criteria received the next treatment number."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:53:27 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1996">
<DESCRIPTION>
<P>Comment: insufficient information to permit 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:29:02 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Miller-2001">
<DESCRIPTION>
<P>Quote: "Randomization was accomplished in blocks of four patients, two placebo and two drug in each block, which equalized treatment assignment at each treatment centre."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:54:14 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Norris-1979">
<DESCRIPTION>
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:33:57 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Comment: done centrally</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:29:06 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Scelsa-2005">
<DESCRIPTION>
<P>Quote: "Patients were randomised ... by the Beth Israel Pharmacy Department ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 15:05:16 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Weber-2010">
<DESCRIPTION>
<P>Quote: "Two copies of the complete randomisation list were prepared. One was used by the hospital pharmacy in conjunction with the patient&#8217;s trial number to dispense either THC and then placebo or vice versa. Another was stored at a confidential location by the statistician until the time of unblinding."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-12 12:34:43 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Bensimon-1994">
<DESCRIPTION>
<P>Quote: "We conducted a...double-blind...trial...Treatment assignments...were based on randomisation codes...". Furthermore, 24 patients who did not entirely meet the inclusion criteria...were only after unblinding found to be evenly distributed among the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-12 20:27:32 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Bensimon-2002">
<DESCRIPTION>
<P>Quote: "...No information on the previously allocated double-blind treatment was given to the investigator or to the patient..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 19:36:14 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Blin-1989">
<DESCRIPTION>
<P>Quote: "... Des gelules indiscernables de placebo (lactose) ou L-threonine (2 g/j) ..." Translation: "Indistinguishable capsules of placebo (lactose) or L-threonine (2 g/d) were administered."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 19:36:23 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Blin-1992">
<DESCRIPTION>
<P>Quote: "...double blind....lactose powder as placebo..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 13:10:12 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Brooks-2004">
<DESCRIPTION>
<P>All were identical in appearance. The sponsor and investigators were blinded to treatment allocation. Investigators were shipped Q + D, D, and Q in identical blister-pack cards that were dispensed in strict sequence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-09 12:24:58 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Chi_x00f2_-2010">
<DESCRIPTION>
<P>Quote: "To preserve blindness, each patient was followed by 2 physicians: a treating physician, who was aware of the treatment allocation, adjusted the dose of the drug in order to keep the target blood level of lithium, and watched for adverse events; and an evaluating physician, who was not aware of treatment allocation and performed all clinical assessments."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 19:48:01 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-De-Carvalho-2010">
<DESCRIPTION>
<P>As quoted above</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 19:48:11 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Quote: "...This study was designed as a double blind, placebo-controlled randomised clinical trial... placebo (identically-appearing capsules b.i.d.)..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-09 12:28:15 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Gil-1992">
<DESCRIPTION>
<P>Quote: "Chaque traitement etait presente sous la meme forme galenique en suspension buvable de telle sorte que ni le medecin prescripteur, ni le malade ne puissent faire le difference entre les trois prescriptions..." Translation: "Each of the treatments consisted of an identically appearing soluble so that neither the prescribing physician, nor the patient could make out a difference between the three ..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-09 12:28:17 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>Quote: "... Polycose, an odourless glucose polymer resembling creatine monohydrate in colour and form." ... "the independent physician, ignorant to whether A or B was creatine, would instruct the research pharmacist to prepare trial medication A or B. The research pharmacist was the only person who knew the trial code of A or B. Trial medication was packed in blank containers..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 19:49:11 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996">
<DESCRIPTION>
<P>Quote: "...a double-blind, placebo-controlled, multicenter study...the four formulations were identical in appearance"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-14 10:01:31 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996a">
<DESCRIPTION>
<P>Quote: "...identical tablets...".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 19:53:09 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Meininger-2004">
<DESCRIPTION>
<P>Quote: "...Patients were given identical-appearing capsules..."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-03-13 19:53:17 +0000" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Miller-1996">
<DESCRIPTION>
<P>Quote: "...patients were randomly assigned in a double-blinded fashion...". Gabapentin at a dose of 2000 mg per day is expected and did result in statistically significant more fatigue. This carries a risk of unblinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-09 12:29:03 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Miller-2001">
<DESCRIPTION>
<P>Quote: "All capsules were identical in appearance."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 14:54:15 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Norris-1979">
<DESCRIPTION>
<P>Quote: "The present report concerns a short-term, placebo-controlled, double-blind study..." No further information is given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-03-23 14:54:59 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Insufficient information to permit 'Yes' or 'No'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2011-04-09 12:29:07 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Scelsa-2005">
<DESCRIPTION>
<P>Quote: "All study personnel and patients were blinded to treatment. To maintain the blind, the neurologists assessing the outcome measures did not collect the adverse effect data."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-24 14:17:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Weber-2010">
<DESCRIPTION>
<P>Quote: "All investigators and patients were blinded to treatment allocation for the duration of the study. ... The placebo medication contained only sesame oil and looked and tasted identical to the active medication."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-03-14 10:01:33 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1" REF_IDS="CMP-001.01">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-12 12:33:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensimon-1994">
<DESCRIPTION>
<P>Quote: "Overall, 44 patients discontinued treatment during the study (27 in the riluzole group and 17 in the placebo group). Among the 27 patients in the riluzole group, 19 (70%) discontinued treatment because of adverse effects, as compared to 9 of the 15 patients (60%) in the placebo group." Adverse effects comprised increase of asthenia, spasticity, increase in liver enzymes, and elevation in blood pressure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-13 19:35:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensimon-2002">
<DESCRIPTION>
<P>Comment: reasons for an early study termination were adequately specified in both groups. 35 participants discontinued treatment before the end of the study.</P>
<P>Among the 22 withdrawals in the riluzole group, 15 (68%) were due to adverse effects, as compared to 8 of the 13 withdrawals (62%) in the placebo group. Adverse effects comprised impaired respiratory function or liver enzyme elevations</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 14:49:35 +0000" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Blin-1989">
<DESCRIPTION>
<P>Comment: no information concerning incomplete outcome data was provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-13 19:36:26 +0000" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Blin-1992">
<DESCRIPTION>
<P>Quote: "...15 of 23 patients completed..." Comment: reasons given only for 2 of the 8 participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-13 19:47:07 +0000" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Brooks-2004">
<DESCRIPTION>
<P>Insufficient reporting of missing outcome data of participants who discontinued the study due to adverse events to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-07-20 19:53:26 +0100" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Chi_x00f2_-2010">
<DESCRIPTION>
<P>Comment: although the incomplete data was adequately reported there remains a high risk for attrition bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-09 14:45:51 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-De-Carvalho-2010">
<DESCRIPTION>
<P>Comment: adequate reporting of incomplete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 14:50:17 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Quote: "One hundred and forty-six patients (74 in the placebo group and 72 in the a -tocopherol group) did not complete the 12-month treatment period. Of these, 69 died or underwent a tracheostomy during the study period. Of the patients who discontinued treatment before the end of the study for reasons other than death, the principal reasons were withdrawal of consent or the occurrence of adverse events. The number of treatment discriminations, and the reasons for these, were equally balanced between the two groups." Comment: adequate reporting of incomplete data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-13 19:48:52 +0000" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Gil-1992">
<DESCRIPTION>
<P>No information concerning incomplete data is provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 14:50:39 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>In survival data, censoring is unlikely to be introducing bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 14:50:57 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996">
<DESCRIPTION>
<P>Comment: incomplete data reported in detail</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-14 10:01:33 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996a">
<DESCRIPTION>
<P>A detailed report is given in <LINK REF="STD-Lacomblez-1996" TYPE="STUDY">Lacomblez 1996</LINK>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 14:52:44 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Meininger-2004">
<DESCRIPTION>
<P>Comment: discontinuations were reported in detail and were equally distributed among all groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-13 19:53:18 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Miller-1996">
<DESCRIPTION>
<P>Insufficient reporting of outcome data of participants who did not complete the study to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 14:54:02 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Miller-2001">
<DESCRIPTION>
<P>Comment: incomplete data reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-03-23 14:54:15 +0000" MODIFIED_BY="Reto Baldinger" RESULT="NO" STUDY_ID="STD-Norris-1979">
<DESCRIPTION>
<P>No information concerning incomplete data is provided. Comment: probably not done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-13 19:54:02 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Insufficient reporting of outcome data of participants who did not complete the study to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-13 19:54:11 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Scelsa-2005">
<DESCRIPTION>
<P>Insufficient reporting of outcome data of participants who did not complete the study to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-04-09 14:02:37 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Weber-2010">
<DESCRIPTION>
<P>Comment: incomplete data adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-03-13 19:53:49 +0000" MODIFIED_BY="Ruth Brassington" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 12:33:54 +0000" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Bensimon-1994">
<DESCRIPTION>
<P>Incomplete reporting of secondary outcome measures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:35:55 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Bensimon-2002">
<DESCRIPTION>
<P>Although the results of the secondary outcome measures were not reported, it was stated that all of them were not statistically different between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:36:16 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Blin-1989">
<DESCRIPTION>
<P>The results of the secondary outcome measures were not reported. It was stated that all secondary outcomes not reported (reported were measurements of muscle strength using the MRC scale and hand grip dynamometry) were statistically not significantly different between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:36:28 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Blin-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement of &#8216;Low risk&#8217; or &#8216;High risk&#8217;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:25 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Brooks-2004">
<DESCRIPTION>
<P>NCT00021697. Primary and secondary outcome measures were not stated. The results of all outcome measures were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:28 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Chi_x00f2_-2010">
<DESCRIPTION>
<P>The results of all outcome measures were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:34 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-De-Carvalho-2010">
<DESCRIPTION>
<P>Protocol including primary and secondary (all but evaluation of fasciculations, cramps, stiffness and fatigue) outcome measures were published (NCT00353665). The results of all outcome measures were reported except evaluation of fasciculations, cramps, stiffness and fatigue, but a statement was made that none of them were statistically significantly different among the two groups. Summarized cramp results were provided by personal communication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:48:21 +0000" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Although referring to 2 previous studies concerning protocol and primary and secondary outcome measures, not survival but a change in the Norris limb scale (which was a secondary outcome measure in the aforementioned 2 studies) was reported as the primary outcome measure</P>
<P>Cramps were, among other secondary outcome measures, assessed in the so called Efficacy Evaluation (EE) population...using (Quote:) "the principle of last observation carried forward". The number of participants belonging to the EE at 12 months are not explicitly given. Neither are the actual number of assessments (i.e. minimally 1, maximally 4) or the date of the last examination before (i.e. at 3, 6, 9 or 12 months) termination (i.e. early versus regular termination) given, and a systematic difference in the 2 groups cannot be ruled out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:48:53 +0000" MODIFIED_BY="Ruth Brassington" RESULT="UNKNOWN" STUDY_ID="STD-Gil-1992">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:39 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>The results of all outcome measures were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:41 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Lacomblez-1996">
<DESCRIPTION>
<P>Several secondary outcome measures were not reported but a statement that none of them differed statistically significant between the two groups was made</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:49:24 +0000" MODIFIED_BY="Ruth Brassington" RESULT="NO" STUDY_ID="STD-Lacomblez-1996a">
<DESCRIPTION>
<P>Incomplete reporting of secondary outcome measures. The results of some secondary outcome measures (fasciculations, cramps, stiffness, tiredness and CGI) were neither reported nor mentioned (e.g. being not statistically different)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:46 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Meininger-2004">
<DESCRIPTION>
<P>The results of all outcome measures were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:46 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Miller-1996">
<DESCRIPTION>
<P>The results of all outcome measures were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:53:49 +0000" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Miller-2001">
<DESCRIPTION>
<P>Comment: although reported as assessed in the methods section, no results concerning cramps were presented in the article, but an analysis of secondary outcome measures revealed no difference between the groups</P>
<P>Some results of the secondary outcome measures (e.g. symptom survey) were not reported, but it was stated that none of the secondary outcomes were statistically significantly different between the 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:54:16 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Norris-1979">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:50 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Study registered (NCT00069186) and primary and secondary outcome measures specified. Some results of the secondary outcome measures (e.g. symptom survey) were not reported, but it was stated that none of the secondary outcomes were statistically significantly different among the two groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:51 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Scelsa-2005">
<DESCRIPTION>
<P>The results of all outcome measures were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-20 19:53:54 +0100" MODIFIED_BY="Ruth Brassington" RESULT="YES" STUDY_ID="STD-Weber-2010">
<DESCRIPTION>
<P>Study registered (NCT00812851) and primary outcome measure specified. The results of all outcome measures were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-03-14 10:01:37 +0000" MODIFIED_BY="Reto Baldinger" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 12:33:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensimon-1994">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:35:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bensimon-2002">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:49:38 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Blin-1989">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:49:50 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Blin-1992">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:50:00 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Brooks-2004">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 12:27:29 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Chi_x00f2_-2010">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-09 14:49:03 +0100" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-De-Carvalho-2010">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-13 19:48:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Desnuelle-2001">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:50:30 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Gil-1992">
<DESCRIPTION>
<P>No formal stopping rule specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:50:40 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Groeneveld-2003">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:50:59 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-14 10:01:37 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Lacomblez-1996a">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:52:45 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Meininger-2004">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:53:32 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Miller-1996">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:54:04 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Miller-2001">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:54:17 +0000" MODIFIED_BY="Reto Baldinger" RESULT="UNKNOWN" STUDY_ID="STD-Norris-1979">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:55:01 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Rosenfeld-2008">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:55:25 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Scelsa-2005">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-03-23 14:55:34 +0000" MODIFIED_BY="Reto Baldinger" RESULT="YES" STUDY_ID="STD-Weber-2010">
<DESCRIPTION>
<P>Comment: no other bias was observed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2012-03-14 10:27:11 +0000" MODIFIED_BY="Ruth Brassington"/>
<ADDITIONAL_TABLES MODIFIED="2012-03-14 15:17:41 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-05-13 17:06:40 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-05-13 17:06:40 +0100" MODIFIED_BY="[Empty name]">Full text articles not retrieved</TITLE>
<TABLE COLS="1" ROWS="12">
<TR>
<TD>
<P>Study</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Markland-1997" TYPE="STUDY">Markland 1997</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mazzini-1994" TYPE="STUDY">Mazzini 1994</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Mazzini-1998" TYPE="STUDY">Mazzini 1998</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Meininger-1995" TYPE="STUDY">Meininger 1995</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Nagano-2005" TYPE="STUDY">Nagano 2005</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Poutiainen-1994" TYPE="STUDY">Poutiainen 1994</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Strevic-1998" TYPE="STUDY">Strevic 1998</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Szczudlik-1998" TYPE="STUDY">Szczudlik 1998</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tyler-1978" TYPE="STUDY">Tyler 1978</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yanagisawa-1997" TYPE="STUDY">Yanagisawa 1997</LINK>
</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-03-14 15:17:02 +0000" MODIFIED_BY="Ruth Brassington" NO="2">
<TITLE MODIFIED="2012-03-14 10:28:22 +0000" MODIFIED_BY="Ruth Brassington">Summary of findings: tetrahydrocannabinol (THC) (10 mg/d) for cramps in ALS/MND</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Tetrahydrocannabinol (10 mg/d) for cramps in ALS/MND </B>(<LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with cramps in ALS/MND<BR/>
<B>Settings:</B> outpatients in Switzerland<BR/>
<B>Intervention:</B> tetrahydrocannabinol (10 mg/d)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>THC (10 mg/d)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Muscle cramps</B>
<BR/>Severity of muscle cramps in last 24 hours on visual analogue scale (VAS)<BR/>Follow-up: 4 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean muscle cramps in the control groups was<BR/>
<B>3.49 VAS (0-10)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean muscle cramps in the intervention groups was<BR/>
<B>0.24 higher</B>
<BR/>(0.32 to 0.81 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>44<BR/>(1 study, <LINK REF="STD-Weber-2010" TYPE="STUDY">Weber 2010</LINK>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>The authors discuss a potential carry-over effect which may have masked treatment effects</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group mean. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>ALS/MND:</B> amyotrophic lateral sclerosis/motor neuron disease; <B>CI:</B> confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> we are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2012-03-14 15:14:10 +0000" MODIFIED_BY="Ruth Brassington" NO="3">
<TITLE MODIFIED="2012-03-14 12:38:37 +0000" MODIFIED_BY="Ruth Brassington">Summary of findings: indinavir (2400 mg/d) for cramps in ALS/MND</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Indinavir (2400 mg/d), cramps as an adverse event in ALS/MND</B> (<LINK REF="STD-Scelsa-2005" TYPE="STUDY">Scelsa 2005</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with cramps in ALS/MND<BR/>
<B>Settings:</B> outpatients in the USA<BR/>
<B>Intervention:</B> indinavir (2400 mg/d)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Indinavir (2400 mg/d)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Muscle cramps</B>
<BR/>Number of participants reporting muscle cramps as side effect during the observation period<BR/>Follow-up: 9 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>87 per 1000</B>
<BR/>(8 to 893)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 2 </B>
<BR/>(0.19 to 20.55)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>46<BR/>(1 study, <LINK REF="STD-Scelsa-2005" TYPE="STUDY">Scelsa 2005</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group mean. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>ALS/MND:</B> amyotrophic lateral sclerosis/motor neuron disease</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Study underpowered to detect an effect. </P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2012-03-14 15:15:07 +0000" MODIFIED_BY="Ruth Brassington" NO="4">
<TITLE MODIFIED="2012-03-14 10:28:13 +0000" MODIFIED_BY="Ruth Brassington">Summary of findings: vitamin E (1 g/d) for cramps in ALS/MND</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Vitamin E (1 g/d) for ALS/MND </B>(<LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with ALS/MND<BR/>
<B>Settings:</B> outpatients in France<BR/>
<B>Intervention:</B> vitamin E (1 g/d)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Vitamin E (1 g/d)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Muscle cramps</B>
<BR/>Visual analogue scale (VAS) of global impression of cramps<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean muscle cramps in the control groups was<BR/>
<B>30.4 VAS (0-100)</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean muscle cramps in the intervention groups was<BR/>
<B>3.7 higher</B>
<BR/>(2.01 lower to 9.41 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>288<BR/>(1 study, <LINK REF="STD-Desnuelle-2001" TYPE="STUDY">Desnuelle 2001</LINK>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group mean. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>ALS/MND:</B> amyotrophic lateral sclerosis/motor neuron disease</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Risk of selective outcome reporting was judged as high (see 'Risk of bias' table).</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2012-03-14 15:15:28 +0000" MODIFIED_BY="Ruth Brassington" NO="5">
<TITLE MODIFIED="2012-03-14 15:09:20 +0000" MODIFIED_BY="Ruth Brassington">Summary of findings: creatine monohydrate (5 g/d) for cramps in ALS/MND</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Creatine monohydrate (5 g/d) for cramps in ALS/MND </B>(<LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with cramps in ALS/MND<BR/>
<B>Settings:</B> outpatients in the USA<BR/>
<B>Intervention:</B> creatine monohydrate (5 g/d)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Creatine monohydrate (5 g/d)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Muscle cramps</B>
<BR/>Number of participants reporting muscle cramps as side effect during the observation period<BR/>Follow-up: 9 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>241 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>132 per 1000</B>
<BR/>(58 to 306)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.55 </B>
<BR/>(0.24 to 1.27)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>107<BR/>(1 study, <LINK REF="STD-Rosenfeld-2008" TYPE="STUDY">Rosenfeld 2008</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group mean. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>ALS/MND</B>: amyotrophic lateral sclerosis/motor neuron disease</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2012-03-14 15:17:41 +0000" MODIFIED_BY="Ruth Brassington" NO="6">
<TITLE MODIFIED="2012-03-14 10:32:40 +0000" MODIFIED_BY="Ruth Brassington">Summary of findings: memantine (20 mg/d) for cramps in ALS/MND</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>Memantine (20 mg/d) for cramps in ALS/MND </B>(<LINK REF="STD-De-Carvalho-2010" TYPE="STUDY">De Carvalho 2010</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with ALS/MND<BR/>
<B>Settings:</B> outpatients in Portugal<BR/>
<B>Intervention:</B> memantine (20 mg/d)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Memantine (20 mg/d)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Muscle cramps</B>
<BR/>Visual analogue scale (VAS) of global impression of cramps<BR/>Follow-up: 12 months</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>241 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>207 per 1000</B>
<BR/>(80 to 540)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.33 to 2.24)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>58<BR/>(1 study, <LINK REF="STD-De-Carvalho-2010" TYPE="STUDY">De Carvalho 2010</LINK>)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group mean. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>RR:</B> risk ratio; <B>ALS/MND</B>: amyotrophic lateral sclerosis/motor neuron disease</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2012-03-14 15:16:10 +0000" MODIFIED_BY="Ruth Brassington" NO="7">
<TITLE MODIFIED="2012-03-14 10:27:33 +0000" MODIFIED_BY="Ruth Brassington">Summary of findings: L-threonine (2 g/d) for cramps in ALS/MND</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TD COLSPAN="7">
<P>
<B>L-threonine (2 g/d) for ALS/MND </B>(<LINK REF="STD-Blin-1989" TYPE="STUDY">Blin 1989</LINK>;<B> </B>
<LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with ALS/MND<BR/>
<B>Settings:</B> outpatients in France<BR/>
<B>Intervention:</B> L-threonine (2 g/d)<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>L-threonine (2 g/d)</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Muscle cramps</B>
<BR/>Visual analogue scale (VAS) of global impression of cramps since last study visit (varied)<BR/>Follow-up: 2 to 12 weeks</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean muscle cramps in the control groups was<BR/>
<B>29.63 VAS (0-100)</B>
<SUP>1</SUP>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean muscle cramps in the intervention groups was<BR/>
<B>12.61 lower</B>
<BR/>(26.94 lower to 1.72 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>55<BR/>(2 studies, <LINK REF="STD-Blin-1989" TYPE="STUDY">Blin 1989</LINK> and <LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> is the control group mean. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>ALS/MND</B>: amyotrophic lateral sclerosis/motor neuron disease</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>The mean is the weighted average of the two control groups.<BR/>
<SUP>2</SUP>One study (<LINK REF="STD-Gil-1992" TYPE="STUDY">Gil 1992</LINK>) used quasi-randomised allocation of the cross-over sequence (see 'Risk of bias' table).<BR/>
<SUP>3</SUP> Very small sample sizes.</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-03-14 16:13:17 +0000" MODIFIED_BY="Reto Baldinger">
<COMPARISON ID="CMP-001" MODIFIED="2012-03-14 16:12:23 +0000" MODIFIED_BY="Reto Baldinger" NO="1">
<NAME>L-threonine 2 g/d versus placebo</NAME>
<CONT_OUTCOME CHI2="0.26297252876262034" CI_END="1.7239506297169953" CI_START="-26.937381012435946" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-12.606715191359475" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2012-03-14 16:11:10 +0000" MODIFIED_BY="Reto Baldinger" NO="1" P_CHI2="0.6080853473638691" P_Q="1.0" P_Z="0.08467459357323597" Q="0.0" RANDOM="NO" SCALE="59.93" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="28" UNITS="" WEIGHT="100.0" Z="1.7241842107628267">
<NAME>Muscle cramp VAS</NAME>
<GROUP_LABEL_1>L-threonine 2 g/d</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours L-threonine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="7.105251173999445" CI_START="-43.10525117399945" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="33.0" MODIFIED="2010-03-19 15:26:51 +0000" MODIFIED_BY="[Empty name]" ORDER="1" SD_1="19.0" SD_2="30.0" SE="12.809036988447982" STUDY_ID="STD-Blin-1992" TOTAL_1="7" TOTAL_2="8" WEIGHT="32.58393989199343"/>
<CONT_DATA CI_END="7.453586579297799" CI_START="-27.4535865792978" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="28.0" MODIFIED="2010-03-19 15:26:50 +0000" MODIFIED_BY="[Empty name]" ORDER="7" SD_1="25.0" SD_2="31.0" SE="8.905054744357274" STUDY_ID="STD-Gil-1992" TOTAL_1="20" TOTAL_2="20" WEIGHT="67.41606010800658"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-03-14 16:12:40 +0000" MODIFIED_BY="Reto Baldinger" NO="2">
<NAME>Vitamin E 1g/d versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.405000142533273" CI_START="-2.0050001425332677" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.700000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2012-03-11 22:51:30 +0000" MODIFIED_BY="Reto Baldinger" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.20367807076300404" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="144" TOTAL_2="144" UNITS="" WEIGHT="100.0" Z="1.2711422544466509">
<NAME>Muscle cramp VAS</NAME>
<GROUP_LABEL_1>alpha-Tocopherol (Vit. E)</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours vitamin E</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.405000142533273" CI_START="-2.0050001425332677" EFFECT_SIZE="3.700000000000003" ESTIMABLE="YES" MEAN_1="29.6" MEAN_2="25.9" MODIFIED="2010-02-23 09:48:16 +0000" MODIFIED_BY="[Empty name]" ORDER="2" SD_1="26.2" SD_2="23.1" SE="2.9107678444775433" STUDY_ID="STD-Desnuelle-2001" TOTAL_1="144" TOTAL_2="144" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-03-14 16:12:53 +0000" MODIFIED_BY="Reto Baldinger" NO="3">
<NAME>Tetrahydrocannabinol (THC) versus placebo</NAME>
<IV_OUTCOME CHI2="9.826173185649162E-33" CI_END="0.7887899156712153" CI_START="-0.3087899156712153" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.23999999999999996" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.10303865029344283" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.6197887582883941" MODIFIED="2012-03-12 17:24:13 +0000" MODIFIED_BY="Reto Baldinger" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.3913659470650557" Q="0.0" RANDOM="NO" SCALE="7.8" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0" Z="0.857142857142857">
<NAME>Muscle cramp VAS</NAME>
<GROUP_LABEL_1>THC</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours THC</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.7887899156712153" CI_START="-0.3087899156712153" EFFECT_SIZE="0.24" ESTIMABLE="YES" ESTIMATE="0.24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-11-01 19:21:05 +0000" MODIFIED_BY="Reto Baldinger" ORDER="16" SE="0.28" STUDY_ID="STD-Weber-2010" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-03-14 16:13:02 +0000" MODIFIED_BY="Reto Baldinger" NO="4">
<NAME>Memantine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.241505645779265" CI_START="0.3277680245572624" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.35053983707988023" LOG_CI_START="-0.4844334163411066" LOG_EFFECT_SIZE="-0.06694678963061322" METHOD="MH" MODIFIED="2012-03-11 22:52:05 +0000" MODIFIED_BY="Reto Baldinger" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.7532982015112779" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="29" TOTAL_2="29" WEIGHT="100.0" Z="0.31429341243922404">
<NAME>Muscle cramp VAS</NAME>
<GROUP_LABEL_1>Memanine 10mg b.i.d.</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours memantine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.241505645779265" CI_START="0.3277680245572624" EFFECT_SIZE="0.8571428571428571" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.35053983707988023" LOG_CI_START="-0.4844334163411066" LOG_EFFECT_SIZE="-0.06694678963061322" MODIFIED="2011-04-09 14:23:26 +0100" MODIFIED_BY="Reto Baldinger" ORDER="7" O_E="0.0" SE="0.4904674222437513" STUDY_ID="STD-De-Carvalho-2010" TOTAL_1="29" TOTAL_2="29" VAR="0.2405582922824302" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-03-14 16:13:11 +0000" MODIFIED_BY="Reto Baldinger" NO="5">
<NAME>Creatine versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2670687957163453" CI_START="0.23754448951619747" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.548621190130624" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.10280019561656524" LOG_CI_START="-0.6242550397573663" LOG_EFFECT_SIZE="-0.2607274220704005" METHOD="MH" MODIFIED="2012-03-11 22:52:46 +0000" MODIFIED_BY="Reto Baldinger" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.15980866315136757" Q="0.0" RANDOM="NO" SCALE="52.49" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="53" TOTAL_2="54" WEIGHT="100.0" Z="1.4057153629521368">
<NAME>Cramps (side effect)</NAME>
<GROUP_LABEL_1>Creatine 5 g/d</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours creatine</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2670687957163453" CI_START="0.23754448951619747" EFFECT_SIZE="0.548621190130624" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="0.10280019561656524" LOG_CI_START="-0.6242550397573663" LOG_EFFECT_SIZE="-0.2607274220704005" MODIFIED="2010-10-27 19:19:42 +0100" MODIFIED_BY="Reto Baldinger" ORDER="13" O_E="0.0" SE="0.4270758442401061" STUDY_ID="STD-Rosenfeld-2008" TOTAL_1="53" TOTAL_2="54" VAR="0.18239377673339938" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-03-14 16:13:17 +0000" MODIFIED_BY="Reto Baldinger" NO="6">
<NAME>Indinavir versus placebo</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="20.552567517689006" CI_START="0.19462288575660025" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="1.3128660835898294" LOG_CI_START="-0.710806092261867" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" MODIFIED="2012-03-12 21:36:59 +0000" MODIFIED_BY="Reto Baldinger" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5598217775556726" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="23" WEIGHT="100.0" Z="0.5831062528883534">
<NAME>Cramps (side effect)</NAME>
<GROUP_LABEL_1>Ind
inavir</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours indi
navir</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="20.552567517689006" CI_START="0.19462288575660025" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3128660835898294" LOG_CI_START="-0.710806092261867" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-10-27 19:21:52 +0100" MODIFIED_BY="Reto Baldinger" ORDER="14" O_E="0.0" SE="1.1887150534341144" STUDY_ID="STD-Scelsa-2005" TOTAL_1="23" TOTAL_2="23" VAR="1.4130434782608696" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-03-14 16:11:11 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-03-14 13:10:13 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATAAAANUCAIAAAC7Y+bBAAAqHUlEQVR42u3dvW4kxfrH8ZFICCZw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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-03-14 16:11:11 +0000" MODIFIED_BY="Reto Baldinger" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_MORE_DECIMALS:NO;SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 6 L-threonine, outcome: 6.1 Muscle cramp VAS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAv0AAACQCAMAAACs7SSLAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-03-13 20:36:18 +0000" MODIFIED_BY="Ruth Brassington">
<APPENDIX ID="APP-01" MODIFIED="2012-03-13 20:36:04 +0000" MODIFIED_BY="Kate Jewitt" NO="1">
<TITLE MODIFIED="2012-03-13 20:36:04 +0000" MODIFIED_BY="Angela Gunn">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-05 12:31:57 +0000" MODIFIED_BY="Kate Jewitt">
<P>1 randomised controlled trial.pt.<BR/>2 controlled clinical trial.pt.<BR/>3 randomized.ab.<BR/>4 placebo.ab.<BR/>5 clinical trials as topic.sh.<BR/>6 randomly.ab.<BR/>7 trial.ti.<BR/>8 or/1-7<BR/>9 (animals not (animals and humans)).sh.<BR/>10 8 not 9<BR/>11 exp Motor Neuron Disease/<BR/>12 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp.<BR/>13 ((Charcot marie$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 syndrome$1)).mp.<BR/>14 ((Charcot marie$1 adj5 disease) or (Lou Gehrig$1 adj5 disease)).mp.<BR/>15 Amyotrophic Lateral Sclerosis.mp.<BR/>16 or/11-15<BR/>17 10 and 16</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2012-03-13 20:36:18 +0000" MODIFIED_BY="Kate Jewitt" NO="2">
<TITLE MODIFIED="2012-03-13 20:36:18 +0000" MODIFIED_BY="Angela Gunn">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-01-05 12:31:58 +0000" MODIFIED_BY="Kate Jewitt">
<P>1 crossover-procedure/<BR/>2 double-blind procedure/<BR/>3 randomised controlled trial/<BR/>4 single-blind procedure/<BR/>5 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or (doubl$ adj blind$) or (singl$ adj blind$) or assign$ or allocat$ or volunteer$).tw.<BR/>6 or/1-5<BR/>7 human/<BR/>8 6 and 7<BR/>9 human/ or nonhuman/<BR/>10 6 not 9<BR/>11 8 or 10<BR/>12 exp Motor Neuron Disease/<BR/>13 (moto$1 neuron$1 disease$1 or moto?neuron$1 disease).mp.<BR/>14 ((Charcot marie$1 adj5 syndrome$1) or (Lou Gehrig$1 adj5 syndrome$1)).mp.<BR/>15 ((Charcot marie$1 adj5 disease) or (Lou Gehrig$1 adj5 disease)).mp.<BR/>16 Amyotrophic Lateral Sclerosis.mp.<BR/>17 or/12-16<BR/>18 11 and 17</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2011-07-20 19:58:37 +0100" MODIFIED_BY="Ruth Brassington" NO="3">
<TITLE MODIFIED="2011-07-20 19:58:37 +0100" MODIFIED_BY="Ruth Brassington">Cochrane Central Register of Controlled Trials (CENTRAL)</TITLE>
<APPENDIX_BODY MODIFIED="2010-09-30 08:51:35 +0100" MODIFIED_BY="[Empty name]">
<P>#1MeSH descriptor Motor Neuron Disease explode all trees<BR/>#2(amyotrophic NEXT lateral NEXT sclerosis) OR (motor NEXT neuron* NEXT disease*) OR (motoneuron* NEXT disease*)<BR/>#3(lou NEXT Gehrig*)<BR/>#4(#1 OR #2 OR #3)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>

<EXTENSION ID="AFF_15460_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS"><ALIAS ALIAS_ID="15460"><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University Hospital Basel</ORGANISATION><CITY>Basel</CITY><COUNTRY CODE="CH">Switzerland</COUNTRY></ADDRESS></ALIAS></EXTENSION></EXTENSIONS>
</COCHRANE_REVIEW>